|
|
·|û¡G©t¨àÃÄ10140658 µoªí®É¶¡:2017/7/26 ¤U¤È 02:22:07
|
2022.01-¤@´Á¼Æ¾Ú¤§Àu¤Æ²³ø(Y¥h¦~¤E¤ë®³³oª©À³¸Ó·|¦n¤@ÂI):ir.aslanpharma.com/static-files/2a7f1481-a0b3-47d1-87ef-e6ed30321475 2022.01-KOL²³ø:ir.aslanpharma.com/static-files/379e7107-c421-4401-b035-e43c4b682d19 2022.05.12- ir.aslanpharma.com/static-files/20941066-3bc3-418b-a970-9951565de0f2 2022.06²³ø-ir.aslanpharma.com/static-files/1c525489-d209-42c4-af7e-992f23c4251c 2022.09.15²³ø-ir.aslanpharma.com/static-files/1511fefc-ba34-4ee4-aac0-32f8bc4754a8 |
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2023/3/31 ¤W¤È 09:48:55²Ä 6081 ½g¦^À³
|
7¤ëªì¤½§iªºASLSN004 2b¸Ñª¼¼Æ¾Ú ¥«È¼ÒÀÀ¡G Y ¤@¡BIGA0,1>54%/15%(¹ï·Ó组) ADR¥Ø¼Ð»ù31¡D25¬ü¤¸¡D ¶Ò资»ù25¬ü¤¸ ¥«È25¬ü¤¸x4¸U¤dªÑ=10»õ¬ü¤¸ ¤G¡BIGA0,1=45%/15%(¹ï·Ó组) ADR¥Ø¼Ð»ù15¡ã20¬ü¤¸¡D¶Ò资»ù12¡ã16¬ü¤¸ ¥«È4.8¡ã6.4»õ¬ü¤¸¡D |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2023/3/31 ¤W¤È 09:33:03²Ä 6080 ½g¦^À³
|
¨p¶Ò2000¸U¬ü¤¸¤Î8000¸U¬ü¤¸»{ªÑÅvªº¨Ì¾Ú¡Bªñ80%x300¤H 2b ªº¥¼¸Ñª¼x16¶gªvÀø«áªº¼Æ¾Ú¡D CEO ³Å«i»{¬°°ª¾¯¶qIGA,0,1Àø®Ä¦Ü¤Ö44%.vs 15%(¹ï·Ó组) ¥i«H«×°ª! ¦³1/3ªºÁ{§É¤¤¤ß±¾ASLN ¡B¦h©â¤@¨Ç¦å¡B§Y¥i¤ÀªR¦å²G¤¤ªºÃĶq¦s¶q¡B¥i¦³®Ä预测¬ÛÃö¼Æ¾Ú?!(¤£ª¾¬O§_¦p¦¹°õ¦æ?) |
|
|
·|û¡G¬õ¹Ð¦³¹Ú10150039 µoªí®É¶¡:2023/3/31 ¤W¤È 09:22:51²Ä 6079 ½g¦^À³
|
¥i§_½Ð¤Ñ©R¤j¤ÀªR¤@¤U ¤U±³oӼƾڪº»ùÈ |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2023/3/31 ¤W¤È 08:09:33²Ä 6078 ½g¦^À³
|
H.C. Wainwright Autoimmune & Inflammatory Disease Virtual Conference (Skin Diseases, Conditions and Disorders) - March 30, 2023 journey.ct.events/view/61f3dfa3-80fd-4977-954c-981a5ef92fda CEO ³Å«i¦^µªªº²Ä¤TÓ°ÝÃD¡D ¥D«ù¤H¡G³¯¤ÀªR®v(µØ¤H¡B¥Íª«³Õ¤h) °Ý¡G½Í½Í7¤ë¥÷n¸Ñª¼ªº2b AD Á{§É! µª¡G¡K预´Á°ª¾¯¶qªºIGA0,1Àø®Ä¦Ü¤Ö44% ¹ï·Ó组¬ù15%.... |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2023/3/30 ¤U¤È 10:59:46²Ä 6077 ½g¦^À³
|
ASLN CEO ¥¿¨üH.C.WAINWRIGHT& CO.¨é°Ó³¯¥ý¥Í³X°Ý¡B 7¤ëªì 004 2b¸Ñª¼ CEO预´ÁIGA0,1 400mgxQ2WÀø®Ä¦Ü¤Ö(Min.)44%vs15%(¹ï·Ó组) |
|
|
·|û¡Gªü¦Ì¤ÚìÂÎ10145310 µoªí®É¶¡:2023/3/26 ¤U¤È 02:29:12²Ä 6076 ½g¦^À³
|
¤Ñ©R¤jºâ¥X¨Óªº¥§¡»ù®æÀ³¸Ó¬O¥]§t¤§«áªº»{ªÑÅvÃÒ? |
|
|
·|û¡Gªü¦Ì¤ÚìÂÎ10145310 µoªí®É¶¡:2023/3/26 ¤U¤È 02:17:53²Ä 6075 ½g¦^À³
|
¥X°âªÑ东ªº关¨t °£¤Wªí脚ª`¤¤¥t¦³©ÜÅS¦}¦p¤U©Òz¥~¡A¥X°âªÑ东¤¤没¦³¥ô¦ó¤@个¤H¦b过¥h¤T¦~¤¤ü®¥ô过§Ú们ªº职¦ì¡B职务©Î¨ä¥L«n关¨t¡C 2023¦~2¤ë24¤é¡A§Ú们ÉO¥X°âªÑ东©Î购买¤è签订¤F单¦ì购买协议¡A®ÚÕu该协议¡A§Ú们¦P·N¦V购买¤è¥X°â¡]i¡^59,957,865ªÑ´¶³qªÑ¡]©Î¬Û当¤_2,398,314 ADS¡^©M¡]ii¡^52,401,685ªÑ´¶³qªÑ¡A¥i¦æ¨Ï预¥ý资§Uªº认ªÑ权证¡]©Î¬Û当¤_2,096,067 ADS¡^¡Aɲ®æ为¨CªÑ´¶³qªÑ0.178¬ü¤¸¡]©Î¨CADS 4.45¬ü¤¸¡^©M¨C个预¥ý资§Uªº认ªÑ权证4.4475¬ü¤¸¡C¨p¶Ò结§ô¤_2023¦~2¤ë27¤é¡C §@为¨p¶Òªº¤@³¡¤À¡A购买¤è还获±o¤F两个¥i¦æ¨Ïªº认ªÑ权证¡A总¦@¥i¦æ¨Ï276,545,560´¶³qªÑ©ÎTranche预¥ý资§Uªº认ªÑ权证¡A¥i¦æ¨Ï11,061,822 ADS¡C²Ä¤@§å认ªÑ权证¥]¬A¡]i¡^50¢Hªº认ªÑ权证¡A¦b发¦æ¦Z¤Î¤½¥¬§Ú们TREK-AD²Ä2b´Á临§É试验调¬datopic dermatitis¤¤eblasakimab¤½§i¤§¤é°_60¤Ñ内¦æ¨Ï¡A¦æ¨Ïɲ®æ为¨CADS 6.50¬ü¤¸¡A¥H¤Î¡]ii¡^50¢Hªº认ªÑ权证¡A¥u¯à¦beblasakimab¤½§i¦Z60¤Ñ内¦æ¨Ï¡A¦æ¨Ïɲ®æ°ò¤_ADSªº¥[权¥§¡É²®æ¡]VWAP¡^¡A该ɲ®æ¦beblasakimab¤½§i¦Zªº¯S©w´Á间内测¶q¡C²Ä¤G§å认ªÑ权证¦Pý©¥]¬A¡]i¡^50¢Hªº认ªÑ权证¡A¦b发¦æ¦Z¤Î¤½¥¬§Ú们计¦E进¦æªº²Ä2阶¬q·§©À验证试验调¬dfarudodstat时发¥¬¦Ü60¤Ñ内¦æ¨Ï¡A¦æ¨Ïɲ®æ为¨CADS 8.15¬ü¤¸¡C Relationships with Selling Shareholders Except as otherwise disclosed in the footnotes to the table above and as described below, none of the selling shareholders has, or within the past threeyears has had, any position, office or other material relationship with us. On February 24, 2023, we entered into the Unit Purchase Agreement with the selling shareholders, or the Purchasers, pursuant to which we agreed tosell to the Purchasers, in the Private Placement, an aggregate of (i) 59,957,865 ordinary shares (or the equivalent of 2,398,314 ADSs) and (ii)52,401,685 ordinary shares issuable upon the exercise of Pre-Funded Warrants (or the equivalent of 2,096,067 ADSs), at a purchase price of $0.178 perordinary share (or the equivalent of $4.45 per ADS) and $4.4475 per Pre-Funded Warrant. The Private Placement closed on February 27, 2023. As part of the Private Placement, the Purchasers also received two tranches of Warrants exercisable in the aggregate for up to 276,545,560 ordinaryshares or Tranche Pre-Funded Warrants exercisable for 11,061,822 ADSs. The first tranche of Warrants is comprised (i) 50% of Warrants that areexercisable upon issuance and until 60 days after the public announcement of our topline data from our TREK-AD Phase 2b clinical trial investigating eblasakimab in atopic dermatitis, or the eblasakimab announcement, at an exercise price of $6.50 per ADS, and (ii) 50% of warrants which can only beexercised within 60 days after the eblasakimab announcement at an exercise price based on the higher of $6.50 and a 50% discount to the ADSs¡¦ volume-weighted average price, or VWAP, measured across a specified period after the eblasakimab announcement. The second tranche of Warrants issimilarly comprised (i) 50% of Warrants that are exercisable upon issuance until 60 days after the public announcement of topline interim data from ourplanned Phase 2 proof of concept trial investigating farudodstat , or the farudodstat announcement, at an exercise price of $8.15 pe |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2023/3/26 ¤W¤È 08:41:39²Ä 6074 ½g¦^À³
|
¥»¦¸¶Ò¸ê¤@»õ¬ü¤¸¡B¥Î388,905,110ì©lªÑ¡D ADR(1¡G25)= 388,905,110/25=15,556,204ªÑADR ¥§¡¨CªÑ6.42¬ü¤¸. |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2023/3/26 ¤W¤È 07:07:38²Ä 6073 ½g¦^À³
|
¥»¦¸»{Áʪº4¤j¤½¥q»{ÁÊ(§t»{ÁÊÅvÃÒ)ì©lªÑ¼Æ//¨p¶Ò«e«ùªÑ//¥¼¨Ó«ùªÑ¦Xp 1.BVF 272¡B233¡B565 2.TANG 38,890,515//(¨p¶Ò«eì«ùªÑ26,824,625)¡B¥¼¨Ó«ùªÑ¦Xp65,715,140 3.K2¡C 38,890,515//(¨p¶Ò«eì«ùªÑ1,402,891) 4.Florian38,890,515//(¨p¶Ò«eì«ùªÑ9,131,810) ¦Xp 388,905,110// ir.aslanpharma.com/static-files/8ef0bdc0-36a2-45f0-9424-fe9c5722521d P.10 Name of Selling Shareholder Shares Beneficially Owned Prior to Offering(1) Number of Shares Being Offered SharesBeneficiallyOwnedAfterOffering(2) Number Percent Number Percent 1.Entities affiliated with BVF Partners L.P. (3) 42,445,150 9.99% 272,233,565 ¡X ¡X 2.Tang Capital Partners, LP(4) 41,134,322 9.99% 38,890,515 26,824,625 6.56% 3.K2 HealthVentures Equity Trust LLC(5) 26,466,126 6.24% 38,890,515 1,402,891 * 4.Florian Schönharting(6) 20,394,529 4.99% 38,890,515 9,131,810 2.23% * Represents benefi |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2023/3/25 ¤U¤È 03:31:05²Ä 6072 ½g¦^À³
|
7¤ëªì¤½§iªºASLSN004 2b¸Ñª¼¼Æ¾Ú ¥«È¼ÒÀÀ¡G Y ¤@¡BIGA0,1>54%/15%(¹ï·Ó组) ADR¥Ø¼Ð»ù31.25¬ü¤¸¡D ¶Ò资»ù25¬ü¤¸ ¥«È25¬ü¤¸x4¸U¤dªÑ=10»õ¬ü¤¸ ¤G¡BIGA0,1=45%/15%(¹ï·Ó组) ADR¥Ø¼Ð»ù15¬ü¤¸¡D¶Ò资»ù12¬ü¤¸ ¥«È4.8»õ¬ü¤¸¡D |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2023/3/25 ¤U¤È 03:13:56²Ä 6071 ½g¦^À³
|
3¬ü¤¸º¦¨ì30¬ü¤¸ªº¼ç¤O⋯7¤ë ¦b6550¥_·¥¬P¬Ý¹L¡A10¤¸/ªÑ¨p¶Ò30»õ¥x¹ô¡Aº¦¨ì100¤¸/ªÑ¡C2021/¤¸¤ë¡ã2022/02 µM«á¤T´Á¸Ñª¼¦¨¥\º¦¨ì232¡]2022/09¡^¡A¥Ø«e¦^¨ì96¤¸¡C ·|µu缐¾Þ§@ªÌ¡A¤£·|©ñ±¼¦¹10¿Â½º¦ªº¾÷·|ªº¡C Tang ¸ê¥»¤½¥q¡A§t»{ªÑÅvÃÒ¡A¦@¥[½X¨ì5¸U¤dªÑì©lªÑ¡A¥Ø«eADR¡]1:25¡^¬ù2000¤dªÑ¡C¡]²Ä¤G¤jªÑªF¡^¡A12¤ë©³«ùªÑ1072¤dªÑADR¡]1:25¡^ |
|
|
·|û¡G©t¨àÃÄ10140658 µoªí®É¶¡:2023/3/25 ¤U¤È 02:46:47²Ä 6070 ½g¦^À³
|
´«ºâ¦^´¶³qªÑ¥u¦³2.91/25*30=·s¥x¹ô3.49/ªÑ¡A¹ï«Ü¦h¦Ñ·à¤ÍÁÙ¬O«Ü¨¯Wªº»ù®æ¡F§Y¨ÏADRº¦¨ì25¶ô¤]¬O¥x¹ô30¶ô¡AÁÙ¬O¦Ñ¸Ü¤@¥y¡A§Æ±æ¦Ñ·à¤Í̳£¯à¸Ñ®M~~~~~~~~~ |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2023/3/25 ¤W¤È 10:10:18²Ä 6069 ½g¦^À³
|
2022¦~¡B²Ä4©u°]³ø 2022/12/31 ²{ª÷¡G56.9¦Ê¸U¬ü¤¸ ²bÈ¡G8¦Ê36¸U¬ü¤¸ 2022¦~5100¸U¬ü¤¸¤§损¥¢(¥Dn¬ãµo¶O¥Î3600¸U¬ü¤¸¡D¥§¡¨C©u1400¸U¬ü¤¸¥ª¥k¡B ¡K¡K¥H¤W¬°¨p¶Ò¥D¦]¤§¤@ Cash and cash equivalents total $56.9 million as of December 31, 2022 |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2023/3/25 ¤W¤È 09:55:25²Ä 6068 ½g¦^À³
|
¥Ø«e¸ê¥»ÃBADR¡B4¸U¤dªÑ(ADR:1:25) ¦©°£¤wµo¦æ¡B¤º³¡¿EÀy¤Îk2»{ªÑ¡B ©Ò³Ñ¬ù8000¤dªÑADR¥i¥«³õ¾P°â©Î¥]¾P¡K ³Ì°ª¶Ò2»õ¬ü¤¸¡B¥Ø¼Ð¶Ò¸ê»ù25¬ü¤¸/ADR ±À¦ô25/80%=30¬ü¤¸¤@¤@³Ì°ª¤½¥q»{¬°¥i¯àªº¥Ø¼Ð»ù¡D 2/24¨p¶Ò0.89*5=4.45¬ü¤¸(2000¸U¬ü¤¸) 2/24»{ªÑÅv(1.3-1.603)x5=6.5-9.15 (¶Ò8000¸U¬ü¤¸,7¤ë¸Ñª¼«á60¤Ñ¤º»{ÁÊ¡D Tang资¥»¤½¥q2¤ë24¤é¥ç¦³»{¨p¶Ò¡D ¬°²Ä¤G¤j«ùªÑ(2¤ë28¤é)¡B¦Xp«ùªÑ¬ù4.1¸U¤dªÑì©lªÑ¡B©MBVF¶°¹Î¬Û·í¬Ò¬°9.99% |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2023/3/25 ¤W¤È 09:13:19²Ä 6067 ½g¦^À³
|
1.³Ì°ª2»õ¬ü¤¸ªº¶Ò¸êp¹º(2023/03/24´£¥X) ir.aslanpharma.com/static-files/0f9bf9a7-f0e1-4b22-9f67-4bbfa0a5dae8 SUBJECT TO COMPLETION, DATED MARCH 24, 2023 PROSPECTUS $200,000,000(2»õ¬ü¤¸ªº¶Ò¸êp¹º) Ordinary Shares American Depositary Shares representing Ordinary Shares ¤£¥]¬A¤§«e(2¤ë24¤é)³Ì°ª¨p¶Ò1»õ¬ü¤¸. ¥¼p¥t¥~¤º³¡¿EÀy¤Îk2¨p¶Òp2000¸U¬ü¤¸,¬ù50,000,000ì©lªÑ. ¤º³¡¿EÀy¶}©l»{ªÑ: ir.aslanpharma.com/static-files/80855ba6-3677-446a-ae3d-d4c0d9efb657 ¦Xp¥i¶Ò¸êª÷3.2»õ¬ü¤¸. 2.¦~³ø ir.aslanpharma.com/static-files/44f85422-f9c7-43ba-83cb-5cba2b68d8cb 2¤ë28¤é¤î, «ùªÑ¶W¹L5%ªÑªF¦³4¦ì.----p.106 ¤½¥q¤º³¡«ùªÑ5.26%(22,399,939ì©lªÑ) ¥H¤W¨Ì2023¦~2¤ë28¤é¤wµo¦æ408,681,230 ì©lªÑ. 3.²Öp¦Ü3¤ë20¤é¤wµo¦æ737,628,475ì©lªÑ ir.aslanpharma.com/static-files/8ef0bdc0-36a2-45f0-9424-fe9c5722521d p.8 Equity: Ordinary shares, $0.01 par value per share, 500,000,000 shares authorized, 348,723,365 shares issued and outstanding, actual; and 737,628,475 The number of ordinary shares outstanding in the table above is based on 348,723,365 ordinary shares outstanding as of December 31, 2022 on an actual basis and excludes: • 48,822,715 ordinary shares issuable upon the exercise of share options outstanding as of December 31, 2022 under our 2014 Employee Share Option Scheme Plan, our 2017 Employee Share Option Plan and our 2020 Equity Incentive Plan, at a weighted average exercise price of $0.26 per ordinary share; and • 1,402,891 ordinary shares issuable upon the exercise of an outstanding warrant issued in July 2021 to K2 HealthVentures Equity Trust LLC, at an exercise price of $0.5257 per ordinary share, pursuant to that certain Loan, Guaranty, and Security Agreement with K2 HealthVentures LLC in connection with the drawdown of our loan facilities. In addition, as of the date of this prospectus, 53,393,470 ordinary shares (representing 2,135,738 ADSs) have been issued to JPMorgan Chase Bank, N.A., as depositary, which are being held for future sales and issuances of ADSs, if any, under that certain Open Market Sale AgreementSM that we entered into with Jefferies LLC on October 9, 2020, as amended from time to time. ¤Wªí¤¤µo¦æ¦b¥~ªº´¶³qªÑ¼Æ¶q¬O®Ú¾ÚºI¦Ü2022¦~12¤ë31¤éµo¦æ¦b¥~´¶³qªÑ348,723,365ªÑ¹ê»Ú °ò¦¨Ã±Æ°£¡G • ºI¦Ü 2022 ¦~ 12 ¤ë 31 ¤é¡A®Ú¾Ú§Ú̪º 2014 ¦~¥¼¦æ¨ÏÁʪÑÅv¡A¥iµo¦æ 48,822,715 ªÑ´¶³qªÑ û¤uªÑ²¼´ÁÅvp¹º¡B§Ú̪º 2017 ¦~û¤uªÑ²¼´ÁÅvp¹º©M§Ú̪º 2020 ¦~ªÑÅv¿EÀyp¹º¡A«ö¥[Åv ¥§¡¦æ¨Ï»ù¬°¨CªÑ´¶³qªÑ 0.26 ¬ü¤¸¡F ©M • 1,402,891 ªÑ´¶³qªÑ¥i¦b 2021 ¦~ 7 ¤ë¦V K2 HealthVentures Equity Trust µo¦æªº¥¼¦æ¨Ï»{ªÑÅvÃÒ¦æ¨Ï«áµo¦æ LLC¡A®Ú¾Ú»P K2 ñqªº¯S©w¶U´Ú¡B¾á«O©M¾á«O¨óij¡A¦æ¨Ï»ù¬°¨CªÑ´¶³qªÑ 0.5257 ¬ü¤¸ HealthVentures LLC ³B²z§Ú̶U´ÚÃB«×ªº´£¨ú¡C ¦¹¥~¡AºI¦Ü¥»©ÛªÑ»¡©ú®Ñµo¥¬¤§¤é¡A¤w¦V¼¯®Ú¤j³q»È¦æµo¦æ 53,393,470 ªÑ´¶³qªÑ¡]¬Û·í©ó 2,135,738 ªÑ¬ü°ê¦s°U¾ÌÃÒ¡^¡A N.A.¡A§@¬°«OºÞ¤H¡A®Ú¾Ú§Ú̽T©wªº¬Y¨Ç¤½¶}¥«³õ¾P°â¨óijSM¡A¬°¥¼¨Ó¾P°â©Mµo¦æ ADS¡]¦pªG¦³¡^¦Ó«ù¦³ ©ó 2020 ¦~ 10 ¤ë 9 ¤é»P Jefferies LLC ñq¡A¨Ã¸g¤£®É×q¡C shares issued and outstanding as adjusted |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2023/3/23 ¤W¤È 10:09:49²Ä 6066 ½g¦^À³
|
ASLAN004 2B AD ³Ì·s²§°Ê: °±¤î¦¬®×,¹ê»Ú¦¬®×302¤H,6¤ë30§¹¦¨¥Dn(16¶g)Á{§É. clinicaltrials.gov/ct2/show/NCT05158023 Phase 2b Study of ASLAN004 in Adults With Moderate-to-Severe Atopic Dermatitis Study Type : Interventional (Clinical Trial) Actual Enrollment : 302 participants Allocation: Randomized Intervention Model: Parallel Assignment Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) Primary Purpose: Treatment Official Title: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Dose-Ranging Trial to Evaluate the Efficacy and Safety of ASLAN004 in Adult Patients With Moderate-to-Severe Atopic Dermatitis Actual Study Start Date : March 16, 2022 Estimated Primary Completion Date : June 30, 2023 Estimated Study Completion Date : September 30, 2023 |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2023/3/16 ¤W¤È 08:54:17²Ä 6065 ½g¦^À³
|
¬Ý¹L65/83(78%)¥¼¸Ñª¼ªºBVF¤½¥q¡B¤w¤j¶q¶R2000¸U¬ü¤¸¡D(0.89*5=4.45³æ»ù/ADR¡B1¡G25) ¸Ñª¼«eªº¦æ±¡³Ì°ª15-22.25,¨é°Ó¥Ø¼Ð»ù ¤£¨ì4Ó¤ë¡B¦³¦p¦¹Ãz§Qªº¼Ðªº¡D ¥@¬É¨ºùاä? ¸Ñª¼«e½æ¤@½ëµu½uÀò§Q¥i¯à¼Æ¿?¡D ¬Ý¬ÝCNTB 2021¦~7¤ë15¤é2b AD¸Ñª¼«eªº¦æ±¡¡D15¬ü¤¸º¦¨ì26¬ü¤¸¡D (2021/11¤ë¡B¤½§G¸Ñª¼¼Æ¾Ú) |
|
|
·|û¡G³v®ö«È10146323 µoªí®É¶¡:2023/3/15 ¤U¤È 11:18:14²Ä 6064 ½g¦^À³
|
¬üªÑ«®À4¡B500ÂI¡A Asln¤@ªK¿W¨q¡A¦bº¦¤°»ò¡H ªÑ²¼¥«³õ¸¹ºÙ³Ì¦³®Ä²vªº¥«³õ¡A ©Ò¥H©O¡H Ä~Äò¬ÝÀ¸¡ã |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2023/3/15 ¤U¤È 11:06:49²Ä 6063 ½g¦^À³
|
¤j®a¦¨¥»¦U¦³¤£¦P¡A¥§¡¸¨¦b5~7¬ü¤¸¤§¶¡³Ì¦h¡A²{¦b«ùªÑ¥u³Ñ¤¤À¤§¤@¡A25¬ü¤¸¥H¤W½æÀ£¤~·|¤ñ¸û«¡A ¥H¤W¬OÓ¤H±À´ú¡A¶È¨Ñ°Ñ¦Ò¡C |
|
|
·|û¡G¥d¦b¥b¤s¸y10153098 µoªí®É¶¡:2023/3/15 ¤U¤È 10:41:23²Ä 6062 ½g¦^À³
|
¥xªÑ¤U¥««e4¤dªÑ ÅÜADR/5=800 ³o¦¸´î¸ê/5=160ªÑ ¨ºnº¦¨ì10¦h¶ô¤~¯à¦^¥»QQ ºGµ´¤H¾Èªü |
|
|
·|û¡G¸Ø±i10133098 µoªí®É¶¡:2023/3/15 ¤U¤È 01:43:48²Ä 6061 ½g¦^À³
|
111¦~8¤ë23¤é¤½§i¦¨¥ß65³Bªº¦¬®×¤¤¤ß¡B 112¦~1¤ë30¤é¦A·s¼W18³B¦¬®×¤¤¤ß(¬Ò¦ì¦bªiÄõ)¡A¦@83³B¡B¤µ¦~2¤ë24¤é¤½§i³Ì«á¤@¦ì¤w©Û¶Ò¡C 8¤ë23¤éªº65³B¦¬®×¤¤¤ß+2Ӥ몺¦¬ªv+16¶g¸ÕÅç+1Ó¤ë¼Æ¾Ú¾ã²z=112¦~3¤ë23¤é (°ò¥»¤W«DªiÄõªº¦¬®×¤¤¤ß³£¤wµ²®×) 8¤ë23¤éªº65³B¦¬®×¤¤¤ß¼Æ¾Ú°÷¤µ¦~5¤ë¦bªF¨Ê°ê»Ú¥Ö½§¯f¾Ç¬ã¨s·|·|ijµoªí¤F¡C (¨È·à±dª½±µ¬D³ÌÃøªºµoªí¡G±´°Q eblasakimab ¦bÀYÀV³¡µ¥Ãøªv³¡¦ìªºÁ{§ÉÀø®Ä) |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2023/3/15 ¤W¤È 10:14:26²Ä 6060 ½g¦^À³
|
clinicaltrials.gov/ct2/history/NCT05158023?A=12&B=13&C=merged#StudyPageTop ¤¸¤ë30¤é ·s¼W18³B©Û¶ÒÂI,¦@83³B, ¤G¤ë24¤é¤½§i³Ì«á¤@¦ì¤w©Û¶Ò. 16¶gªvÀø. ³Ì§Ö6¤ë16¤é¥i¸Ñª¼. ¥Ø«e¤w§¹¦¨16¶gªvÀøªº¥i¯àªñ65/83=78%. Ó¤H²q¤½¥q¥i¯à¬O6¤ë¤¤¤U¦¯¥ý¸Ñª¼,¥ý¥h½Í¥]¾P»ù«á,7¤ëªì¬ü°ê°ê¼y°²´Á«á¤½§G¼Æ¾Ú. |
|
|
·|û¡G¸Ø±i10133098 µoªí®É¶¡:2023/3/15 ¤W¤È 09:57:45²Ä 6059 ½g¦^À³
|
¦A¸É¥R¡G 5¤ë¦³¥i¯à¬O7¤ë¸Ñª¼«eªº³Ì«á¤@¦¸°ê»Ú¥Ö½§¯f¾Ç¬ã¨s·|·|ij¡C 쥻¤µ¦~4¤ë¨È·à±d¬On004¸Ñª¼ªº¡C ¤]´N¬O004ªº9¦¨Àø®Ä4¤ë¥÷´Nª¾¹D¤F¡C¨È·à±d¥u¬O§âì©w4¤ënµoªíªº¼Æ¾Ú¡A´«Ó¼Ò¦¡©ó5¤ëªF¨Ê°ê»Ú¥Ö½§¯f¾Ç¬ã¨s·|·|ij´¦ÅS¦Ó¤w¡C ºî¾ã¡G004ªº¼Æ¾Ú¬O¥¿¦Vªº¡C¥u¬O¤£¾å±oÀø®ÄĹ¹L§ùÁת¢¦h¤Ö¦Ó¤w¡C |
|
|
·|û¡G¸Ø±i10133098 µoªí®É¶¡:2023/3/15 ¤W¤È 09:15:02²Ä 6058 ½g¦^À³
|
³o¦¸5¤ë¦bªF¨Ê¡A¨È·à±dµoªíªº¬O±´°Q eblasakimab ¦bÀYÀV³¡µ¥Ãøªv³¡¦ìªºÁ{§ÉÀø®Ä¡A¥H¤Î¡K¡K¡K¡C (ÅÞ¿è«ä¦Ò)¤]´N¬O»¡¡G 1.«DÃøªv³¡¦ì(Âß·F¡B¥|ªÏ)©Ò®i²{ªºÁ{§ÉÀø®Ä¬O¥¿¦Vªº¡C 2.¬JµM³o¦¸¬O±´°Q¦bÀYÀV³¡µ¥Ãøªv³¡¦ìªºÁ{§ÉÀø®Ä¡A´«¥y¸Ü»¡¡A´N¬O³sÀYÀV³¡µ¥Ãøªv³¡¦ìªºÁ{§ÉÀø®Ä¤]¬O¥¿¦Vªº¡C(¤£µM´N¤£¥Î®³¥X¨Ó±´°Q¤F) |
|
|
·|û¡G³¯¤p©ú10152293 µoªí®É¶¡:2023/3/14 ¤U¤È 07:18:37²Ä 6057 ½g¦^À³
|
2023-03-14 ASLAN Pharmaceuticals «Å§G¦b²Ä¤@©¡°ê»Ú¥Ö½§¯f¾Ç¬ã¨s·|·|ij¤W±µ¨ü¨â¥÷ºKn¶i¦æ®ü³ø®i¥Ü ¥[§QºÖ¥§¨È¦{¸t°¨¯S¶ø©M·s¥[©Y¡A2023 ¦~ 3 ¤ë 14 ¤é¡]Àô²y·s»DªÀ¡^¡X¡X ASLAN Pharmaceuticals¡]¯Ç´µ¹F§JªÑ²¼¥N½X¡GASLN¡^¬O¤@®aÁ{§É¶¥¬q¡B±Mª`©ó§K¬Ì¾Çªº¥Íª«»sÃĤ½¥q¡AP¤O©ó¶}µo³Ð·sÀøªk¥H§ïÅܱwªÌªº¥Í¬¡¡A¤µ¤Ñ«Å¥¬¨â®a¤½¥q ¦b 2023 ¦~ 5 ¤ë 10 ¤é¦Ü 13 ¤é¦b¤é¥»ªF¨ÊÁ|¦æªº²Ä¤@©¡°ê»Ú¥Ö½§¯f¾Ç¬ã¨s·|·|ij¤W¡AÃö©ó eblasakimab ªººKn¤w³Q±µ¨ü¥Î©ó®ü³ø®i¥Ü¡C ·|ij¤W®i¥Üªº®ü³ø±´°Q¤F eblasakimab ¦bÀYÀV³¡µ¥Ãøªv³¡¦ìªºÁ{§ÉÀø®Ä¡A¥H¤Î¥¦¦b¯SÀ³©Ê¥Öª¢¤¤³q¹L¦hºØ¤À¤l³~®|´î»´¼ç¦bæ±Äo©M¶W±Ó·Pı¯«¸gÅÖºûªº¼ç¤O¡C ²Ä¤@©¡°ê»Ú¥Ö½§¯f¾Ç¬ã¨s·|·|ij®ü³ø¸Ô±¡ ®ü³ø 1¡G¦b 1 ´Á¬ã¨s¤¤¡AEblasakimab ³æ¤@Àøªk¥i§ïµ½¾ãÓ¸Ñå°Ï°ìªº¤¤«×¦Ü««×¯SÀ³©Ê¥Öª¢¯gª¬ ¡]ºKn½s¸¹¡G657¡^ ®ü³ø 2¡G³q¹L¨Ï¥Î eblasakimab ¹v¦V IL-13R£\1 ¨ÓªýÂ_°£æ±Äo¤§¥~ªº¯«¸g½Õ¸` ¡]ºKn½s¸¹¡G1594¡^ ®ü³ø¥i¥Î¤é´Á¡G2023 ¦~ 5 ¤ë 10 ¤é ®ü³ø±N¦bºt¥Ü«á¦b¨È·à±dºô¯¸ªº§ë¸êªÌÃö«Y³¡¤À¦b½u¬d¬Ý¡C¡C |
|
|
·|û¡G³¯¤p©ú10152293 µoªí®É¶¡:2023/3/14 ¤U¤È 06:04:31²Ä 6056 ½g¦^À³
|
¤Ñ©R¤j ¸Ø±i¤j»¡ªº´Á¤¤³ø§i¡A¤£¬O«ü¥¿¦¡ªº¸Ñª¼³ø§i¡A ¬O«üBVF¤@©w¦³¬Ý¨ì2b¬ÛÃö¸ÕÅç¼Æ¾Ú¡A ¸g¸Ó¤½¥q¬ã§P¦³¦¨¥\¾÷·|¡A¤~·|°µ¦¹¨M ©w¡A¥ý§ë¸ê2000¸U¬üª÷¡A2b¦¨¥\«á¦A§ë¤J8000¸U¬üª÷¡A |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2023/3/14 ¤U¤È 05:32:54²Ä 6055 ½g¦^À³
|
¸Ø±i¤j¡A BVF ¬Ý¨ìªº¬O¥¼¸Ñª¼ªº¦U¶µ«ü¼Ð¡A¬Ò¬O¥§¡¼Æ¡C ASLAN ·|´£¨Ñ¤À§é¡ABvF¤]·|§ä±M®a¤À§é¡C ¨S¦³´Á¤¤¸Ñª¼³ø§iªº¦s¦b¡C |
|
|
·|û¡G¸Ø±i10133098 µoªí®É¶¡:2023/3/14 ¤U¤È 05:09:46²Ä 6054 ½g¦^À³
|
BVF Partners L.P. (Biotechnology Value Fund) is a Hedge Fund Manager located in San Francisco, CA United States, North America, and was founded in 1993. , SWFI has 2 personal contacts available for CSV Export. BVF Partners L.P.¤]¬O¤@®a¹ï¨R(¥Í§Þ)°òª÷¡A¦Ó¥¦¬O¯¸¦b¨È·à±d³oÃ䪺¡ABVF Partners L.P.À³¸Ó¬Ý¹L¨È·à±d004ªº´Á¤¤³ø§i«á¤~É¥X¥x¹ô6»õ¤¸¡C²{¦bBVF Partners L.P.¦b¸ò¨ä¥L¹ï¨R°òª÷¹ï½ä¡C 7¤ë¥÷´Nª¾¹Dµ²ªG¤F¡C |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2023/3/14 ¤U¤È 12:01:04²Ä 6053 ½g¦^À³
|
¨ÌIGA0,1=44% ©Î54% ¦Ó©w, Y54%¥i¬°44%°ª¤@¿¥Ø¼Ð»ù. ¨Ì¾Ú¥D¤Oú³°ÓPiper Sandler¥Ø¼Ð»ù3*5¬ü¤¸ADR(1:25). ¥]¾P»ù=3*80%*5=12¬ü¤¸ADR(1:25).-------IGA0,1=44%,¥«È4.8»õ¬ü¤¸ ¥]¾P»ù=3*80%*2*5=24¬ü¤¸ADR(1:25).-------IGA0,1=54%,¥«È9.6»õ¬ü¤¸ ¤@.°²³]:ASLAN004 2b ,IGA0,1=44%,©MLebrikizumab ¬Û·í, ¥«³õ=dupilumab 80»õ¬ü¤¸*46%(9/15°¾¦n½Õ¬d)*50%(©MLebrikizumab ¥¤À¥«³õ)=18.4»õ¤¸¦y峄¾P°â **¤G½uAD=18.4*66%*70%(¦©°£«D¶Ç²ÎAD)=8.5»õ¬ü¤¸¦y峄¾P°â **¨ä¥L¾AÀ³¯g=18.4/.55*.45=15»õ¤¸¦y峄¾P°â-- AD§é²{26.9/20*11*95%(§é²{¦]¤l¦]¤É®§¦Ó¼W¥[)=14»õ¬ü¤¸ ¨ä¥L¾AÀ³¯g§é²{15/20*11*50%*95%=3.9»õ¬ü¤¸ ²{ª÷:3»õ¬ü¤¸ 003¥«È°²³]0.6*3=1.8»õ¬ü¤¸ ¥H¤W¦Xp=22.7»õ¬ü¤¸---³Q¨ÖÁÊ»ù ªÑ»ùADR(1:25):22.7»õ¬ü¤¸/4¸U¤dªÑADR=57¬ü¤¸/ADR----³Q¨ÖÁÊ»ù ¤G.°²³]:ASLAN004 2b ,IGA0,1=54% ¥«³õ=dupilumab 80»õ¬ü¤¸*46%(9/15°¾¦n½Õ¬d)=36.8»õ¤¸¦y峄¾P°â **¤G½uAD=36.8*66%*70%(¦©°£«D¶Ç²ÎAD)=17»õ¤¸¦y峄¾P°â) **¨ä¥L¾AÀ³¯g=36.8/.55*.45=30»õ¤¸¦y峄¾P°â-- §é²{53.8/20*11*95%(§é²{¦]¤l¦]¤É®§¦Ó¼W¥[)+30/20*11*50%*95% =28.1+7.8 =35.9»õ¬ü¤¸ ²{ª÷:3»õ¬ü¤¸ 003¥«È°²³]0.6*3=1.8»õ¬ü¤¸ ¥H¤W¦Xp=40.7»õ¬ü¤¸---³Q¨ÖÁÊ»ù ªÑ»ùADR(1:25):40.7»õ¬ü¤¸/4¸U¤dªÑADR=102¬ü¤¸/ADR----³Q¨ÖÁÊ»ù |
|
|
·|û¡G¸Ø±i10133098 µoªí®É¶¡:2023/3/14 ¤W¤È 11:13:38²Ä 6052 ½g¦^À³
|
¤Ñ©R¤j¤j3¨Æ½Ð±Ð¡G 1.¨Ì±z¤âÃä¸ê®Æ¤Î¸gÅç¨Ó¬Ý ¨È·à±d004ªº¼Ú¬w±ÂÅvª÷¬ù²ö¬O¦h¤Ö»õ¬üª÷??? Ans¡G00»õ~00»õ¬üª÷ 2.004¤T´Á©Ò»Ý¸êª÷¬ù²ö»Ý´X»õ¬üª÷ Ans¡G00»õ~00»õ¬üª÷ 3.¦©°£¼Ú¬w±ÂÅvª÷«á¡AY7¤ë ¨p¶Ò20,000¥aªÑ¡A¦X²zªÑ»ù°Ï¶¡??? Ans¡G00~00¬ü¤¸/ADR ·PÁ±z |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2023/3/14 ¤W¤È 10:49:52²Ä 6051 ½g¦^À³
|
Lebrikizumab 2b IGA0,1Àø®Ä 1.125mgxQ4W=26.6% 2.250mgxQ4W=33.7% 3.250mgxQ2W=44.6% 4.¹ï·Ó组=15.3% ¦©°£¹ï·Ó组«e¤T组¥§¡34.9% ¥¼¸Ñª¼«e¤ñDupilumab 3´Á38%/36%®t¡D Lebrikizumabªº¤½¥qDERM¸Ñª¼«eªÑ»ù§e³Ì§C¬ù5¶ô¦h¬ü¤¸¡D ¸Ñª¼«á¥]¾P»ù13.25¬ü¤¸ ³Q¨ÖÁÊ»ù18.75¬ü¤¸(11»õ¬ü¤¸) ASLAN004 2b ¨Ñ¥|组¹êÅç组¤Î¤@组¹ï·Ó组¡D Ó¤H¤ÀªRIGA0,1¡B³Ì°ª¾÷²v¡D¦p¤U¡G 1.¹ï·Ó组IGA0,1=15%¥ª¥k 2.Q4Wx400mg 27% 3.Q4WX600mg¬ù33%(ªñLebr.) 3.Q2Wx400mg¬ù45%~54% Q2Wx300mg¬ù38% |
|
|
·|û¡G«Ó°¶10144972 µoªí®É¶¡:2023/3/14 ¤W¤È 10:26:30²Ä 6050 ½g¦^À³
|
§Ú¤]§Æ±æBVFÀ£ª`¬O¹ïªº¡A¯¬ºÖ¤j®a |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2023/3/14 ¤W¤È 09:44:00²Ä 6049 ½g¦^À³
|
BVF ªá2000¸U¬ü¤¸(6»õ¥x¹ô)¡B«÷2b¸Ñª¼¦¨¥\¡B 预©w»{ªÑÅv³Ì°ª8000¸U¬ü¤¸(24»õ¥x¹ô) ±M·~¥Í§Þ§ë资°òª÷¡B¦p¦¹¤Uª`¡D |
|
|
·|û¡G«Ó°¶10144972 µoªí®É¶¡:2023/3/14 ¤W¤È 09:30:12²Ä 6048 ½g¦^À³
|
Àò§Q´î¸ê¸òÁ«·l´î¸ê®t«Ü¦h¦n¶Ü? µ´¤j³¡¤ÀªºÁ«·l´î¸ê´î¨ì³Ì«á³£¬OªÑ¼ÆÅܫܤ֪ѻù¤]ÅܫܧC Á`¤§...ÁöµM§Ú¨S½æ¡A¦ý¹ï¨È·à±d´XµL´Á«Ý §Ú¦Û¤v¤w·í§@³oµ§¿ú¨S¤F¡A¤C¤ë¦A¨Ó¬Ý¬ÝªÑ»ùÅÜ«ç¼Ë ¤j®aÀ³¸Ó¤]n¦³³o¼Ëªº»{ª¾ |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2023/3/13 ¤U¤È 11:17:26²Ä 6047 ½g¦^À³
|
¦ÑÁªº´î¸ê«Øij°ê¥¨¸³®yÅ¥¶i¥h¤F¡A ¦b·~ÁZ¦nªº®ÉÔ¨CªÑÀò§Q·|¦]¬°ªÑ¥»´î¤Ö¦Ó¼W¥[¡A´¿³y´N¤d¤¸ªÑ»ù¡A¥i¥H ·j´M¥H¤U¼ÐÃD¡A¾é¸Ñì¥Ñ °ê¥¨²Ä5¦¸´î¸ê¡n¹L¥h4¦¸½G¨ ±qÂû³J¤ô»åÅܤdª÷ªÑ ´î¸ê¬OªÑ»ù¸UÆF¤¦¡H |
|
|
·|û¡Gonly10135877 µoªí®É¶¡:2023/3/13 ¤U¤È 10:50:13²Ä 6046 ½g¦^À³
|
¦n³B¬Oadr ºÞ²z¶O¤Ö80% |
|
|
·|û¡G³¯¤p©ú10152293 µoªí®É¶¡:2023/3/13 ¤U¤È 10:27:36²Ä 6045 ½g¦^À³
|
ASLAN Pharmaceuticals Limited¡]¯Ç´µ¹F§JªÑ²¼¥N½X¡GASLN¡^ªñ´Á¦^¸¨ 25% ¼W¥[¤@¦~Á«·l¡A¹ï¨R°òª÷©Ò¦³ªÌ¥i¯à±Ä¨úÄY¼F±¹¬I «n¨£¸Ñ Ų©ó¾÷ºc«ù¦³¤j¶qªÑ²¼¡A¨È·à±dªºªÑ»ù¥i¯à·|¨ü¨ì¨ä¥æ©ö¨M©wªº¼vÅT BVF Partners L.P. ¾Ö¦³¤½¥q 63% ªºªÑ¥÷ ±N¤½¥q¹L¥h·~ÁZªº¼Æ¾Ú»P©Ò¦³Åv¬ã¨s¤@°_¨Ï¥Î¡A¥i¥H§ó¦n¦aµû¦ô¤½¥q¥¼¨Óªº·~ÁZ ASLAN Pharmaceuticals Limited¡]¯Ç´µ¹F§JªÑ²¼¥N½X¡GASLN¡^ªº¨C¤@¦ì§ë¸êªÌ³£À³¸Ó¤F¸Ñ³Ì±j¤jªºªÑªF¸sÅé¡C ¹ï¨R°òª÷¾Ö¦³70%ªºªÑ¥÷¡A¾Ö¦³¸Ó¤½¥qªº³Ì¤jªÑ¥÷¡C ´«¥y¸Ü»¡¡A¸Ó¶°¹Î±N±q¥L̹綠¥qªº§ë¸ê¤¤Àò±o³Ì¦h¡]©Î·l¥¢³Ì¦h¡^¡C ¤W¶g¡A¹ï¨R°òª÷§ë¸êªÌªº«ùªÑ»ùȤU°¤F 25%¡C ³Ìªñªº·l¥¢¥[¤WªÑªF 29% ªº¤@¦~·l¥¢¡A¥i¯à¤£·|Åý³o¸s§ë¸êªÌº¡·N¡C ¹ï¨R°òª÷³q±`±Ä¥Î¿E¶iªººÞ²z¤è¦¡¡A³q±`¥HÃöª`µu´Á§Q¼í¬°¥Ø¼Ð¡C Ų©ó¥L̦b ASLAN Pharmaceuticals ªº°ª«ùªÑ¶q¡A¥L֦̾³¥¨¤jªºÅv¤O¡A¨Ã¥B«ùÄòªí²{¤£¨Î¥i¯à¾ÉP¥L̼vÅTºÞ²z¨Mµ¦¡A¦Ó³o¨Ç¨Mµ¦¥i¯à¤£·|µû¦ô¤½¥qªºªø´Á«e´º¡C Åý§ÚÌ¥J²Ó¬Ý¬Ý¤£¦PÃþ«¬ªºªÑªF¥i¥H§i¶D§Ú̦³Ãö¨È·à±d»sÃĪºþ¨Ç«H®§¡C ¬d¬Ý§Ú̹ï¨È·à±d»sÃĪº³Ì·s¤ÀªR ©Ò¦³Åv¤À¸Ñ ¾÷ºc©Ò¦³Åv§i¶D§ÚÌÃö©ó¨È·à±d»sÃĪº¤°»ò«H®§¡H ¾÷ºc§ë¸êªÌ³q±`±N¦Û¤vªº¦^³ø»P´¶¹MÃöª`ªº«ü¼Æªº¦^³ø¶i¦æ¤ñ¸û¡C ¦]¦¹¡A¥L̳q±`·|¦Ò¼{ÁʶR¬ÛÃö°ò·Ç«ü¼Æ¤¤¥]§tªº¸û¤j¤½¥q¡C ASLAN Pharmaceuticals ¤w¸g¦bªÑ¥÷µn°O³B¾Ö¦³¾÷ºc¡C ¨Æ¹ê¤W¡A¥L̦b¤½¥q¾Ö¦³¥iÆ[ªºªÑ¥÷¡C ³o·N¨ýµÛ¬°³o¨Ç¾÷ºc¤u§@ªº¤ÀªR®v¤w¸g¬Ý¹L³o°¦ªÑ²¼¨Ã¥B¥L̳ßÅw¥¦¡C ¦ý´N¹³¨ä¥L¤H¤@¼Ë¡A¥LÌ¥i¯à¬O¿ùªº¡C ·í¦hÓ¾÷ºc¾Ö¦³¤@°¦ªÑ²¼®É¡A¥¦ÌÁ`¬O¦s¦b³B©ó¡§¾ÖÀ½¥æ©ö¡¨¤¤ªº·ÀI¡C ·í³o¼Ëªº¥æ©ö¥X²{°ÝÃD®É¡A¦h¤è¥i¯à·|Äv¬Û§Ö³t¥X°âªÑ²¼¡C ¦b¨S¦³¼Wªø¾ú¥vªº¤½¥q¤¤¡A³oºØ·ÀI§ó°ª¡C ±z¥i¥H¦b¤U¤è¬d¬Ý ASLAN Pharmaceuticals ªº¾ú¥v¦¬¯q©M¦¬¤J¡A¦ý½Ð°O¦í¡A¬G¨ÆÁ`¬O¦³§ó¦h¤º®e¡C ¦¬¯q©M¦¬¤J¼Wªø §Ú̪º¼Æ¾Úªí©ú¡A¹ï¨R°òª÷¾Ö¦³ ASLAN Pharmaceuticals 70% ªºªÑ¥÷¡C ³o¤Þ°_¤F§Úªºª`·N¡A¦]¬°¹ï¨R°òª÷¦³®É·|¸Õ¹Ï¼vÅTºÞ²z¼h¡A©Î±a¨Ó·|¬°ªÑªF³Ð³yªñ´Á»ùȪºÅܤơC ¤½¥q²Ä¤@¤jªÑªF¬°BVF Partners L.P.¡A«ùªÑ63%¡C ³o¹ê½è¤W·N¨ýµÛ¥L̹綠¥qªº¥¼¨Ó¦³¼sªxªº¼vÅT¡A¦pªG¤£¬O§¹¥þ±±¨îªº¸Ü¡C ´NI´º¦Ó¨¥¡A²Ä¤G¤jªÑªF«ù¦³¬ù 6.7% ªº¤wµo¦æªÑ¥÷¡A¨ä¦¸¬O²Ä¤T¤jªÑªF«ù¦³ 3.5% ªºªÑ¥÷¡C ¦¹¥~¡Aº®u°õ¦æ©x Carl Alan Jason Firth ¾Ö¦³¤½¥q 0.9% ªºªÑ¥÷¡C ÁöµM¬ã¨s¤@®a¤½¥qªº¾÷ºc©Ò¦³Åv¼Æ¾Ú«Ü¦³·N¸q¡A¦ý¬ã¨s¤ÀªR®vªº±¡ºü¥H¤F¸Ñ·¦V¤]«Ü¦³·N¸q¡C ÁöµM¦³¤@¨Ç¤ÀªR®v³ø¾É¡A¦ý¸Ó¤½¥q¥i¯à¨Ã¥¼³Q¼sªx³ø¾É¡C ¦]¦¹¡A¥¦¥i¥H¦b¥¼¨ÓÀò±o§ó¦hÃöª`¡C ¨È·à±d»sÃĪº¤º³¡«ùªÑ ¤º³¡¤Hªº©w¸q¦b¤£¦P°ê®a¥i¯à²¤¦³¤£¦P¡A¦ý¸³¨Æ·|¦¨ûÁ`¬O«nªº¡C ¤½¥qºÞ²z¼h¹ï¸³¨Æ·|t³d¡A«áªÌÀ³¥NªíªÑªFªº§Q¯q¡C ȱoª`·Nªº¬O¡A¦³®É°ª¼hºÞ²z¤Hû¦Û¤v¤]¬O¸³¨Æ·|¦¨û¡C ¤j¦h¼Æ¤H»{¬°¤º³¡¤H«ùªÑ¬O¿n·¥ªº¡A¦]¬°¥¦¥i¥Hªí©ú¸³¨Æ·|»P¨ä¥LªÑªF«O«ù¤@P¡C µM¦Ó¡A¦b¬Y¨Ç±¡ªp¤U¡A¹L¦hªºÅv¤O¶°¤¤¦b³oÓ¸sÅ餤¡C §Ú̷̳sªº¼Æ¾ÚÅã¥Ü¡A¤º³¡¤H¤h«ù¦³¨È·à±d»sÃĦ³¤½¥qªº³¡¤ÀªÑ¥÷¡C ¤º³¡¤H¤h¥H¥L̦ۤvªº¦W¸q«ù¦³³o®a»ùÈ 2.29 »õ¬ü¤¸ªº¤½¥q»ùÈ 290 ¸U¬ü¤¸ªºªÑ²¼¡C «Ü°ª¿³¬Ý¨ì¤º³¡¤H¤h¶i¦æ¤@¨Ç§ë¸ê¡A¦ý¥i¯àȱoÀˬd¤@¤U³o¨Ç¤º³¡¤H¤h¬O§_¤@ª½¦bÁʶR¡C ¤@¯ë¤½¦³»s ¥]¬A´²¤á§ë¸êªÌ¦b¤ºªº¤½²³¾Ö¦³¸Ó¤½¥q 13% ªºªÑ¥÷¡A¦]¦¹¤£®e©¿µø¡C ÁöµM³oºØ³W¼Òªº©Ò¦³Åv¥i¯à¤£¨¬¥H¨Ï¬Fµ¦¨M©w¹ï¥L̦³§Q¡A¦ý¥L̤´µM¥i¥H¹ï¤½¥q¬Fµ¦²£¥Í¶°Åé¼vÅT¡C |
|
|
·|û¡G³v®ö«È10146323 µoªí®É¶¡:2023/3/13 ¤U¤È 10:26:06²Ä 6044 ½g¦^À³
|
¬JµM¨S¶]¡A´N¼ÖÆ[¤@ÂI§a¡I °®£|£¸£±¤]¬O¥u¯à¬Ý¦oªíºt¡A ¦ó¤£¯¬ºÖ¦Û¤v«e³~¥ú©ú🤩 §Ú¿@ÁY«áÁÙ¦³3¸U¦hªÑ¡A ¸é²î·d¤£¦n¤]¯àº¡¸ü¦ÓÂk¡I Á|ªM¡ã¯¬§ÚÌ⋯ |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2023/3/13 ¤U¤È 10:23:23²Ä 6043 ½g¦^À³
|
¤j®a¤£¥Î¤Ó´dÆ[¡A³Ì¤Ö½æÀ£´î¤Ö¦Ê¤À¤§¤K¤Q¡A½æÀ£¤Ö¸I¨ì¦n®ø®§·|³y¦¨°l»ùªºÁ`¶R¶i²{¶H¡C |
|
|
·|û¡G«Ó°¶10144972 µoªí®É¶¡:2023/3/13 ¤U¤È 09:55:53²Ä 6042 ½g¦^À³
|
´N¬O¸é²î¨S¿ù...§Ú³Ñ4000ªÑ´N·íÃz±¼¤F |
|
|
·|û¡G³¯¤p©ú10152293 µoªí®É¶¡:2023/3/13 ¤U¤È 04:43:25²Ä 6041 ½g¦^À³
|
¬Ý¨ìªÑ¼ÆÅܦ¨7620ªÑ ¤ß²z«Ü·F¡A¤W¤F¸é²î¡Ä ¤@¯ë´î¸ê«á·|¦AÄò¶^ |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2023/3/13 ¤W¤È 10:15:30²Ä 6040 ½g¦^À³
|
2020/08/25 ADR:ì©lªÑ=1:5 ,1/5=0.20 2023/03/13 ADR:ì©lªÑ=1:25, 1/25=0.04 ¤µ¤Ñªº¥½L»ù=0.571*5=2.855¬ü¤¸ ú³°Ó¥Ø¼Ð»ù²z½×¤W¬°: 3*5 ~ 4.5*5=15~22.5¬ü¤¸ |
|
|
·|û¡G¸Ø±i10133098 µoªí®É¶¡:2023/3/13 ¤W¤È 09:51:21²Ä 6039 ½g¦^À³
|
ìªÑ¼Æ*0.04 ¦¬¨ì²°T ¤µ¤Ñ¥Í®Ä ¦³ºâ¿ù¶Ü??? |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2023/3/9 ¤U¤È 08:51:17²Ä 6038 ½g¦^À³
|
ASLN is undergoing a reverse split of 1:5 on March 13 ASLN¦b3¤ë13¤é¶i¦æ1:5ªº¤Ï¦V©î¤À(´î¸ê) www.nasdaq.com/market-activity/stock-splits |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2023/3/7 ¤W¤È 11:52:35²Ä 6037 ½g¦^À³
|
2023¦~/3¤ë6¤é ¤î ¤wµo¦æ424,870¤dªÑì©lªÑ/(84,974 ¤dªÑADR) BVF ¶°¹Î¦û9.99%«ùªÑ.¬ù8500¤dªÑADR(1:5) ¥¼¥]§t»{ªÑÅv: ¬ù38,000¤dªÑADR,1A/1B/2A/2B, 1A/1B(004¸Ñª¼)¦û55%)// 2A/2B(003¸Ñª¼)¦û45% BVF¶°¹ÎÁ`«ùªÑ(§t»{ªÑÅv)¹F¬ù46,500¤dªÑADR, ¦û¥¼¨ÓÁ`µo¦æªÑ20¸U¤dªÑADR(1:5)¬ù23% |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2023/3/7 ¤W¤È 08:54:40²Ä 6036 ½g¦^À³
|
ir.aslanpharma.com/static-files/600458ef-6f6c-4770-9d91-5d1e3f8930c7 3¤ë6 ¤é, »{ªÑÅv10®a¤½¥q(2Ó¶°¹Î)ªº¸Ô²ÓªÑ¼Æ,95%¥H¤W¶°¤¤¦bBVF¶°¹Î. ¥»¦¸¨p¶Ò59,957,865ì©lªÑ/(11,991¤dªÑADR). ¤wµo¦æ424870¤dªÑì©lªÑ/(84,974 ¤dªÑADR) ¥H¤U¦Ê¤À¤ñ°ò©ó¤À¥À¡A¤À¥À¬°¡G(i) ºI¦Ü 2022 ¦~ 6 ¤ë 30 ¤éªº 348,723,365 ªÑ¤wµo¦æªÑ²¼¡A ³o¬Oµo¦æ¤H¦b¦VÃҨ鴣¥æªº 424B5 ªí®æªº©ÛªÑ»¡©ú®Ñ¤¤©ÜÅSªº¤wµo¦æªÑ¥÷Á`¼Æ¡A¥H¤Î ¥æ©ö©eû·|©ó 2022 ¦~ 9 ¤ë 30 ¤é¡A(ii) 59,957,865 ªÑ¦]µo¦æ¤Hªº¨p¶Òµo¦æ¦Óµo¦æªº ©ó 2023 ¦~ 2 ¤ë 24 ¤éÃö³¬¡A¦p 2023 ¦~ 2 ¤ë 24 ¤é¦V¬ü°êÃÒ¨é¥æ©ö©eû·|´£¥æªº 6-K ªí®æ¤¤ªºµo¦æ¤H³ø§i¤¤©Òz (iii) 16,190,000 ªÑ³ø§i¤H¾Ö¦³ªº¬Y¨Ç¹wª`¸ê»{ªÑÅvÃÒªº¬ÛÃöªÑ¥÷¡]¦p¾A¥Î¡^¡C The following percentages are based on a denominator which is the sum of: (i) 348,723,365 Shares outstanding as of June 30, 2022, which is the total number of Shares outstanding as disclosed in the Issuer¡¦s Prospectus on Form 424B5 filed with the Securities and Exchange Commission on September 30, 2022, (ii) 59,957,865 Shares issued in connection with a private placement by the Issuer that closed on February 24, 2023 as reported in the Issuer¡¦s Report of Foreign Issuer on Form 6-K filed with the SEC on February 24, 2023 and (iii) 16,190,000 Shares underlying certain Pre-Funded Warrants owned by the Reporting Persons, as applicable. |
|
|
·|û¡G³¯¤p©ú10152293 µoªí®É¶¡:2023/3/6 ¤U¤È 10:34:44²Ä 6035 ½g¦^À³
|
¬ü°ê¤H¤w¤W¯Z¤F ªÑ»ùªÑ¼Æ¦p |
|
|
·|û¡GªL®õ10030886 µoªí®É¶¡:2023/3/6 ¤U¤È 07:31:26²Ä 6034 ½g¦^À³
|
¬ü°ê¤HÁÙ¨S¦³¥¿¦¡¤W¯Z |
|
|
·|û¡G³¯¤p©ú10152293 µoªí®É¶¡:2023/3/6 ¤U¤È 05:59:07²Ä 6033 ½g¦^À³
|
¤µ¤Ñ½L«e½L¡A ªÑ»ùÁÙ¬O¨SÅÜ¡Aºû«ù0.7575¤¸ ´î¸ê¤é´ÁÁÙ¨S¨ì¶Ü¡A |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2023/3/6 ¤U¤È 01:34:08²Ä 6032 ½g¦^À³
|
°²³]°ò缐EASI28 EASI90 ,¥¼³Q²M°£ªÌ³Ñ2¡P8¤ÀªºEASI ¥¼¹FIGA01,§Y¦³2/3Ó³¡¦ì¥¼§¹¥þ²M°£¡C ¨C¤@³B¬O¤@¤À©Î¤G¤ÀªºªºEASI °ò¥»¤W¦³9¡ã16¶gªº®É¶¡¨Ó§¹¥þ²M°£¡AÀ³¸Ó«Ü®e©ö¡I |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2023/3/6 ¤U¤È 01:19:08²Ä 6031 ½g¦^À³
|
ir.aslanpharma.com/static-files/5af23249-0b59-4bb1-95eb-199556171feb 6¤Hªº400mg ²Õ, EASI90 °ª¹F67% ¤@¯ë¤T´Á16¶gªºÁ{§ÉÀø®Ä ¹FEASI90 ªº¤ñ²v§C©óIGA0,1 1.Dupilumab ¤T´Á ¤GÓÁ{§É: IGA0/1 38%/36% EASI90 36%/30% www.nejm.org/doi/full/10.1056/nejmoa1610020 2.Lebrikizumab IGA0/1 43%/33.1% EASI90 38.1%/30.2% www.almirall.com/documents/portlet_file_entry/4257831/300322_ORI+Lebri+pres+ENG+%2B+pres+vf.pdf/5ad7034f-0dd9-492f-eb83-1515071417de IGA0,1: °ò½u©Û¦¬IGA0,1=4 ©Î3. §¹¥þ²M°£=IGA0 ¨ä¤¤¦³¤@³¡¦ì¨S§¹¥þ²M°£,IGA=1 ¨ä¤¤¦³¤G³¡¦ì¨S§¹¥þ²M°£,IGA=2 ¨ä¤¤¦³¤T³¡¦ì¨S§¹¥þ²M°£,IGA=3 ¨ä¤¤¦³¥|³¡¦ì¨S§¹¥þ²M°£,IGA=4 ¨Åé¦@¤À¥|¿³¡¦ì. IGA0,1,ªí¥Ü0©Î1Ó³¡¦ì©|¥¼§¹¥þ²M°£. ------------------------------- EASI¿Å¶q¨t²Î ¥þ¨¥ç¤À¥|Ó³¡¦ì, ¨CÓ³¡¦ì³Ì°ª18¤À,(¦³¼ÆÓ¤p¶µ¥Ø: ¬õ¯l...) --------------------------------- IGA0/1 38%.36% EASI90 34%/32% |
|
|
·|û¡G§d½n¶¯10142119 µoªí®É¶¡:2023/3/6 ¤U¤È 12:44:44²Ä 6030 ½g¦^À³
|
IGA 0/1¥NªíÁ{§Éªv·U²v¡A 004¦b1b 8week Mitt 400mg¹êÅç²ÕVS¹ï·Ó²Õ¬°14%:15% 600mg¹êÅç²ÕVS¹ï·Ó²Õ¬°44%:15% ©Ò¥H¤Ñ©R¤j¤~¥Î44¢H§@¬°IGA 0/1ªº´Á«ÝÈ Dupilumab¬O¦b²Ä12 week¤~¹F¨ìÅãµÛ ¹ï¤ñ©óLeb. 2b 8week IGA 0/1¹êÅç²ÕVS¹ï·Ó²Õ¬°31%:5%¡]26¢H¡^ 2b 16week IGA 0/1¹êÅç²ÕVS¹ï·Ó²Õ¬°45%:15%¡]30¢H¡^ IGA 0/1»Ýn®É¶¡¨Ó±À¶i¡Kµ¥«ÝÁ{§É¼Æ¾Ú¨Ó¸Ñµª |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2023/3/6 ¤W¤È 11:55:10²Ä 6029 ½g¦^À³
|
www.globenewswire.com/news-release/2022/01/05/2361507/0/en/Connect-Biopharma-Reports-Detailed-Positive-Dataset-from-the-Global-Phase-2b-Trial-of-CBP-201-in-Adult-Patients-with-Moderate-to-Severe-Atopic-Dermatitis.html CBP201 2B IGA0,1 28.1% VS 10.7% (¬Û®t17.4%) °ò½u¦ôEASI25 2.Dupilumab ¤T´Á IGA0,1 ¤GÓ¤T´Á©M¹ï·Ó²Õ¬Û®t28% (38%/10%) (26%/8%) 3.Lebrikizumab mmm ¤T´Á¨âÓÁ{§ÉIGA0,1 www.almirall.com/documents/portlet_file_entry/4257831/300322_ORI+Lebri+pres+ENG+%2B+pres+vf.pdf/5ad7034f-0dd9-492f-eb83-1515071417de AdvO.1 43%VS12.8%(29.6%) ADVO.2 33.1%VS12.9%(22.2%) °ò½u: EASI28.8/29.7 °ê»Ú¤W¬Ýªº¬O©M¹ï·Ó²Õªº¬Û´î®t²§.¤Îµ´¹ïªº¤ñ²v CBP201 ªº¤¤°ê2bÁ{§É¤v°µ§¹,IGA0,1 ¥ý«e®t¤£¦h, ¥Ø«e¶Ò¤£¨ì¤T´Á¸êª÷¬O¨Æ¹ê. |
|
|
·|û¡G³¯¤p©ú10152293 µoªí®É¶¡:2023/3/6 ¤W¤È 11:34:06²Ä 6028 ½g¦^À³
|
CNTB CBP2012b IGA0,1 29%vs10%(¹ï·Ó组)¡A¬ù¬°2.9¿ ASLAN004¦p¸¨¦b IGA0,1 44%vs15%(¹ï·Ó组)¡A¬ù¬°2.93¿ ¹ïCNTB¦³¦óÀu¶Õ¦s¦b¡H |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2023/3/6 ¤W¤È 11:12:28²Ä 6027 ½g¦^À³
|
¤½¥q9/15¤é¡BR and D day °²³]°ª©ódupilumab 8% À³¬O¦X²z预´Á¡D ¤½¥q¤@ª½±j½Õ³s¦X¤G½uAD¡B¥i¦¨¬°¤@½uº¿ï¡D ©Ò¥H¸¨¦bIGA0,1=44%/15%(¹ï·Ó组) ¾÷·|«D±`¤j¡D ¸¨¤JCBP201§CÀø®Ä组¡B«D±`§C¡D §_«hBVP¤ÎK ¤½¥q¡B¤£·|¥æ2000¸U¬ü¤¸¡D¶R¶i23%¤äªÑ¡B联¦X8000¸U¬ü¤¸ªº»{ªÑÅv§Q¡D ³oºØ¤½¥q«Ü¼F®`ªº¡D |
|
|
·|û¡G¸Ø±i10133098 µoªí®É¶¡:2023/3/6 ¤W¤È 10:32:25²Ä 6026 ½g¦^À³
|
¥Ø«e¥«³õµ¹ASLN ªº¥«»ù¡B´N¦p¦PCNTB ¥¼¨Ó004¸Ñª¼ªºÀø®ÄY¦pCBP201, ¥iÃø¶Ò¤T´Á¸êª÷¡D ½Ð±Ð¤Ñ©R¤j¤j ´N±z¤â¤W²{¦³¸ê°T ¥¼¨Ó004¸Ñª¼ªºÀø®ÄÀu©óCBP201 ªº¾÷·|¬O¦p¦ó??? |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2023/3/6 ¤W¤È 09:37:39²Ä 6025 ½g¦^À³
|
BVF ¤½¥q¶ÈºÞ²z49»õ¬ü¤¸ªº¤p¤½¥q¡D ASLN³Q¨ÖÁʪºÁͶդ£ÅÜ!(³Ì¥i¯à状ªp) ¦³¤组¥¼¸Ñª¼ªº¼Æ¾Ú²V¦b¤@°_¡B¹ê¦b¤£ª¾³Ì¦n¤@组·|°ª¨ì¨º¸Ì¡D Lebrikizumab 2b IGA0,1 Q2Wx250mg=44% Q4Wx250mg=33% ¹ï·Ó组=15% ¥H¤W¥¼¸Ñª¼ªº¼Æ¾Ú²V¦b¤@°_¡B¹ê¦b¤À¤£¥X¡D ¥»¦¸¨p¶Ò0.89¬ü¤¸¡D ASLN¥«È8900¸U¬ü¤¸¡D ©MCNTB 7000¸U¬ü¤¸¥«È®t¤£¦h¡D CNTB CBP2012b IGA0,1 ¶È 29%vs10%(¹ï·Ó组) EASI75=47% ¥Ø«e¥«³õµ¹ASLN ªº¥«»ù¡B´N¦p¦PCNTB ¥¼¨Ó004¸Ñª¼ªºÀø®ÄY¦pCBP201, ¥iÃø¶Ò¤T´Á¸êª÷¡D |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2023/3/6 ¤W¤È 09:03:18²Ä 6024 ½g¦^À³
|
BVF is based out of San Francisco. BVF is a hedge fund with 5 clients and discretionary assets under management (AUM) of $4,920,045,461 (Form ADV from 2022-03-31). Their last reported 13F filing for Q4 2022 included $2,369,483,196 in managed 13F securities and a top 10 holdings concentration of 45.23%. BVF¡¦s largest holding is MoonLake Immunotherapeutics with shares held of 21,751,284 whalewisdom.com/filer/bvf-inc-il |
|
|
·|û¡G§d½n¶¯10142119 µoªí®É¶¡:2023/3/6 ¤W¤È 09:03:16²Ä 6023 ½g¦^À³
|
¼W¸ê¬O¥ÑBVF Partners LP¡BK2 HealthVentures ©M¬Y¨Ç²{¦³§ë¸êªÌ©Ò°^Ämªº ¨Ã¤£¬O³£¥ÑBVF´£¨Ñ... K2 HealthVentures¦b2021¦~¦³´£¨Ñ2000+2500¸U¬ü¤¸ªº¿Ä¸ê¡A³o¦¸¬O¦A¥[½X... |
|
|
·|û¡G³v®ö«È10146323 µoªí®É¶¡:2023/3/6 ¤W¤È 08:48:58²Ä 6022 ½g¦^À³
|
«Øij¡G 1¡B¥¼¶RªÌ¡G³o®a¤½¥q¹L©¹§¢©V¡A«e´º³ô¼~¡A¸ê°T¤£©ú¡A¤£©y¶R¤J¡C 2¡B¤w¶R¬Ý®tªÌ¡G³o®a¤½¥q«ù¦³h¤ß¡A¸ê°T¥i¯à¤£¹ê¡A¬°ÁקK³Ò¯«¶Ë°]¡A¶X¥¼¤U¥«¡A°±·l½æ¥X¡C 3¡B¤w¶R¬Ý¦nªÌ¡GÁa¨Ï¼ÖÆ[¡A¦ý§ë¸ê·sÃĪѡA¥ô¦ó¤½¥q¦b·Nªº±q¨Ó³£¤£·|¬O§ë¸ê¤H¡A»{¯uµû¦ô«ù¦³¡C 4¡B·¥«×¼ÖÆ[ªÌ¡GÄ~ÄòµL·NÃÑ«ù¦³¡Aµ¥Â½µP¬Ýµ²ªG¡A¿é¤F§Oú¡AŤF¦Û¤v¯º¡C |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2023/3/6 ¤W¤È 08:45:18²Ä 6021 ½g¦^À³
|
BVF ¡]¥Í§Þ²£·~ªº§ë¸ê°òª÷¤½¥q¡^¡A¦ûASLNªÑÅv¤w¦¨³Ì¤j¡C ¤@¡B2¤ë©³¨p¶Ò0.8895¬ü¤¸¡þADR ¡]1:5¡^¡A»{ÁÊ2000¸U¬ü¤¸¡A112¡A359¡A550ªÑì©lªÑ¡]22¡A471¡A910ADR¡^x$0.178 ¥Ø«e¤wµo¦æ¶q¡]§t¤º¿EÀy¡^¬ù10¸U¤dªÑªºADR¡C BVF «ùªÑ22471¤dªÑADR¡A¦û22¡P47%¡]³Ì¤jªÑªF¡^ ð¸ê¥»¤½¥q«ùªÑ5364¤dªÑADR¡A¦û5.36%¡]²Ä¤G¤jªÑªF¡^ ²H°¨¿ü¤½¥q«ùªÑ1678¤dªÑADR ¦û1¡P67%¡]²Ä¤¤jªÑªF¡^ ¤G¡BBvFªº»{ªÑÅv ¦@¬ù55¡A309¤dªÑADR¡]1:5¡^¡A³Ì°ª»{ÁÊ8000¸U¬ü¤¸ 1¡B004 2b ¸Ñª¼¼Æ¾Ú¤½¥¬«á60¤Ñ¤º¡C ¡]1¡^50% ¡A¨Ì1.3¬ü¤¸p»ù¡C»{Áʼƶq¦ô40%¡]1.3/1.63=79.75%,¨Ì³æ»ù¦ô004¦û80%¡A003¦û20%¡^¡A55¡A390x40%=22,156¤dªÑADR (2)50% ¡AMAX(¨Ì¼Æ¾Ú¤½¥¬«á¤@¬q®É¶¡ªº¥[Åv¥§¡³æ»ùx50%,1¡P3¬ü¤¸¡^ 2¡B003 2A ¸Ñª¼¼Æ¾Ú¤½¥¬60¤Ñ¤º¡C ¡]1¡^50%¡A¨Ì1.63¬ü¤¸¡A»{Áʼƶq¦ô10%¡A55¡A390x10%=539¤dªÑ¡AADR¡C ¡]2¡^50% ¡AMAX(¨Ì¼Æ¾Ú¤½¥¬«á¤@¬q®É¶¡ªº¥[Åv¥§¡³æ»ùx50%,1¡P63¬ü¤¸¡^ ¥¼¨ÓªÑ¥»ADR´î¸ê«á4¸U¤dªÑ¡C BVF«ùªÑ ¡]¬ù55¡A309+22¡A471/5=11,511¤dªÑ¡]ADR 1:25¡^ 11¡A511/40¡A000=28.78% ¥H¤W¸Ñª¼¼Æ¾Ú>=BvFªº¹w´Á¡C¤è·|°õ¦æ»{ªÑÅv¡C BVF¬O²{¦b¤Î¥¼¨Ó¤@¦~¤º³Ì¤jªÑªF¡A¤w¬O¨Æ¹ê¡C |
|
|
·|û¡G³¯¤p©ú10152293 µoªí®É¶¡:2023/3/6 ¤W¤È 08:13:32²Ä 6020 ½g¦^À³
|
³o®a¥»¨Ó´N¬O¥Ö¥]¤½¥q¶BÄF¶°¹Î¡A ¤@¨ÆµL¦¨¡A¥u³Î韮µæ ²{¦b´î¸ê¡A¥¼³qª¾©Ò¦³ªÑªF¡A´N¬O´ÛÄF 2b´Á¤¤¼Æ¾Ú¦pªG¤£¿ù¡Aì©l¤jªÑªF¦p²H°¨¿ü·|¤£À´§ë¸ê¶Ü¡A ´N¬O¦]¬°¹ï¤½¥q°ª¼hªº§@¬°¥¢±æ ¥¼¤½¶}¤§«e»¡ªº¼Æ¾Ú·Án¡A¥i¯à³£¬O¬°»~¾É¤j²³¡A±q¥xÆWÄF¨ì¬ü°êªº¦L«×ªü¤TCEO ªü«i ¡A ³o®a¤½¥q¸Û«H¦³°ÝÃD¨S±Ï¤F¡A§O¦A¬°¥L»¡¸Ü¤F¡A |
|
|
·|û¡Gjimmylin10141563 µoªí®É¶¡:2023/3/5 ¤U¤È 11:27:16²Ä 6019 ½g¦^À³
|
¨«¨ì¤µ®É¤µ¤é®Ú¥»°ÝÃD´N¬O±qasln1~3¸Ñª¼³£¥¢±Ñ ±q¦Û¤j¦Û¸ó¸Ø¨ì²{¦b¤´¤@¨ÆµL¦¨¡A±qÀù¯g¥ÎÃħﰵ¥Öª¢¤@´Á¤´¤£²z·Q¡A ¨C¨C½Ð¤ÀªR®v³Û°ª»ù¡A«o¤´©ñ¥ôªÑ»ù¶^¸¨¨¦©³¨ì§Ö¤U¥« Á{§É¼Æ¾Ú±q¤£³z©ú¡A¹ï§ë¸ê¤H¸ê°T¤£¹ïºÙ¤£¤Íµ½¡A «Øij¤£n¹L«×¼ÖÆ[¤ñ»ù¨ä¥LÃļt¡A³o®a¤½¥q¤j¤á¬O¨S¦bÅUªº µ¥¤HÄ@·N¦¬ÁʦӤw |
|
|
·|û¡G³v®ö«È10146323 µoªí®É¶¡:2023/3/5 ¤U¤È 10:46:46²Ä 6018 ½g¦^À³
|
Ó¤H¬Ýªk¡G ¤@¯ë§ë¸ê¤HÁ`·|»{¬°´î¸ê¬O¤£§Qªº¡A¦ý¨ä¹ê´î¸ê·í¤U¡AªÑ´î»ù¼W¡AÁ`»ùÈÁÙ¬O¤£Åܪº¡F nÃö¤ß¯d·Nªº¬O¥H«áªºµo®i¡F ¥xªÑ´î¸ê«á¨götªº®×¨Ò¤£³ÓªTÁ|¡A¨Ò¦p°ê¥¨¡BÛ¸¡B¥ß³Í⋯³£¬O¥¿±ªº®×¨Ò¡C ¨Æ±¡Á`¬O¦³È±oÆ[¹îªº¦a¤è¡A´²¤á©Ò¯à°µªº¡ã´N¬OÆ[¹î¡ABVFªº§ë¤J§Y¬O¡I ±¯½´¦¶}«e´N¬ORiskªº®£Äß¡A´¦¶}«áªÑ»ù¤]³\¤w¹L¸U«¤s¡I §à¾Ü¨S¦³¹ï¿ù¡A«eµ{¦¹¥h¨â¯í¯í¡AºÝ¬ÝÓ¤H³y¤Æ¡I |
|
|
·|û¡G©t¨àÃÄ10140658 µoªí®É¶¡:2023/3/5 ¤U¤È 09:50:35²Ä 6017 ½g¦^À³
|
³o¬q®É¶¡¨ÇÁÂÁ¤j®a¦b¦¹ª©¤W¤À¨É«Ü¦h·Qªk¸òÆ[ÂI¡A´Ý§ÔªºX«i°µ¤F´î¸êµLºÃ¬O¹ï¥xÆWì©l§ë¸ê¤H³Ì¤jªº¶Ë®`(¥xªÑ«ù¦³¦Ü¤µÁY´î¤F1/25)¡A§ë¸ê¥»¨Ó´N¬O¿éŦU¦³¡A¬ÕÁ«¦Ût¡A©Ò¥H¤]¨S¬Æ»ò¦n©ê«è;³Ì«á¤@ÂI¤p¬Ýªk¤À¨É¡A¦pªG¨S¦³¥¿¦V´Á¤¤¼Æ¾Ú¡Aªí©w7¤ë¸Ñª¼n¦nªº¾÷·|¤£°ª¡A³Ì«á§Æ±æ·s·à¤Í³£¯à¥þ¨¥þ°h¡C |
|
|
·|û¡G«Ó°¶10144972 µoªí®É¶¡:2023/3/5 ¤U¤È 07:13:30²Ä 6016 ½g¦^À³
|
¬Ý«e±ª©¤Í´£¨ìºÞ²z¶O §Úµo²{§Ú¨È·à±d¥h¦~¨S¸ò§Ú¦¬ºÞ²z¶OC «e¦~¦³¦¬¡A¥h¦~¨S¦¬ ¬O¦]¬°¥h¦~¶^¤Ó¦h©ó¤ß¦³·\¶Ü? |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2023/3/5 ¤U¤È 12:15:03²Ä 6015 ½g¦^À³
|
¤Ñ©R¤j ±À½×«Ü¦X²z¡A¥X¿úªº¬O¦Ñ¤j¡A¦b«O±K¨óij¤UÀ³¸Ó¥i¥H¬Ý¨ì¥¼§¹¦¨ªº¤Gb¼Æ¾Ú¡A¼Æ¾Ú¤£¨Î·F¹À¥X¿ú»{ªÑ¡H |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2023/3/5 ¤W¤È 10:54:41²Ä 6014 ½g¦^À³
|
¥xÁÞ¤j¡A Á׶}3¤ë26¤éªº¤U¥«·ÀI¡C n¶}ªÑªF·|¶·¤½§i¤@Ó¤ë¡C ⋯⋯ ¤ß±o¡G BVF ¥i¯à¬Ý¹L¥Ø«e¤x¦³¡A§¹¦¨16¶gªvÀøªº¥¼¸Ñ¨w¼Æ¾Ú¡]¬ù80%¡^¤~·|¥ý»{ÁÊ2000¸U¬ü¤¸ªºADR¡C¡]2¤ë27¤é§¹¦¨¡^ ¤½¥q¤]¥²´£¥X¥i²Õªº¼Æ¾Ú¹w´ú¡A¤~¦³¥t¥~8000¸U¬ü¤¸ªº»{ªÑ¿ï¾ÜÅv¡C 1.3/50%x5=13¬ü¤¸¡]¤½¥q»{¬°2b¸Ñª¼«á¡A¥i¯à¹F¨ìªº³Ì§C¥§¡¥«»ù¡^ 13¬ü¤¸x4¸U¤dªÑADR=5.2»õ¬ü¤¸¡]2b¸Ñª¼¦¨¥\³Ì§C¥«È¡^ 2ú³°ÓADR¥Ø¼Ð»ù15¡ã22.5 ¶Ò¸ê»ù=¥Ø¼Ð»ùx80% ¡×12¡ã18¬ü¤¸ ¥«È4.8»õ¬ü¤¸¡ã7.2»õ¬ü¤¸¤§¶¡¡C ¥Ñ¥H¤W¤ÀªR¡A2b¸Ñª¼³Ì¨ÎQ2w*400mg ²ÕªºÀø®ÄIGA0,1À³¸Ó¸¨¦b44%vs15%¡]¹ï·Ó²Õ¡^¡C Y¤j´T©Ô¤WIGA0,1 50%-60%¡A¤~¦³©Ô°ª¥Ø¼Ð»ùªº¾÷·|¡C IGA0¡A1 ¤£¦p¹w´Á¡ABvF¤£·|»{2000¸U¬ü¤¸ADR¡C¤G½uAD¤]·|¥[³t¶i¦æ¡A¤G缐Á{§É¸ê°T¤x40¤Ñ¥¼§ó·s¤F¡C ¤G½uªº°ÝÃD¡A¥i¯à·|¿z¿ï±¼¬Æ¦hªº«D¶Ç²ÎAD¡]«D¤G«¬ª¢¯g¡^±wªÌ¡C ¥H¤WÓ¤HÆ[¹î¤ß±o¡C |
|
|
·|û¡G³ßô10031624 µoªí®É¶¡:2023/3/5 ¤W¤È 10:25:25²Ä 6013 ½g¦^À³
|
ºI¿ý·à¤lªº¤½§i«nÃöÁä ½Ð°Ñ¾\¤U± ¼¯®Ú¤j³q银¦æ¡AN.A¡C 麦}逊¤j¹D383号¡A11楼 纽约¡A纽约¡A电话¡G10179 ª`·N¡G¦s¦«ú«证¶°团 邮½c¦a§}¡GDR _ Global _ CSM@jpmorgan.com ¡]¤G¡^ ASLAN Pharmaceuticals Limited ²H马锡¤j¹D3号¡A18层¡A ¦Ê¦~纪©À¶ð¡A ·s¥[©Y039190 ª`·N¡GKiran Asarpota¡Aº®u财务©x 电¤l邮¥ó¦a§}¡Gkiran.asarpota@aslanpharma.com ªþ赠电¤l邮¥ó¦Ü¡Gben.goodger@aslanpharma.com ¥H电¤l«H®§传°e¤è¦¡发°e³qª¾¡A应视为¦b发¥ó¤H开©l¦V¤Wz电¤l邮¥ó¦a§}发°e³qª¾¡]¦p发¥ó¤Hªº记录©Ò¥Ü¡^时¦³®Ä¡A§Y¨Ï预©w¦¬¥ó¤H¦b¥H¦Zªº¤é´Á¨ú¦^该邮¥ó¡B¥¼¯à¨ú¦^该邮¥ó©Î¥Ñ¤_¨ä¥¼¯à«O«ù«ü©wªº电¤l邮¥ó¦a§}¡B¥¼¯à«ü©w´À¥N电¤l邮¥ó¦a§}©Î¥X¤_¥ô¦ó¨ä¥Lì¦]¦Ó¥¼¯à¦¬¨ì该³qª¾¡C ²Ä2.06节¡C¦Û«O¦s¤Hº¦¸«Å¥¬¤§¤é°_¡A¨C¥÷ADS©Ò¥NªíªºªÑ¥÷数¶q应从¡§5¡¨×§ï为¡§25¡¨¡C ²Ä2.07节¡C发®i¦¨ªG评¦ôªí®æ²Ä¡]5¡^´Ú²Ä¤G¥y¥H¤Î©Ò¦³©|¥¼执¦æªº发®i¦¨ªG评¦ô×¥¿¦p¤U¡G «O¦s¤H©Î¨ä¥ô¦ó¥N²z¤H§¡¤£对ADS©MADRªº«ù¦³¤H©Î¨ü¯q©Ò¦³¤H¤£¿í¦uÓì¥Îªº税ªk¡B规则©M/©Î条¨Ò©Óü®责¥ô¡C尽ºÞ«O¦s¤H¦³权n¨D现¥ô©M«e¥ô¨ü¯q©Ò¦³¤H¥I´Ú¡A¦ý«O¦s¤H¡]¥H¤Î©Ò¦³«e¥ô«ù¦³¤H¡^©Ó认¦}¦P·N¡A«O¦s¤H没¦³úå务n¨D现¥ô©Î«e¥ô¨ü¯q©Ò¦³¤H¤ä¥I¥»´Ú©Ò规©wªº¤í´Ú¡C ²Ä2.08节¡C发®i¦¨ªG评¦ôªí®æ²Ä¡]5¡^¬q²Ä9¥y¥H¤Î©Ò¦³©|¥¼执¦æªº发®i¦¨ªG评¦ô×¥¿¦p |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2023/3/5 ¤W¤È 10:04:31²Ä 6012 ½g¦^À³
|
·PÁ¤ѩR¤j Pica¤j»¡©ú ªk³Wªº¨Æ±¡n¾é¸Ñªº¤H¤~À´¡A¶}Ó¸³¨Æ·|´N¨M©w¡A¥¼§K¤Ó¹L±MÂ_¡C |
|
|
·|û¡GPica10150664 µoªí®É¶¡:2023/3/5 ¤W¤È 08:52:42²Ä 6011 ½g¦^À³
|
¥u¦³ÁÈ¿ú®É¡A¤~·|¥Î¬Õ¾l°tªÑ¡AÅýªÑªFªºªÑ¼Æ¼W¥[¡AªÑ»ù°§C¡A°§C¶RªÑªºªùÂe¡C |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2023/3/5 ¤W¤È 08:51:16²Ä 6010 ½g¦^À³
|
¥¼¨Óªº2¸UADR¡]1:25¡^¡ABVF¡A¥i¥ý»{ªÑ¬ù1¸UªÑ¡]1.3*5=6.5¬ü¤¸/1.6*5=8¬ü¤¸©Î¥§¡ªÑ»ùx50%°ª»ùªÌ¡^¡C¶Ò8¤d¸U¬ü¤¸¡C ¥t¥~¬ù1¸UªÑ2b¸Ñª¼«á¶Ò¸ê¥Î¡C ©Mì©lªÑªFµLÃö¡C |
|
|
·|û¡GPica10150664 µoªí®É¶¡:2023/3/5 ¤W¤È 08:47:17²Ä 6009 ½g¦^À³
|
¥x¿}¤j¡A ¼W¸êÀ³¸Ó¬O§ä¤H¤J¸ê¡AµM«áµ¹¥LªÑ²¼¡C ¸ò§Ú̳o¨Ç¦ÑªÑªFµLÃö¡C §Ú̪ºªÑ¼Æ´N¬O³Ñ1/5¦Ó¥H¡C |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2023/3/5 ¤W¤È 08:31:57²Ä 6008 ½g¦^À³
|
¤Ñ©R¤j ¥Ø«eÁ`µo¦æ¶q10¸U¤dªÑ ADR ÁY¬°2¸U¤dªÑADR,¥¼¨Ó·|¦A¼W¸ê¨ì4¸UªÑADR(100¸U¤dªÑì©lªÑ)¡A¥¼¨Ó¼W¥[4¸UªÑ¤j®a«ùªÑ昰§_¨Ì¤ñ²v¼W¥[¡H ¤]´N¬O¤QªÑÅܦ¨¨âªÑ¡A¦AÅܦ¨4ªÑ¡C ¥Ø«e¦³¤H«ùªÑ¯uªº´î¤Ö¦Ê¤À¤§80¶Ü¡H |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2023/3/5 ¤W¤È 08:04:18²Ä 6007 ½g¦^À³
|
BVF ¤½¥qªº¨p¶Ò³æ»ù0.178¬ü¤¸/ì©lªÑ ,ADR(1:25) ¦¨¥»4.45¬ü¤¸. *** purchase price of $0.178 per Ordinary Share ADR ,1:25 0.178*25=4.45¬ü¤¸------ BVF ·sªºADR¦¨¥» -------------------------------------------------------------------- ASLAN Pharmaceuticals Announces Private Placement On February 24, 2023, ASLAN Pharmaceuticals Limited (the ¡§Company¡¨) entered into a Unit Purchase Agreement (the ¡§Purchase Agreement¡¨) with fund entities affiliated with BVF Partners L.P. (collectively, ¡§BVF¡¨) and the other purchasers named therein (the ¡§Purchasers¡¨), pursuant to which the Company agreed to sell to the Purchasers, in a private placement offering, an aggregate of (i) 112,359,550 ordinary shares, par value $0.01 per share (the ¡§Ordinary Shares¡¨), and (ii) pre-funded warrants (the ¡§Pre-Funded Warrants¡¨) to purchase five Ordinary Shares (represented by the Company¡¦s American Depositary Shares (¡§ADSs¡¨)) at a purchase price of $0.178 per Ordinary Share (or the equivalent of $0.89 per ADS) and $0.8895 per Pre-Funded Warrant, respectively, which represents a 15% premium to the ADSs¡¦ ten-day volume-weighted average price (¡§VWAP¡¨) (the ¡§Private Placement¡¨). Each ADS represents five Ordinary Shares. The Private Placement is expected to close on or about February 27, 2023 (the ¡§Closing¡¨), subject to customary closing conditions. ir.aslanpharma.com/financial-information/sec-filings/ |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2023/3/5 ¤W¤È 06:43:40²Ä 6006 ½g¦^À³
|
¤w³qª¾ADRªººÞ²z»È¦æ°õ¦æ´î资ªº°Ê§@¡D ¥xÁÞ¤j¡B¥iÀˬd±zªº«ùªÑ¼Æ¬O§_¤w´î80%. ¤U¶g¤@ªºªÑ»ù¶}½L»ù·|¦Û°Ê¸õ°ª5¿¨ì 0.7575*5=3.787¬ü¤¸¡D |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2023/3/5 ¤W¤È 06:18:27²Ä 6005 ½g¦^À³
|
ir.aslanpharma.com/static-files/91342411-adb8-4daa-b914-9c495834b780 2023/03/03 ASLN ¤½¥q¸³¨Æ·|³q¹L,¦p¤W ¤½¥q3¤ë3¤é ¤W¶ÇSECªºÀɮסBºô§}¦p¤W |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2023/3/4 ¤U¤È 10:55:15²Ä 6004 ½g¦^À³
|
¤Ñ©R¤j ³o»ò«¤jªº´î¸ê°T®§¬°¦ó¤½¥q©xºô¨S¦³¤½§i¡AªÑªF¤]¨S¦³¦¬¨ì¶l¥ó§i¤§¡A·|¤£·|¬O°²°T®§¡H |
|
|
·|û¡G³v®ö«È10146323 µoªí®É¶¡:2023/3/4 ¤U¤È 09:26:37²Ä 6003 ½g¦^À³
|
¬Ý¨Óú¶O®É¶¡³£¤£¤j¬Û¦P §Úªº¦b11¤ë¦hú¤F4¤d¦h¬üª÷ ¦³¹Ú³Ì¬ü¡AÄ~Äò°µ¹Ú§a¡I |
|
|
·|û¡G§d½n¶¯10142119 µoªí®É¶¡:2023/3/4 ¤U¤È 09:07:14²Ä 6002 ½g¦^À³
|
§ÚªººÞ²z¶O10¤ë¤~ú¡]¤¸¤j¡^ ¨S¯S§Oª`·N¤°»ò®ÉÔµ²ºâªº... «ÂIÁÙ¬O2bªº¼Æ¾Ú¯à¤Ï¬M¦h¤Ö»ùÈ¡A1¡G5 1¡G25 ¤À¥ÀÅܤp¦Ó¤w ad¬ãµo¤¤ªºÃĪ«¹ê¦b«Ü¦h¡A¦³³»¦y¼Æ¾Ú¤~¦³°ª»ùÈ¡A ¶q¤O¦Ó¬°¡AYı±o«e´º¤£©úªº¡A½æ¤@½æ¤]¦w¤ß... |
|
|
·|û¡G¤p¾ð10152786 µoªí®É¶¡:2023/3/4 ¤U¤È 08:37:54²Ä 6001 ½g¦^À³
|
¤µ¦~ªºADSªººÞ²z¶Oªºµ²ºâ¤é´Á¬O2023/3/2¡A©Ò¥HºÞ²z¶O¨S¦³¬Ù¨ì³á¡I ¥¿½T¨Ó»¡¡G©ó2/3¥ýµ²ºâ¥¨¶qºÞ²z¶O¡B©ó3/3¤§«áªÑ²¼¼Æ¶q³Ñ¡G1/5 ³o¯uªº«ÜÁV¿|ªº·Pı |
|
|
·|û¡G§d½n¶¯10142119 µoªí®É¶¡:2023/3/4 ¤U¤È 07:58:27²Ä 6000 ½g¦^À³
|
³o¼Ë¤@¨Ó¡A¤µ¦~ªºADSªººÞ²z¶O ¥i¥H¬Ù«Ü¦h¤F |
|
|
·|û¡G³¯¤p©ú10152293 µoªí®É¶¡:2023/3/4 ¤U¤È 07:45:14²Ä 5999 ½g¦^À³
|
¤W¦¸¦]004 1b¸Ñª¼¼Æ¾Ú¤£¨Î¡A ªÑ»ù±q±q3.25¤U¶^¨ì1¬ü¤¸¥H¤U¡A ¥B«ùÄò¹F§Ö1¦~¡A±Á{´î¸ê©Î¤U¥«¦M¾÷¡A ´Á¤¤¨ÃµL¤j¤O±ÏªÑªº§@¬° ³o¦¸´î¸ê8¦¨¡AªÑ»ù¦^¨ì3.79¤¸¡A ¦pªG7¤ë¥÷004 2b¸Ñª¼¤S¥X·N¥~¡A §Ú»{¬°¤S·|«ºt1b¸Ñª¼ªº¤U³õ¡A ±q¦¹§¹¥þ°h¥X¥Í§Þ¥«³õ¡A ³Å«i¥»¨Ó´N¬O¤@ÓµL¯à¡A¥u·|¥X±i¼Lªº¤H¡A³Ì°_½X¥L¤wÄF±o¹S³Ò¡A §Ú»{¬°¨È·à±d¥»¨´N¬OÓ¯º¸Ü¡A ¤ñ¦X¤@fb825³£¤£¦p¡A°_½X¥L¦³°ê»Ú±ÂÅv¡A |
|
|
·|û¡GªL®õ10030886 µoªí®É¶¡:2023/3/4 ¤W¤È 09:29:19²Ä 5998 ½g¦^À³
|
¦p¦¹ªº¸Ü Ó¤Hªº´¢´ú´N¦h¾l¤F ÁÂÁ©R¤j |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2023/3/4 ¤W¤È 09:29:00²Ä 5997 ½g¦^À³
|
ASLAN Pharmaceuticals Announces Private Placement On February 24, 2023, ASLAN Pharmaceuticals Limited (the ¡§Company¡¨) entered into a Unit Purchase Agreement (the ¡§Purchase Agreement¡¨) with fund entities affiliated with BVF Partners L.P. (collectively, ¡§BVF¡¨) and the other purchasers named therein (the ¡§Purchasers¡¨), pursuant to which the Company agreed to sell to the Purchasers, in a private placement offering, an aggregate of (i) 112,359,550 ordinary shares, par value $0.01 per share (the ¡§Ordinary Shares¡¨), and (ii) pre-funded warrants (the ¡§Pre-Funded Warrants¡¨) to purchase five Ordinary Shares (represented by the Company¡¦s American Depositary Shares (¡§ADSs¡¨)) at a purchase price of $0.178 per Ordinary Share (or the equivalent of $0.89 per ADS) and $0.8895 per Pre-Funded Warrant, respectively, which represents a 15% premium to the ADSs¡¦ ten-day volume-weighted average price (¡§VWAP¡¨) (the ¡§Private Placement¡¨). Each ADS represents five Ordinary Shares. The Private Placement is expected to close on or about February 27, 2023 (the ¡§Closing¡¨), subject to customary closing conditions. ir.aslanpharma.com/financial-information/sec-filings/ 2/24¤W¶Ç¬üSECªº¨p¶Ò¸ê®Æ¡B¦³ª`©úì©lªÑ¡B¤ÎADR³æ«K¡B¤Î5´«1ªº´«ªÑ¤ñ¨Ò¡D |
|
|
·|û¡GªL®õ10030886 µoªí®É¶¡:2023/3/4 ¤W¤È 09:15:05²Ä 5996 ½g¦^À³
|
¥H¤W¬OÓ¤H´¢´ú ¦pªGadr´î¸ê«á ¿ï¾ÜÅv»ùÁÙ¬O1.6 ¥u¯à»¡¤½¥q¯Ê¸êª÷ ¥u¯à¥ô°Ñ»P¶Ò¸êªÌ®_¨î |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2023/3/4 ¤W¤È 09:10:12²Ä 5995 ½g¦^À³
|
¤§«eASLN¹ï¥~¶Ò¸ê¡B³æ»ù·|¦P®Éñì©lªÑ¤ÎADR³æ»ù¡D |
|
|
·|û¡GªL®õ10030886 µoªí®É¶¡:2023/3/4 ¤W¤È 09:07:32²Ä 5994 ½g¦^À³
|
¦pªGadr ¿ï¾ÜÅv»ù®æ´î¸ê«áÁÙ¬O1.6 BVF ·|Áȫܤj ¦P®É¤]·t¥Ü ¤U¶g¤@ªÑ»ù·|¥Ñ3 ÂI¦h©¹ 1.6 ¤U¦æ |
|
|
·|û¡GªL®õ10030886 µoªí®É¶¡:2023/3/4 ¤W¤È 08:56:22²Ä 5993 ½g¦^À³
|
½Ð±Ð¤Ñ©R¤j BVF 1.6 ¿ï¾ÜÅvªº»ù®æ ¬O¤£¬O¤]n¼¥H5 ¦¨¬°8 Áâ¡H |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2023/3/4 ¤W¤È 08:42:27²Ä 5992 ½g¦^À³
|
´î¸ê«á, ¥¼¨Ó³Q¨ÖÁÊÁ`»ùȤ£·|ÅÜ ¨é°Óªº¥Ø¼Ð»ù¥Ñ¥Ø«e³Ì°ª4.5¬ü¤¸¡A¦Û°Ê¤Wº¦¦Ü22.5 (4.5*5=22.5)¬ü¤¸ ªø´Á´N¤£©ö¶^¦^¤@¤¸¥H¤U,³Q¨ÖÁÊ«e¤£·|¦³¦]ªÑ»ù§C©ó¤@¬ü¤¸³W«hªº¤U¥«·ÀI. |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2023/3/4 ¤W¤È 08:14:38²Ä 5991 ½g¦^À³
|
ASLN ADRªÑ¼Æ´î80%, ¥Ø«eÁ`µo¦æ¶q10¸U¤dªÑ ADR ÁY¬°2¸U¤dªÑADR, ¥¼¨Ó·|¦A¼W¸ê¨ì4¸UªÑADR(100¸U¤dªÑì©lªÑ) ªÑ»ù¤U¶g¤@¶}½L»ùÀ³¬°¤µ¤é¦¬½Lªº5¿ 0.7575*5=3.79¬ü¤¸ |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2023/3/4 ¤W¤È 08:03:35²Ä 5990 ½g¦^À³
|
SECTION 2.06. Effective on the date first announced by the Depositary, the number of Shares represented by each ADS shall be amended from ¡§five¡¨ to ¡§twenty-five¡¨. ADRº¦¸«Å¥¬¤§¤é°_¥Í®Ä¡A¨C¥÷ ADS ©Ò¥NªíªºªÑ¥÷¼Æ¶qÀ³¬° ¥Ñ¡§¤ªÑ¡¨×§ï¬°¡§¤G¤Q¤ªÑ¡¨¡C ir.aslanpharma.com/static-files/91342411-adb8-4daa-b914-9c495834b780 2023/03/03 ASLN ¤½¥q¸³¨Æ·|³q¹L,¦p¤W |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2023/3/2 ¤W¤È 10:47:55²Ä 5989 ½g¦^À³
|
¥Ñ2/24¨p¶Ò±À¡G §¹¦¨2A·§©À©ÊÁ{§É¡A¸Ñª¼¦¨¥\«á»ùÈ¡G ASLAN003ªº»ùȼW¥[1.63-1.3=0.33¬ü¤¸¡þªÑ 0.33x20¸UªÑADR=6600¸U¬ü¤¸ªº¥«È¡A§¹¦¨60¤Hªº2AÁ{§É«á¦¨¥\«áªº³Ì§C¥«È¡C ¤@¤@¤@¤@¤@¤@ 2023-02-24 ASLAN Pharmaceuticals «Å¥¬¥Ñ BVF Partners LP ²oÀYªº 2000 ¸U¬ü¤¸¨p¶Ò°t°â¡A¨Ã¦³¥i¯àÃB¥~Àò±o°ª¹F 8000 ¸U¬ü¤¸ The first tranche of warrants is comprised (i) 50% of purchase warrants that are exercisable upon issuance and until sixty days after the public announcement of ASLAN¡¦s topline data from its TREK-AD Phase 2b clinical trial investigating eblasakimab in atopic dermatitis at an exercise price of $1.30 per ADS and ¤@¤@¤@¤@ (ii) 50% of purchase warrants which can only be exercised within sixty days after the public announcement of ASLAN¡¦s topline data from its TREK-AD Phase 2b clinical trial investigating eblasakimab in atopic dermatitis at an exercise price based on the higher of $1.30 and a 50% discount to the ADS VWAP measured across a specified period after the public announcement of data. ii) 50%ªº购买权证¡A¥u¯à¦bASLAN¤½开«Å¥¬¨ä调¬d¥ì¥¬©Ô¦è单§Üªv疗¯S应©Ê¥Öª¢ªºTREK-AD 2b´Á临§É试验ªº顶线数Õu¦Z60¤Ñ内¦æ¨Ï¡A¦æ¨Ïɲ°ò¤_1.30¬ü¤¸©M¤½开«Å¥¬数Õu¦Z¯S©w时´Á内¬ü国¦s¦«ú«证VWAP¡]¯S©w´Á¶¡ADR¥§¡»ù®æ¡^ªº50%§é¦©¡A¥H两ªÌ¤¤较°ªªÌ为ã¡C xxxVWAP¡G¦p¤½¥¬¸Ñª¼¼Æ¾Ú«áADR 10¤Ñªº¥§¡»ù®æ x50% Y¤Wº¦¦Ü¥§¡7¬ü¤¸¡A«h7x50%=3.5¬ü¤¸¨CªÑADR°µ¬°»{ÁÊ»ù¡A«D1.3¬ü¤¸¡C ¤@¤@¤@¤@ The second tranche of warrants is similarly comprised (i) 50% of purchase warrants that are exercisable upon issuance until sixty days after the public announcement of topline interim data from ASLAN¡¦s planned Phase 2 proof of concept trial investigating farudodstat at an exercise price of $1.63 per ADS and ( ¤@¤@¤@ ii) 50% of purchase warrants which can only be exercised within sixty days after the public announcement of topline interim data from ASLAN¡¦s planned phase 2 proof of concept trial investigating farudodstat at an exercise price based on the higher of $1.63 and a 50% discount to the ADS VWAP measured across a specified period after the public announcement of data. ii¡^50%ªº购买权证¡A¥u¯à¦bASLAN计¦Eªº调¬dfarudodstatªº²Ä¤G阶¬q·§©À验证试验ªº顶线¤¤´Á数Õu¤½¥¬¦Z60¤Ñ内¦æ¨Ï¡A¦æ¨Ïɲ为1.63¬ü¤¸©M数Õu¤½¥¬¦Z¯S©w时´Á内¬ü国¦s¦«ú«证VWAPªº50%§é¦©¡A¥H两ªÌ¤¤较°ªªÌ为ã¡C |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2023/3/2 ¤W¤È 10:35:27²Ä 5988 ½g¦^À³
|
²æ¾vªvÀø120»õ¬ü¤¸¥«³õ¡]2028¦~¡^ µoªí·s¸ÜÃD ¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1¶ ·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/6/15 ¤U¤È 10:08:55 ·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2022/6/15 ¤U¤È 09:47:22²Ä 5390 ½g¦^À³ ²æ¾vªvÀø¥«³õ¤ÀªR www.coherentmarketinsights.com/market-insight/alopecia-treatment-market-1847 ¥_¬ü36»õ¬ü¤¸/¥þ²y87»õ¬ü¤¸¡]2021¦~¡^¡A¦~¦¨ªø²v5¡A3% ·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/6/15 ¤U¤È 10:12:43²Ä 1 ½g¦^À³ º¤ä¤fªA¨rÀYÃÄ ¢Ô¢Ò¢Ï§åã 2022/06/15 05:30 ¡e½sĶ©Pi¨Z¡þºî¦X³ø¾É¡f¬ü°ê¹«~ÃĪ«ºÞ²z§½¡]FDA¡^¤Q¤T¤é§åã¬ü°ê»sÃĤ½¥q¡u§¨Ó¡v¬ãµoªº¡u·R·Àª¢¡v¡]Olumiant¡^¥Î¨ÓªvÀøÄY«¶ê¨r±wªÌ¡A¦¨¬°¬ü°ê¨C¦~¹O¤Ê¸U¦W¨ü¡u°«cÀY¡v§xÂZªº¥Ö½§¯f¤Hªº²Ä¤@¤ä¤fªAÃÄ¡C ¶ê¨r¬O¦ÛÅé§K¬Ì¯e¯f¡A¥ô¦ó¦³Åé¤òªº³¡¦ì¬Ò¥i¯à¦¨¬°±w³¡¡A¶Ç²ÎªvÀø¥H§½³¡Ãþ©T¾Jª`®g¬°¥D¡A¥i¨ë¿E¤ò¾v¥Íªø¦ý©ö´_µo¡A¤µ¦~¦b¶ø´µ¥d¹{¼ú¨å§¾x¥X¥Ï¤Ú´x·ªiªº¼v¬P«Âº¸¥v±K´µ¤§©d§Y¬°±wªÌ¡C ¡u·R·Àª¢¡v¥H¡u¤Ú·ç´À¥§¡v¡]Baricitinib¡^¬°¾Ç¦W¤ÎÃĪ«¦¨¤À¡A¥ý¦b¤G¡³¤@¤»¦~ÀòãªvÀøÃþ·Àã©ÊÃö¸`ª¢¡A¤W¤ë¤SÀòãªvÀøªZº~ªÍª¢¦¨¦~««×±wªÌ¡C ¾Ú¹êÅçµ²ªG¡AÄY«¶ê¨r±wªÌ¦@¤@¤G¡³¡³¤H¨ü¸Õ¡A¤À¨C¤éªA¥Î¤G¡B¥|²@§J¤Î¦w¼¢¾¯²Õ¡A¤Ê¤»¶g«á¡A°ª¾¯¶q²Õªñ¥|¦¨ªø¦^¤K¦¨¤ò¾v¡B§C¾¯¶q²Õ¤Ü¤T¢Hªø¦^¤K¦¨¾v¶q |
|
|
·|û¡G¬õ¹Ð¦³¹Ú10150039 µoªí®É¶¡:2023/3/2 ¤W¤È 10:09:03²Ä 5987 ½g¦^À³
|
¥i§_½Ðª©¤W±M·~ªº¤j¤j´NFarudodstat ¦¨¥\ªº¾÷²v¡A©M¥«³õ³W¼Ò¤ÀªR»¡©ú¤@¤U |
|
|
·|û¡Gjimmylin10141563 µoªí®É¶¡:2023/3/1 ¤U¤È 11:33:04²Ä 5986 ½g¦^À³
|
Æ[¹î°Æ«i¥H©¹§@·´N¬OµL¬°¦Óªvªº·®æ¡A¥L¬O¥uµ¥³Q¦¬ÁʶܡH |
|
|
·|û¡G«Ó°¶10144972 µoªí®É¶¡:2023/3/1 ¤U¤È 08:26:34²Ä 5985 ½g¦^À³
|
®É¦Ü¤T¤ë Áö¤£§Æ±æ¡A¤]±o¦Ò¼{³oÓ°ÝÃD n¬O¨p¶ÒÁÙ¬OµLªk§âªÑ»ù±À¤W1¤¸¡A¸Ó¤£·|ÁÙn°f¤À³Î§a §Úı±o¯à§_¤W1¤¸¯uªº«Ü«n¡A³o¤]¬O«H¤ß©Ò¦b ¤jªÑªFÌ¥[ªo°Ú |
|
|
·|û¡G©t¨àÃÄ10140658 µoªí®É¶¡:2023/3/1 ¤U¤È 02:10:37²Ä 5984 ½g¦^À³
|
¦pªGASLN004¦b¸Ñª¼«e¡AÁÙ¦³´Á¤¤¼Æ¾Ú¥i¨Ñ°Ñ¦Ò¡A¨º´N¤Ó¦n¤F¡A¤£µM©Ò¦³ªº¤@¤Á³£¥u¯à¤¤©Ê¬Ý«Ý¡A¦]¨p¶Ò2000¸U¯uªº¨S¬Æ»ò¡A¹ï©ó¤@Ó¤jÃĨӻ¡¡A¬O¤£¦hªº~ |
|
|
·|û¡G¥d¦b¥b¤s¸y10153098 µoªí®É¶¡:2023/2/28 ¤U¤È 09:53:49²Ä 5983 ½g¦^À³
|
¨rÀYªº¤H¦³±Ï¤F ¤j®a¬èë¨È®v±d |
|
|
·|û¡G³v®ö«È10146323 µoªí®É¶¡:2023/2/28 ¤U¤È 09:52:23²Ä 5982 ½g¦^À³
|
ASLAN Pharmaceuticals to Advance Novel DHODH Inhibitor Farudodstat Into Phase 2 Clinical Testing as Potential First-In-Class Treatment for Alopecia Areata ASLAN¨î药¤½¥q将±À进·s«¬DHODH§í¨î剂Farudodstat进¤J2´Á临§É测试¡A§@为ªv疗脱发¯gªºýͦb²Ä¤@类药ª« |
|
|
·|û¡G³¯¤p©ú10152293 µoªí®É¶¡:2023/2/28 ¤U¤È 08:11:57²Ä 5981 ½g¦^À³
|
aslan003 ³Ì·s¶i«× 2023-02-28 ¡Ä ASLAN Pharmaceuticals ±N·s«¬ DHODH §í»s¾¯ Farudodstat ±À¶i 2 ´ÁÁ{§É¸ÕÅç¡A§@¬°´³¨rªº¼ç¦b¤@¬yªvÀøÃĪ« ´³¨r (AA) ¬O¤@ºØ±`¨£ªº¦Û¨§K¬Ì©Ê¯e¯f¡A¦b¬ü°ê¼vÅT¶W¹L 700,000 ¦W±wªÌ¡A¨ä¯f¦]¬O¤òÅn¤¤§K¬Ì¯SÅv (IP) ªº³à¥¢¥H¤ÎÀH«á¤Àªc IFN£^ ªº§K¬Ì²ÓMªº§ðÀ» Farudodstat ¬O¤@ºØ¦³®Äªº¤fªA DHODH §í»s¾¯¡A¤w³QÃÒ©ú¥i§í¨î IFN£^ ¤Àªc¡A´î¤Ö§K¬Ì²ÓM¼W´Þ¡A¨Ã¥i¯à¦b¤HÃþ AA ¯e¯f¼Ò«¬¤¤¨¾¤î IP ±Y¼ì AA ¤¤ farudodstat ªº 2 ´Á·§©ÀÅçÃÒ¸ÕÅç¹wp±N©ó 2023 ¦~²Ä¤G©u«×¦b¬ü°ê¶}©l©Û¶Ò±wªÌ ASLAN ±N©ó¬ü°êªF³¡®É¶¡ 2023 ¦~ 3 ¤ë 16 ¤é¤W¤È 10:00 ¡V 11:30 »PC¾|¤j¾Ç¥Ö½§¯f¾Ç°Æ±Ð±Â Brett King MD ³Õ¤h¤@°_Á|¿ìÃö©ó farudodstat ªºµêÀÀ¬ãµo¤é¡A°Q½×¾÷ºÞ§½¥¼º¡¨¬ªºÂåÀø»Ý¨D©M·í«eªºªvÀø±¡ªp ¥[§QºÖ¥§¨È¦{¸t°¨¯S¶ø©M·s¥[©Y¡A2023 ¦~ 2 ¤ë 28 ¤é¡]Àô²y·s»DªÀ¡^¡X¡X ASLAN Pharmaceuticals¡]¯Ç´µ¹F§JªÑ²¼¥N½X¡GASLN¡^¡A¤@®aÁ{§É¶¥¬q¡B±Mª`©ó§K¬Ì¾Çªº¥Íª«»sÃĤ½¥q¡A¶}µo³Ð·sÀøªk¥H§ïÅܱwªÌªº¥Í¬¡¡A¤µ¤Ñ«Å¥¬ ¥¦¥¿¦b±À¶i¨äÁ{§Ép¹º¡A¥H¬ã¨s¤fªA¤G²B¨Å²M»Ä²æ²B酶 (DHODH) §í»s¾¯ farudodstat¡A§@¬°´³¨r (AA) ªº¼ç¦b¤@¬yªvÀø¤èªkªº²Ä 2 ¶¥¬q·§©ÀÅçÃÒ¸ÕÅç¡C AA ¬O¤@ºØ¦Û¨§K¬Ì©Ê¯e¯f¡A¨ä¯S¼x¬O¤òÅn¤¤§K¬Ì¯SÅv (IP) ªº³à¥¢¡A³q¹L I Ãþ¥Dn²Õ´¬Û®e©Ê½Æ¦Xª« (MHC I) ªí¹Fªº¼W¥[¨Ó¿Å¶q¡A¨Ã¥B¬O¥Ñ¤zÂZ¯À£^ (IFN£^) ªº¿E¬¡©M¼W´ÞÅX°Êªº -¤Àªc§K¬Ì²ÓM¤¶¾É¤òÅnªº§ðÀ»¡A¾ÉPÀY¥Ö©M¨Å駹¥þ©Î³¡¤À²æ¾v¡C AA »PÄY«ªº¤ß²zt¾á¬ÛÃö¡AªvÀø¿ï¾Ü¦³¡A¼vÅT¬ü°ê¶W¹L 700,000 ¦W±wªÌ¡C §í¨î DHODH ¬OªvÀø¦hºØ¦Û¨§K¬Ì©Ê¯e¯fªº¬J©w¾÷¨î¡C DHODH §í»s¾¯¤wÀò§åã¨Ã¼sªx¥Î©ó¦hµo©Êµw¤Æ¯g©MÃþ·Àã©ÊÃö¸`ª¢¡A¦ý²Ä¤@¥N§í»s¾¯ªº®Ä¤O©M¦w¥þ©Ê¯Ê³´¦³¡C Farudodstat ¬O¤@ºØ°ª¿ï¾Ü©Ê DHODH §í»s¾¯¡A¨ä®Ä¤O¬O¦PÃþ¤wÀò§åãÃĪ«ªº 30 ¿¡A¨Ã¥B¨ã¦³¨}¦nªº@¨ü©Ê¦w¥þ©Ê¡C Åé¥~¬ã¨sªí©ú¡Afarudodstat ¥i§í¨î§K¬Ì²ÓM¼W´Þ©M IFN£^ ªº²£¥Í¡C ³Ìªñ¦bÂ÷Åé¤HÃþ AA ¯e¯f¼Ò«¬¤¤ªºÂà¤Æ¬ã¨sªí©ú¡Afarudodstat ´î¤Ö¤F MHC I ³J¥Õ»¤¾É¡A³o¬O IP ·l¥¢ªº¼Ð»x©Ê¯S¼x¡C ¸Ó¼Ò«¬ÁÙ²£¥Í¤F¨ä¥L¥\®Ä¸ñ¶H¡Aªí©ú farudodstat ¥i¯à¼ç¦b¦a«OÅ@¤òÅn§K¨ü¿E¬¡ªº§K¬Ì²ÓMªº§ðÀ»¡C ASLAN Pharmaceuticals º®u°õ¦æ©x Carl Firth ³Õ¤hµû½×¹D¡G¡§§ÚÌ«Ü°ª¿³±À¶i farudodstat ªºÁ{§É¶}µo¡A¥¦¦³¥i¯à¦¨¬°¤@¬yªºªvÀø¤èªk¡A¸Ñ¨M´³¨r±wªÌ¥¼º¡¨¬ªº»Ý¨D¡C¡¨ ¡§¾¨ºÞ³Ìªñ¦bªvÀø¤è®×¤è±¨ú±o¤F¶i®i¡A¦ý AA Àøªkªºªø´Á¦w¥þ©Ê¤´µM¬OÂå¥Íªººn¥ô°È¡C §Ṳ́w¸g²£¥Í¤F¥O¤H¹ª»Rªº¼Æ¾Ú¡A¤ä«ù§Ú̪º«H©À¡A§Y farudodstat ¥i¥H¹w¨¾¨Ã¥i¯à«ì´_¤òÅn¤¤§K¬Ì¯SÅvªº³à¥¢¡A¬° AA ´£¨Ñ¨ã¦³Ävª§¤Oªº¦w¥þ¦³®ÄªºªvÀø¿ï¾Ü¡C¡¨ 2a ´Á·§©ÀÅçÃÒ¸ÕÅç¬O¤@¶µ 2:1 ÀH¾÷¸ÕÅç¡A±wªÌ¨C¤Ñ¨â¦¸¤fªA farudodstat ©Î¦w¼¢¾¯¡A«ùÄò 12 ¶g¡AµM«á¬O¥æ¤eªvÀø´Á¡C ¸Ó¸ÕÅç±N¦b¬ü°ê©Û¶Ò¬ù 60 ¦W±wªÌ¡A¹wp±N©ó 2023 ¦~²Ä¤G©u«×¶}©l¤J²Õ¡C²Ä¤@Ó 12 ©PªvÀø´Á«áªº¤¤´Á³»½uŪ¼Æ¹wp±N©ó 2024 ¦~²Ä¤@©u«×¤½§G¡A¨Ã±N¬°«áÄò 2b ´Áªº³]p´£¨Ñ«H®§ ¾¯¶q½d³ò¬ã¨s¡C ¸Ó¸ÕÅ窺¥Dn¥Øªº¬Oµû¦ô farudodstat ¦b±w¦³ÄY«´³¨rªº¦¨¦~¨ü¸ÕªÌ¤¤ªº¦w¥þ©Ê¡B@¨ü©Ê©M¦³®Ä©Ê¡C farudodstat µêÀÀ¬ãµo¤é ASLAN ªººÞ²z¹Î¶¤±N©ó¬ü°êªF³¡®É¶¡ 2023 ¦~ 3 ¤ë 16 ¤é¬P´Á¥|¤W¤È 10:00 ¦Ü¤W¤È 11:30 »PC¾|¤j¾Ç¥Ö½§¯f¾Ç°Æ±Ð±Â Brett King MD ³Õ¤h¤@°_¦b farudodstat ¤WÁ|¿ìµêÀÀ¬ãµo¤é¡C ¶i¤@¨Bªº²Ó¸`±N¦b«á±¡C nµù¥U¸Ó¬¡°Ê¡A½Ð³æÀ»¦¹³B¡C ¬¡°Ê«¼½©Mºt¥Ü§÷®Æ±N¦b ASLAN Pharmaceutical ºô¯¸ªº§ë¸êªÌÃö«Y³¡¤À´£¨Ñ¡C Ãö©ó farudodstat Farudodstat ¬O¤@ºØ¦³®Äªº¤fªA DHODH §í»s¾¯¡A¥i³q¹LªýÂ_ DNA ½Æ»s©Ò»ÝªºáGÔr±qÀY²£¥Í¨Ó§í¨î§K¬Ì²ÓM¼W´Þ©M IFN£^ ¤Àªc¡C »P²Ä¤@¥N DHODH §í»s¾¯¬Û¤ñ¡Afarudodstat ¤w³QÃÒ©ú¦b§í¨î DHODH ©M¨î T ²ÓM¬¡©Ê¤è±ªº®Ä¤O¤j¬ù°ª¥X 30 ¿¡A¨Ã¥B¨ã¦³¨}¦nªº@¨ü©Ê¦w¥þ©Ê¡C ASLAN ¥Í¦¨ªº¼Æ¾ÚÅã¥Ü farudodstat |
|
|
·|û¡G³¯¤p©ú10152293 µoªí®É¶¡:2023/2/28 ¤U¤È 08:06:49²Ä 5980 ½g¦^À³
|
2023-02-28 003 ³Ì·s®ø®§ ASLAN Pharmaceuticals ±N·s«¬ DHODH §í»s¾¯ Farudodstat ±À¶i 2 ´ÁÁ{§É¸ÕÅç¡A§@¬°´³¨rªº¼ç¦b¤@¬yªvÀøÃĪ« ´³¨r (AA) ¬O¤@ºØ±`¨£ªº¦Û¨§K¬Ì©Ê¯e¯f¡A¦b¬ü°ê¼vÅT¶W¹L 700,000 ¦W±wªÌ¡A¨ä¯f¦]¬O¤òÅn¤¤§K¬Ì¯SÅv (IP) ªº³à¥¢¥H¤ÎÀH«á¤Àªc IFN£^ ªº§K¬Ì²ÓMªº§ðÀ» Farudodstat ¬O¤@ºØ¦³®Äªº¤fªA DHODH §í»s¾¯¡A¤w³QÃÒ©ú¥i§í¨î IFN£^ ¤Àªc¡A´î¤Ö§K¬Ì²ÓM¼W´Þ¡A¨Ã¥i¯à¦b¤HÃþ AA ¯e¯f¼Ò«¬¤¤¨¾¤î IP ±Y¼ì AA ¤¤ farudodstat ªº 2 ´Á·§©ÀÅçÃÒ¸ÕÅç¹wp±N©ó 2023 ¦~²Ä¤G©u«×¦b¬ü°ê¶}©l©Û¶Ò±wªÌ ASLAN ±N©ó¬ü°êªF³¡®É¶¡ 2023 ¦~ 3 ¤ë 16 ¤é¤W¤È 10:00 ¡V 11:30 »PC¾|¤j¾Ç¥Ö½§¯f¾Ç°Æ±Ð±Â Brett King MD ³Õ¤h¤@°_Á|¿ìÃö©ó farudodstat ªºµêÀÀ¬ãµo¤é¡A°Q½×¾÷ºÞ§½¥¼º¡¨¬ªºÂåÀø»Ý¨D©M·í«eªºªvÀø±¡ªp |
|
|
·|û¡G§d½n¶¯10142119 µoªí®É¶¡:2023/2/28 ¤U¤È 02:17:17²Ä 5979 ½g¦^À³
|
1/27¤½§i¦¬®×¤¤¤ß¥Ñ65Ó¼W¥[¦Ü83Ó¡K2/24³Ì«á¤@Ó¯f¤H¤J¦C ±q1b¥H«á¡A²Ó¬Ý¤½¥q¾ãÓÁ{§É¹êÅ窺¥¬§½¤Î¬yµ{¡Bµoªíªº½×¤å Åã¥Ü¤½¥q¹ï004¤´¥Rº¡«H¤ß ˼Æ120¤Ñ¡A¼ÆÄCÀY¶}©l¡K |
|
|
·|û¡G³v®ö«È10146323 µoªí®É¶¡:2023/2/28 ¤W¤È 10:03:39²Ä 5978 ½g¦^À³
|
¨S¬Ýì¤å¡Aª½±µ½Æ»s½Ķ ì¨Ó¬O½Õ°¡AÃø©Ç¶^5%¦h ¤£¹LÓ¤H¬Ýªk¡ã°_¥ñÃø§K¡A¥Ø«eÁͶե¼ÅÜ¡I Ä~Äò¬ÝÀ¸ |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2023/2/28 ¤W¤È 09:43:03²Ä 5977 ½g¦^À³
|
ASLAN Pharmaceuticals¡¦s PT cut by Piper Sandler to $3.00. ¥t¥~¤@®a¨é°Ó¥ç½Õ°¥Ø¼Ð»ù¥Ñ4¬ü¤¸¦Ü3¬ü¤¸¡D www.marketbeat.com/stocks/NASDAQ/ASLN/price-target/ ªÑ¥»§Ö³t¼êµÈµ²ªG¡D 2bÀø®Ä¡B¥«³õ预测¥i¯à±µªñLebrikizumab IGA0,1=45% vs15%(¹ï·Ó²Õ) |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2023/2/28 ¤W¤È 09:17:27²Ä 5976 ½g¦^À³
|
¨é°Ó¥Ø¼Ð»ù³Ì°ª4.5¬ü¤¸¡D 4.5¬ü¤¸x80%x20¸U¤dªÑADR=7.2»õ¬ü¤¸¥«È 2b 7¤ë¸Ñª¼«á¡B¥«³õ¥]¾P»ù 4.5¬ü¤¸x80%=3.6¬ü¤¸ 3.6¬ü¤¸x6¸U¤dªÑADR¬ù2.1»õ¬ü¤¸ ¥»¤ë¨p¶Ò2¤d¸U¬ü¤¸+¥¼¨Ó8¤d¸U¬ü¤¸=1»õ¬ü¤¸ ¦Xp¶Ò¸ê¬ù3»õ¬ü¤¸¡D 2b¸Ñª¼´Á±æÈ¡G IGA0,1 >44%vs15%(¹ï·Ó组) |
|
|
·|û¡G³¯¤p©ú10152293 µoªí®É¶¡:2023/2/27 ¤U¤È 10:34:06²Ä 5975 ½g¦^À³
|
Hc Wainwright ±N¨È·à±d¥Ø¼Ð»ù½Õ° ¥Ñ7¬ü¤¸ÅÜ4.5¬ü¤¸ |
|
|
·|û¡G³v®ö«È10146323 µoªí®É¶¡:2023/2/27 ¤U¤È 10:09:06²Ä 5974 ½g¦^À³
|
HC ·Å¿à¯S½Õ¾ãªü´µÄõÃÄ«~ªº¥Ø¼Ð»ù®æ±q $4.50 ±q 7 ¬ü¤¸¡A«O«ù¶R¤Jµû¯Å ¡ã³o®a²´·ú«G¤F |
|
|
·|û¡G©t¨àÃÄ10140658 µoªí®É¶¡:2023/2/27 ¤U¤È 09:33:38²Ä 5973 ½g¦^À³
|
ªü·à±q§Ä§Ä¥i¦MÅܦ¨¤¤©Ê¡A¦Ó¬O§_¯àÂର¤@¸ôªø¦h? ´N¨ú¨M©óBVF¬O§_¬Ý¨ìÁͶվÀÂS¤À©úªº¥¿¦Vª¼¼Æ¾Ú¤F¡A¥[ªo~ |
|
|
·|û¡GPica10150664 µoªí®É¶¡:2023/2/27 ¤U¤È 05:12:26²Ä 5972 ½g¦^À³
|
¨SÂà adr ªº¡C µ¥°t®§¡Aµ¥³Q¨Ö¡Aµ¥Âà adr ¡C²{¦b¤°»ò³£¤£¯à°µ¡A¥u¯àµ¥³o¤TºØ¾÷·|¨ÓÁ{¡C |
|
|
·|û¡G¥d¦b¥b¤s¸y10153098 µoªí®É¶¡:2023/2/27 ¤U¤È 02:29:33²Ä 5971 ½g¦^À³
|
³oÃ䦳¨È®v±d¿à¸s¶Ü? ÁÙ¦³§Ú¬O¤§«e¥xªÑ¶Rªº ¦¨¥»¤ñ²{¦b°ª«Ü¦h ±i¼Æ¤£¦h §Ñ¤F¸òµÛÂà´«ADR ¥Ø«eÁö¬OªÑªF ¦ý¬O¨S¦³±b¤áªÑ¼Æ¥i¥H¥æ©ö ³on«ç»ò³B²z? |
|
|
·|û¡G³v®ö«È10146323 µoªí®É¶¡:2023/2/26 ¤U¤È 07:04:23²Ä 5970 ½g¦^À³
|
²ö°Ý¦h¤Ö¡A¥ý°Ý¦Û¤v¦³¦h¤Ö¡H¦@«j¡I¨þ¨þ😄 µ¹§AÓ¤]³\·|¦¨¯uªº¹Ú¡ã ¡§·í±z«ù¦³ASLN 25,000ªÑADR, 2-3¦~¤º¤½¥q³Q¨ÖÁÊ,¥Ø¼Ð¨ÖÁÊ»ù60¬ü¤¸/ADR ¸ê²£¦³¾÷·|¤W¬Ý150¸U¬ü¤¸.¦¨¬°¥xÆW«e1%´I¯Î.¡¨ |
|
|
·|û¡G¥d¦b¥b¤s¸y10153098 µoªí®É¶¡:2023/2/26 ¤U¤È 03:08:15²Ä 5969 ½g¦^À³
|
½Ð°Ý¤j®a ¬OADR¤~¶RªºÁÙ¬O¦b¥x±¾µP®É¤w¸g¶Rªº ¦¨¥»¦h¤Ö°Ú? |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2023/2/25 ¤W¤È 01:32:37²Ä 5968 ½g¦^À³
|
¤½¥q¥ø¹Ï¤ß«Ü±j¡A°]°Èª¬ªpÀò±o§O®a¤½¥q¬Û®¼»P§ïµ½¨Ï¬I®i·~°ÈªºªÅ¶¡§ó¥[¶}ÂX¡A·Ó³oºØº¦´T¤ë©³´N·|¹L1¬ü¤¸¡A¤T¤ë¹L3¬ü¤¸¡A¨ì¤C¤ë¤½§G´Á¤¤¼Æ¾Úè¦n¹L7¬ü¤¸²Å¦X§ë¸ê¾÷ºc¹w´Á¡Aµ¥«Ý¨H¨S¤w¤[ªº¨È´µÄõ}´µ¸¹°_¸¼Q¥X¡C |
|
|
·|û¡G§d½n¶¯10142119 µoªí®É¶¡:2023/2/24 ¤U¤È 10:46:35²Ä 5967 ½g¦^À³
|
1¤¸«O½Ã¾Ô¡A´N¥æµ¹BVF Partners LP¤F.... |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2023/2/24 ¤U¤È 10:17:19²Ä 5966 ½g¦^À³
|
³o¼Ëªº»{ªÑÅv§G§½¡AÓ¤H§PÂ_¡G¥Dn½T«O¯à¦b¶i¤J¤T´Á®É¡A¯à¤ä¥I3000¸U¬ü¤¸µ¹CSL¡A¦Ó¶¶§Q®i¶}¡C ¶i®i¨ì2024¦~Q2¡A§Æ±æ¦b¦¹¤§«e¯à³Q¨ÖÁʱ¼¡C 2b ¸Ñª¼¼Æ¾Ú¯à¶W¶V¹w´Á IGA0,1 >44%vs 15%(¹ï·Ó²Õ¡^ ¥H¤W¼Æ¾Ú¨é°Óµ¹4¡ã7¬ü¤¸ªº¥Ø¼Ð»ù¡C 4x50%=2¬ü¤¸ 7x50%=3.5¬ü¤¸ ¥»¦¸ 1.3¡ã2¡ã3¡P5¬ü¤¸ªº»{ªÑÅvÃÒÃÒ»ù´Á±æÈ¡C ¦pªGIGA0,1 ¯à©¹¤W©Ô¨ì50%¡ã60%¥«³õ¤~·|©Ô°ª¥Ø¼Ð»ù¡C |
|
|
·|û¡G³v®ö«È10146323 µoªí®É¶¡:2023/2/24 ¤U¤È 10:02:50²Ä 5965 ½g¦^À³
|
°Ó·~½Í§P¬O²{¹êªº¡A ¨S¦³¼ç¦b§Q¯q¡A½ÖÄ@·N±Ç¿ú¡H ¨S¦³°Â°â¡AÅSÓ»ùÈ¡A½Öª¾¹D¦³¼ç¦b§Q¯q¡H ³ÌºC3/16¤§«e¡A1¤¸±N¦¨¾ú¥v |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2023/2/24 ¤U¤È 09:46:02²Ä 5964 ½g¦^À³
|
As part of the financing, the Investors will also receive two tranches of warrants initially exercisable in the aggregate for up to 55,309,112 ADSs (or pre-funded warrants). The first tranche of warrants is comprised (i) 50% of purchase warrants that are exercisable upon issuance and until sixty days after the public announcement of ASLAN¡¦s topline data from its TREK-AD Phase 2b clinical trial investigating eblasakimab in atopic dermatitis at an exercise price of $1.30 per ADS and ¤@¤@¤@¤@ (ii) 50% of purchase warrants which can only be exercised within sixty days after the public announcement of ASLAN¡¦s topline data from its TREK-AD Phase 2b clinical trial investigating eblasakimab in atopic dermatitis at an exercise price based on the higher of $1.30 and a 50% discount to the ADS VWAP measured across a specified period after the public announcement of data. ii) 50%ªº购买权证¡A¥u¯à¦bASLAN¤½开«Å¥¬¨ä调¬d¥ì¥¬©Ô¦è单§Üªv疗¯S应©Ê¥Öª¢ªºTREK-AD 2b´Á临§É试验ªº顶线数Õu¦Z60¤Ñ内¦æ¨Ï¡A¦æ¨Ïɲ°ò¤_1.30¬ü¤¸©M¤½开«Å¥¬数Õu¦Z¯S©w时´Á内¬ü国¦s¦«ú«证VWAP¡]¯S©w´Á¶¡ADR¥§¡»ù®æ¡^ªº50%§é¦©¡A¥H两ªÌ¤¤较°ªªÌ为ã¡C xxxVWAP¡G¦p¤½¥¬¸Ñª¼¼Æ¾Ú«áADR 10¤Ñªº¥§¡»ù®æ x50% Y¤Wº¦¦Ü¥§¡7¬ü¤¸¡A«h7x50%=3.5¬ü¤¸¨CªÑADR°µ¬°»{ÁÊ»ù¡A«D1.3¬ü¤¸¡C ¤@¤@¤@¤@ The second tranche of warrants is similarly comprised (i) 50% of purchase warrants that are exercisable upon issuance until sixty days after the public announcement of topline interim data from ASLAN¡¦s planned Phase 2 proof of concept trial investigating farudodstat at an exercise price of $1.63 per ADS and ( ¤@¤@¤@ ii) 50% of purchase warrants which can only be exercised within sixty days after the public announcement of topline interim data from ASLAN¡¦s planned phase 2 proof of concept trial investigating farudodstat at an exercise price based on the higher of $1.63 and a 50% discount to the ADS VWAP measured across a specified period after the public announcement of data. ii¡^50%ªº购买权证¡A¥u¯à¦bASLAN计¦Eªº调¬dfarudodstatªº²Ä¤G阶¬q·§©À验证试验ªº顶线¤¤´Á数Õu¤½¥¬¦Z60¤Ñ内¦æ¨Ï¡A¦æ¨Ïɲ为1.63¬ü¤¸©M数Õu¤½¥¬¦Z¯S©w时´Á内¬ü国¦s¦«ú«证VWAPªº50%§é¦©¡A¥H两ªÌ¤¤较°ªªÌ为ã¡C Both tranches of the purchase warrants also include a mandatory exercise provision subject to the satisfaction of certain pre-specified conditions. 这两§å购买权证还¥]¬A¤@个üL¨î¦æ¨Ï条´Ú¡A¦ý¥²须满¨¬¬Y¨Ç预¥ý«ü©wªº条¥ó¡C |
|
|
·|û¡G©t¨àÃÄ10140658 µoªí®É¶¡:2023/2/24 ¤U¤È 08:55:31²Ä 5963 ½g¦^À³
|
¤¤©Ê°¾¦hªº¨p¶Ò¡A¬Ý¨Ó¤£·|´î¸ê¤F¡A·à¤ÍÌ¡A¥[ªo!! |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2023/2/24 ¤U¤È 08:54:50²Ä 5962 ½g¦^À³
|
¦p¤µ¤é¤½¥¬¡G¤w¦¬³Ì«á¤@¦ì±wªÌ¡A´Nµ¥7¤ë¤¤¦¯¸Ñª¼³ø§i¡A ¥t¤@½¤j¶Ò¸ê¡A¥t¶Ò3¡ã4»õ¬ü¤¸¡A¤~¨¬¥Hû£°Ê¤T´ÁÁ{§É¡A ¥t¥~¶·±ÂÅv¼Ú¬w°Ï°Ó·~¤ÆÅv§Q¡A¥H¤ä¥ICSL 3000¸U¬ü¤¸ªº¤T´Áû£°Ê¶O¥[9000¸U¬ü¤¸¡]ùµ{ª÷¡A¥i¯à¨ìÃÄÃÒ®Öµo¡^¡C ³o¬Oªº¨p¶Ò¦b凖³Æ©ÔªÑ»ù¥Îªº¡A¥Î±¼2¸U¦hªÑADR¡Cµo¦æ¶qªñ10¸UªÑADR¡Cx1.3¬ü¤¸¡A¥«È¤´¥u¦³1»õ3¤d¸U¬ü¤¸¡C ¤@¤@¬ü°ê°ê¼y°²´Á7¤ë4¤é¡C |
|
|
·|û¡G«Ó°¶10144972 µoªí®É¶¡:2023/2/24 ¤U¤È 08:27:30²Ä 5961 ½g¦^À³
|
µ}ÄÀªÑÅv¤£¥i©È¡A·sÃĪѦ³¿ú(ÁÙ¦³¤Hn)¤ñ¸û«n §A¬Ý¹j¾À´×ªº¬P¤]¬O§C»ù¤j¨p¶Ò¼W¥[¶W¦hªÑ¥»¡A¦ýªÑ»ùº¦¤£´N¦n¤F «ÂIÁÙ¬O¹êÅç¼Æ¾Ú¦n¤£¦n ˬO¤Ñ©R¤jªº5.6¤¸¼W¸ê¦b³o®É¶¡ÂI¥»¨Ó´N¤£¥i¯à ²{¦b³£ÁÙ¨SºÝ¥X¦n¼Æ¾Ú¡A½Ö·|¸ò§A·¸»ù8¿¶R n¬O²{¦b³oµ§¨p¶Ò¯à§âªÑ»ù±À¤W1¬ü¤¸¡A§Ú´Nı±o«Ü¦¨¥\¤F |
|
|
·|û¡G³¯¤p©ú10152293 µoªí®É¶¡:2023/2/24 ¤U¤È 08:26:33²Ä 5960 ½g¦^À³
|
§Úı±o«ÂI¦³2 ¤@. 004 2b©Û¶Ò¯f¨Ò¤Hû¤w§¹¦¨¡A²{¥uµ¥«áÄòÃĮĦ¨ªG¡A¤µ¦~7¤ëªì§Y¥i¸Ñª¼¡A ¦¨±Ñ´N¦b¦¹Á|¡A ¤G.¥Ø«e¨È·à±dÀ³´¤¦³¤@¨Ç´Á¤¤¼Æ¾Ú¡A¥B¼Æ¾Ú¥¿¦V¡A¤~·|¦³¤½¥qÄ@·N¦¹®É°Ñ¥[¨p¶Ò¡A |
|
|
·|û¡G«Ó°¶10144972 µoªí®É¶¡:2023/2/24 ¤U¤È 08:18:32²Ä 5959 ½g¦^À³
|
³o¤£ºâ³Î´µæ§a «ç»ò¬Ý³£ºâ§Q¦h¡AÁٯ෸»ù¨p¶Ò«Ü¦n¤F(ÁÙ¦³¤Hn) ¤@°ï¨p¶Ò³£¬O¤j¬å»ù½â»ù¶Ò ¤ñÃz±¼¦n¦h¤F...·Pı¦³¾÷·|¤W1¬ü¤¸ |
|
|
·|û¡Gªoºj·Æ±¼10153108 µoªí®É¶¡:2023/2/24 ¤U¤È 08:18:27²Ä 5958 ½g¦^À³
|
«Ó°¶¤j¡A·íµM¨S¦³§A̪º¥÷¡A¤§«eªº¼W¸ê³£±ÂÅvµ¹¸³¨Æ·|¥h¿ì²z¤F¡A³oºØ¨p¶Ò·íµM¬O§ä¦n¯S©w¾÷ºc§ë¸êªÌ¥h¿ì²z¨p¶Ò¡A©Ò¥H§Ú¤~»¡¾a³oºØ¨p¶Òµ}ÄÀ§A¦U¦ìªÑÅv¡A´Nºâ³Ì«áaslan004¦³¦nµ²ªG¡A§A¦U¦ì©¾¹êªºªÑªF³ø¹S²v¤]¨S·Q¹³¤¤°ª¡A¦ýn©Ó¾á¥¢±ÑÅܾÀ¯Èªº·ÀI¡A¦Ó¥B³o¦¸¨p¶Ò»ù®æ·¥§C¡A¤Ñ©R¤jºâªº¥Ø¼Ð»ù7*0.8=5.6¼W¸ê»ù¡A¬Ý¨Ó¬O¦³¤@¬q¤£¤pªº¸¨®t©O~~~ |
|
|
·|û¡G«Ó°¶10144972 µoªí®É¶¡:2023/2/24 ¤U¤È 08:12:57²Ä 5957 ½g¦^À³
|
¦³ÂI¤£À´§ë¸êªÌ¨p¶Òªº³¡¤À ·N«ä¬O§Ṳ́]¥i¥H°Ñ¥[¨p¶Ò? |
|
|
·|û¡Gªoºj·Æ±¼10153108 µoªí®É¶¡:2023/2/24 ¤U¤È 08:09:51²Ä 5956 ½g¦^À³
|
¨Ó¤F¨Ó¤F¡AÀH«K¤@Ó¼W¸ê¡A³Ì°ª5500¸UªÑADS¡A§A¦U¦ìªºªÑÅv³Qµ}ÄÀ¤F§Ö¤@¥b¡A¦Ó¥B¤~0.89¤@ªÑ¡A«áÄò¿ï¾ÜÅv¥i¥H¥Î1.6¸ò1.63¤¸¶R¤J¡A¯uªº¬O³Q·í´µæ³Î²n²nXD |
|
|
·|û¡G³¯¤p©ú10152293 µoªí®É¶¡:2023/2/24 ¤U¤È 07:17:30²Ä 5955 ½g¦^À³
|
2023-02-24 ASLAN Pharmaceuticals «Å¥¬¥Ñ BVF Partners LP ²oÀYªº 2000 ¸U¬ü¤¸¨p¶Ò°t°â¡A¨Ã¦³¥i¯àÃB¥~Àò±o°ª¹F 8000 ¸U¬ü¤¸ ASLAN ±NÀò±o 2000 ¸U¬ü¤¸ªº¿Ä¸ê¡A¨Ã¦³¥i¯àÀò±o°ª¹F 8000 ¸U¬ü¤¸ªºÃB¥~¸êª÷¡AÁ`p 1 »õ¬ü¤¸¥Î©óÄ~Äò±À¶ieblasakimab©MfarudodstatªºÁ{§É¶}µo ASLAN ªº¹w´Á²{ª÷¶]¹D¦Ü¤Ö©µªø¨ì 2024 ¦~²Ä¤G©u«×¡A¨Ã¥i¯à®Ú¾Ú 2023 ¦~ 7 ¤ëªì TREK-AD ¬ã¨sªº¥Dn¼Æ¾ÚŪ¥X©Mp¹º©ó 2024 ¦~¶i¦æªº farudodstat ·§©ÀÅçÃÒ¸ÕÅç«á¥i¦æ¨ÏªºÃB¥~»{ªÑÅvÃÒ¶i¤@¨B¦æÅv ¦Û¨§K¬Ì©Ê¥Ö½§¯fªºFarudodstat·§©ÀÅçÃÒ¸ÕÅç¹wp±NÀò±o¥þÃB¸ê§Uª½¦Ü§¹¦¨ ¥[§QºÖ¥§¨È¦{¸t°¨¯S¶ø©M·s¥[©Y¡A2023 ¦~ 2 ¤ë 24 ¤é¡]Àô²y·s»DªÀ¡^-- ASLAN Pharmaceuticals¡]¡§ASLAN¡¨¡A¯Ç´µ¹F§JªÑ²¼¥N½X¡GASLN¡^¡A¤@®aÁ{§É¶¥¬q¡B±Mª`©ó§K¬Ì¾Çªº¥Íª«»sÃĤ½¥q¡AP¤O©ó¶}µo³Ð·sÀøªk¥H§ïÅܱwªÌªº¥Í¬¡¡A¤µ¤Ñ«Å¥¬¤wñq³Ì²×ÁʶR¨óij¡]¡§ÁʶR¨óij¡¨¡^¡A¥HÁʶR»ù®æ¥X°â¨ä´¶³qªÑ¡]©Î¹w¥ý´£¨Ñ¸êª÷ªº»{ªÑÅvÃÒ¡^©MÀHªþªºÁʶR»{ªÑÅvÃÒ¡AÄw¶°¬ù 2000 ¸U¬ü¤¸ªºÁ`¦¬¯qBVF Partners LP¡BK2 HealthVentures ©M¬Y¨Ç²{¦³§ë¸êªÌ¡]¡§§ë¸êªÌ¡¨¡^¨CªÑ´¶³qªÑ 0.178 ¬ü¤¸¡]©Î¬Û·í©ó¨CªÑ¬ü°ê¦s°UªÑ¥÷¡]¡§ADS¡¨¡^0.89 ¬ü¤¸¡^¡C¦¹¥~¡A ¡§§ÚÌ«D±`°ª¿³±o¨ì BVF Partners ©M§Ú̲{¦³§ë¸êªÌªº¤ä«ù¡AÀ°§U±À¶i§Ú̪º¨âÓªvÀø¶µ¥Ø¡A¨Ã¦b¤µ¦~ 7 ¤ëªì§Ú̹ïeblasakimabªº TREK-AD ¬ã¨sªº¹w´ÁŪ¥X³»½u¼Æ¾Ú¤§«e¥[±j§Ú̪º¸ê²£t¶Åªí¦~¡A¡¨ ASLAN Pharmaceuticals º®u°õ¦æ©x Carl Firth³Õ¤h »¡¡C¡§¨Ó¦Û³o¨Çª¾¦W±M·~§ë¸êªÌªº¸êª÷¤ä«ù¬O¹ïeblasakimab§@¬°¯SÀ³©Ê¥Öª¢±wªÌªº·s«¬®t²§¤ÆªvÀøÃĪ«ªº¼ç¤Oªº±j¯P»{¥i¡A¥H¤Îfarudodstat§@¬°¦Û¨§K¬Ì©Ê¥Ö½§¯f DHODH ªº¤U¤@¥N±j®Ä¤fªA§í»s¾¯ªº¼ç¤O¡C¡¨ ¥»¦¸¿Ä¸ê²Å¦XºD¨Ò¦¨¥æ±ø¥ó¡A¹wp±N©ó 2023 ¦~ 2 ¤ë 27 ¤é©Î«e«á§¹¦¨¡C®Ú¾ÚÁʶR¨óijªº±ø´Ú¡A¨È·à±d±Nµo¦æ¦Xp 112,359,550 ªÑ´¶³qªÑ¡]©Î¹w¥ýµù¸ê»{ªÑÅvÃÒ¡^¡A¬Û·í©ó¦Ü 22,471,910 ¥÷¬ü°ê¦s°U¾ÌÃÒ¡A¬Û·í©ó¨C¥÷¬ü°ê¦s°U¾ÌÃÒ 0.89 ¬ü¤¸ªº»ù®æ¡A¤ñ¨C¥÷¬ü°ê¦s°U¾ÌÃÒ 0.77 ¬ü¤¸ªº¬ü°ê¦s°U¾ÌÃÒ¤Q¤Ñ¦¨¥æ¶q¥[Åv¥§¡»ù®æ (VWAP) ·¸»ù 15%¡CASLAN ¥´ºâ±N¨p¶Òªº²b¦¬¯q¥Î©óÀç¹B¸êª÷©M¤@¯ë¤½¥q¥Î³~¡A¥]¬Aeblasakimab©MfarudodstatªºÁ{§É¶}µo¡C §@¬°¿Ä¸êªº¤@³¡¤À¡A§ë¸êªÌÁÙ±N¦¬¨ì¨â§å³Ìªì¥i¦æ¨Ïªº»{ªÑÅvÃÒ¡AÁ`p³Ì¦h 55,309,112 ¥÷¬ü°ê¦s°U¾ÌÃÒ¡]©Î¹w¥ý¿Ä¸êªº»{ªÑÅvÃÒ¡^¡C²Ä¤@§å»{ªÑÅvÃÒ¥]¬A (i) 50% ªº»{ªÑÅvÃÒ¡A¥i¦bµo¦æ«á¦æ¨Ï¡Aª½¦Ü¨È·à±d¥H¦æ¨Ï»ù¤½§G¨ä TREK-AD 2b ´ÁÁ{§É¸ÕÅ窺 TREK-AD 2b ´ÁÁ{§É¸ÕÅ窺¥Dn¼Æ¾Ú«á¤»¤Q¤Ñ¥H¦æ¨Ï»ù¦æ¨Ï¨C ADS 1.30 ¬ü¤¸©M (ii) 50% ªºÁʶRÅvÃÒ¡A¥u¯à¦b ASLAN ±q¨ä TREK-AD 2b ´ÁÁ{§É¸ÕÅ礤½Õ¬d eblasakimab ªvÀø¯SÀ³©Ê¥Öª¢ªº³»½u¼Æ¾Ú¤½§G«á¤»¤Q¤Ñ¤º¦æ¨Ï§ó°ª1.30 ¬ü¤¸©M 50% ªº§é¦©¡A¦b¼Æ¾Ú¤½§G«áªº¯S©w®É´Á¤º´ú±oªº ADS VWAP¡C²Ä¤G§å»{ªÑÅvÃÒ¦P¼Ë¥]§t (i) 50% ªº»{ªÑÅvÃÒ¡A³o¨Ç»{ªÑÅvÃÒ¦bµo¦æ«á¥i¦æ¨Ï¡Aª½¦Ü¨È·à±dp¹ºªº²Ä¤G¶¥¬q·§©ÀÅçÃÒ¸ÕÅç½Õ¬dfarudodstatªº¤¤´Á¼Æ¾Ú¤½§G«á¤»¤Q¤Ñ¡A¦æ¨Ï»ù¬°¨CªÑ 1.63¬ü¤¸ADS ©M (ii) 50% ªºÁʶRÅvÃÒ¥u¯à¦b ASLAN p¹ºªº²Ä¤G¶¥¬q·§©ÀÅçÃÒ¸ÕÅ窺¥Dn¤¤´Á¼Æ¾Ú¤½§G«á¤»¤Q¤Ñ¤º¦æ¨Ï¡A¸Ó¸ÕÅç¥H¸û°ªªº¦æ¨Ï»ù½Õ¬dfarudodstat1.63 ¬ü¤¸¡A¨Ã¥B¦b¼Æ¾Ú¤½§G«áªº¯S©w®É´Á¤º´ú±oªº ADS VWAP ¦³ 50% ªº§é¦©¡C¨â§åÁʶRÅvÃÒÁÙ¥]¬A¦bº¡¨¬¬Y¨Ç¹w¥ý³W©wªº±ø¥óªº±¡ªp¤Uªº±j¨î¦æÅv±ø´Ú¡C ±N¦b¨p¶Ò¤¤¥X°âªºÃÒ¨é¡A¥]¬A»{ªÑÅvÃÒ©M¦æ¨Ï»{ªÑÅvÃÒ«á¥iµo¦æªºÃÒ¨é¡A©|¥¼®Ú¾Ú¸g×qªº 1933 ¦~ÃÒ¨éªk¡]¡§ÃÒ¨éªk¡¨¡^©Î¥ô¦ó¦{©Î¨ä¥L¾A¥ÎªºÃÒ¨éªk¶i¦æµn°O¥qªkºÞÁҰϪºÃÒ¨éªk¡A¨Ã¥B¤£±o¦b¨S¦³µù¥U©Î¥¼¾A¥Î¡mÃÒ¨éªk¡n©M¾A¥Î¦{©Î¨ä¥L¥qªkºÞÁÒ°ÏÃÒ¨éªkªºµù¥Un¨DÁŧKªº±¡ªp¤U¦b¬ü°êµo°â©Î¥X°â¡C¤½¥q¤w¦P·N¦V¬ü°êÃÒ¨é¥æ©ö©eû·|¡]¡§SEC¡¨¡^´£¥æ¤@¥÷µn°OÁn©ú¡Aµn°O¦b¨p¶Ò¤¤µo¦æªºÃҨ骺Âà°â¡C ¥»·s»D½Z¤£ºc¦¨¥X°â³o¨ÇÃҨ骺n¬ù©ÎÁʶR³o¨ÇÃҨ骺n¬ùÁܽСA¤]¤£ºc¦¨¦b¥ô¦ó¥qªkºÞÁҰϤº¹ï³o¨ÇÃҨ骺¥ô¦ón¬ù¡BÁܬù©Î¥X°â¡A¦pªG¦¹Ãþn¬ù¡B©ÛÅó©Î¥X°â¬O«Dªkªº¡C®Ú¾ÚÂà°âµn°OÁn©ú´£¨Ñªº¥ô¦óÃÒ¨é±N¥u¯à³q¹L©ÛªÑ»¡©ú®Ñªº¤è¦¡¶i¦æ¡C |
|
|
·|û¡G³¯¤p©ú10152293 µoªí®É¶¡:2023/2/24 ¤U¤È 07:12:13²Ä 5954 ½g¦^À³
|
2023-02-24 ASLAN Pharmaceuticals «Å¥¬¥Ñ BVF Partners L.P. ²oÀYªº 2000 ¸U¬ü¤¸¨p¶Ò°t°â¡A¨Ã¦³¥i¯àÃB¥~Àò±o°ª¹F 8000 ¸U¬ü¤¸ ASLAN ±NÀò±o 2000 ¸U¬ü¤¸ªº¿Ä¸ê¡A¨Ã¦³¥i¯àÀò±o°ª¹F 8000 ¸U¬ü¤¸ªºÃB¥~¸êª÷¡AÁ`p 1 »õ¬ü¤¸¥Î©óÄ~Äò±À¶i eblasakimab ©M farudodstat ªºÁ{§É¶}µo ASLAN ªº¹w´Á²{ª÷¶]¹D¦Ü¤Ö©µªø¨ì 2024 ¦~²Ä¤G©u«×¡A¨Ã¥i¯à®Ú¾Ú 2023 ¦~ 7 ¤ëªì TREK-AD ¬ã¨sªº¥Dn¼Æ¾ÚŪ¥X©M 2024 ¦~p¹ºªº farudodstat ·§©ÀÅçÃÒ¸ÕÅç«á¥i¦æ¨ÏªºÃB¥~»{ªÑÅvÃÒ¶i¤@¨B¦æÅv ¦Û¨§K¬Ì©Ê¥Ö½§¯fªº Farudodstat ·§©ÀÅçÃÒ¸ÕÅç¹wp±NÀò±o¥þÃB¸ê§Uª½¦Ü§¹¦¨ ¥[§QºÖ¥§¨È¦{¸t°¨¯S¶ø©M·s¥[©Y¡A2023 ¦~ 2 ¤ë 24 ¤é¡]Àô²y·s»DªÀ¡^-- ASLAN Pharmaceuticals¡]¡§ASLAN¡¨¡A¯Ç´µ¹F§JªÑ²¼¥N½X¡GASLN¡^¡A¤@®aÁ{§É¶¥¬q¡B±Mª`©ó§K¬Ì¾Çªº¥Íª«»sÃĤ½¥q¡AP¤O©ó¶}µo³Ð·sÀøªk¥H§ïÅܱwªÌªº¥Í¬¡ ¡A¤µ¤Ñ«Å¥¬¤wñq³Ì²×ÁʶR¨óij¡]¡§ÁʶR¨óij¡¨¡^¡A¥HÁʶR»ù®æ¥X°â¨ä´¶³qªÑ¡]©Î¹w¥ý´£¨Ñ¸êª÷ªº»{ªÑÅvÃÒ¡^©MÀHªþªºÁʶR»{ªÑÅvÃÒ¡AÄw¶°¬ù 2000 ¸U¬ü¤¸ªºÁ`¦¬¯q BVF Partners L.P.¡BK2 HealthVentures ©M¬Y¨Ç²{¦³§ë¸êªÌ¡]¡§§ë¸êªÌ¡¨¡^¨CªÑ´¶³qªÑ 0.178 ¬ü¤¸¡]©Î¬Û·í©ó¨CªÑ¬ü°ê¦s°UªÑ¥÷¡]¡§ADS¡¨¡^0.89 ¬ü¤¸¡^¡C ¦¹¥~¡A¦pªG»PÁʶR¨óij¬ÛÃöªº©Ò¦³ÁʶRÅvÃÒ³£±o¨ì¥R¤À¦æ¨Ï¡AASLAN ±N¦³¥i¯àÀò±o°ª¹F 8000 ¸U¬ü¤¸ªºÃB¥~¦¬¤J¡C ¡§§ÚÌ«D±`°ª¿³±o¨ì BVF Partners ©M§Ú̲{¦³§ë¸êªÌªº¤ä«ù¡AÀ°§U±À¶i§Ú̪º¨âÓªvÀø¶µ¥Ø¡A¨Ã¦b¤µ¦~ 7 ¤ëªì§Ú̹ï eblasakimab ªº TREK-AD ¬ã¨sªº¹w´ÁŪ¥X³»½u¼Æ¾Ú¤§«e¥[±j§Ú̪º¸ê²£t¶Åªí ¦~¡A¡¨ASLAN Pharmaceuticals º®u°õ¦æ©x Carl Firth ³Õ¤h»¡¡C ¡§¨Ó¦Û³o¨Çª¾¦W±M·~§ë¸êªÌªº¸êª÷¤ä«ù¬O¹ï eblasakimab §@¬°¯SÀ³©Ê¥Öª¢±wªÌªº·s«¬®t²§¤ÆªvÀøÃĪ«ªº¼ç¤Oªº±j¯P»{¥i¡A¥H¤Î farudodstat §@¬°¦Û¨§K¬Ì©Ê¥Ö½§¯f DHODH ªº¤U¤@¥N±j®Ä¤fªA§í»s¾¯ªº¼ç¤O¡C¡¨ ¥»¦¸¿Ä¸ê²Å¦XºD¨Ò¦¨¥æ±ø¥ó¡A¹wp±N©ó 2023 ¦~ 2 ¤ë 27 ¤é©Î«e«á§¹¦¨¡C®Ú¾ÚÁʶR¨óijªº±ø´Ú¡A¨È·à±d±Nµo¦æ¦Xp 112,359,550 ªÑ´¶³qªÑ¡]©Î¹w¥ýµù¸ê»{ªÑÅvÃÒ¡^¡A¬Û·í©ó ¦Ü 22,471,910 ¥÷¬ü°ê¦s°U¾ÌÃÒ¡A¬Û·í©ó¨C¥÷¬ü°ê¦s°U¾ÌÃÒ 0.89 ¬ü¤¸ªº»ù®æ¡A¤ñ¨C¥÷¬ü°ê¦s°U¾ÌÃÒ 0.77 ¬ü¤¸ªº¬ü°ê¦s°U¾ÌÃÒ¤Q¤Ñ¦¨¥æ¶q¥[Åv¥§¡»ù®æ (VWAP) ·¸»ù 15%¡C ASLAN ¥´ºâ±N¨p¶Òªº²b¦¬¯q¥Î©óÀç¹B¸êª÷©M¤@¯ë¤½¥q¥Î³~¡A¥]¬A eblasakimab ©M farudodstat ªºÁ{§É¶}µo¡C §@¬°¿Ä¸êªº¤@³¡¤À¡A§ë¸êªÌÁÙ±N¦¬¨ì¨â§å³Ìªì¥i¦æ¨Ïªº»{ªÑÅvÃÒ¡AÁ`p³Ì¦h 55,309,112 ¥÷¬ü°ê¦s°U¾ÌÃÒ¡]©Î¹w¥ý¿Ä¸êªº»{ªÑÅvÃÒ¡^¡C ²Ä¤@§å»{ªÑÅvÃÒ¥]¬A (i) 50% ªº»{ªÑÅvÃÒ¡A¥i¦bµo¦æ«á¦æ¨Ï¡Aª½¦Ü¨È·à±d¥H¦æ¨Ï»ù¤½§G¨ä TREK-AD 2b ´ÁÁ{§É¸ÕÅ窺 TREK-AD 2b ´ÁÁ{§É¸ÕÅ窺¥Dn¼Æ¾Ú«á¤»¤Q¤Ñ¥H¦æ¨Ï»ù¦æ¨Ï ¨C ADS 1.30 ¬ü¤¸©M (ii) 50% ªºÁʶRÅvÃÒ¡A¥u¯à¦b ASLAN ±q¨ä TREK-AD 2b ´ÁÁ{§É¸ÕÅ礤½Õ¬d eblasakimab ªvÀø¯SÀ³©Ê¥Öª¢ªº³»½u¼Æ¾Ú¤½§G«á¤»¤Q¤Ñ¤º¦æ¨Ï ¦b¼Æ¾Ú¤½§G«áªº¯S©w®É´Á¤º´ú±oªº ADS VWAP °ª©ó 1.30 ¬ü¤¸©M 50% ªº§é¦©¡C ²Ä¤G§å»{ªÑÅvÃÒ¦P¼Ë¥]§t (i) 50% ªº»{ªÑÅvÃÒ¡A³o¨Ç»{ªÑÅvÃÒ¦bµo¦æ«á¥i¦æ¨Ï¡Aª½¦Ü¨È·à±dp¹ºªº²Ä¤G¶¥¬q·§©ÀÅçÃÒ¸ÕÅç½Õ¬d farudodstat ªº¤¤´Á¼Æ¾Ú¤½§G«á¤»¤Q¤Ñ¡A¦æ¨Ï»ù¬°¨CªÑ 1.63 ¬ü¤¸ ADS ©M (ii) 50% ªºÁʶRÅvÃÒ¥u¯à¦b ASLAN p¹ºªº²Ä¤G¶¥¬q·§©ÀÅçÃÒ¸ÕÅ窺³»¯Å¤¤´Á¼Æ¾Ú¤½§G«á¤»¤Q¤Ñ¤º¦æ¨Ï¡A¸Ó¸ÕÅç¥H 1.63 ¬ü¤¸©M 50 ¬ü¤¸ªº¸û°ªªÌ¬°°ò¦½Õ¬d farudodstat ¼Æ¾Ú¤½§G«á¯S©w®É´Á¤º´ú±oªº ADS VWAP §éÅý¦Ê¤À¤ñ¡C ¨â§åÁʶRÅvÃÒÁÙ¥]¬A¦bº¡¨¬¬Y¨Ç¹w¥ý³W©wªº±ø¥óªº±¡ªp¤Uªº±j¨î¦æÅv±ø´Ú¡C ±N¦b¨p¶Ò¤¤¥X°âªºÃÒ¨é¡A¥]¬A»{ªÑÅvÃÒ©M¦æ¨Ï»{ªÑÅvÃÒ«á¥iµo¦æªºÃÒ¨é¡A©|¥¼®Ú¾Ú¸g×qªº 1933 ¦~ÃÒ¨éªk¡]¡§ÃÒ¨éªk¡¨¡^©Î¥ô¦ó¦{©Î¨ä¥L¾A¥ÎªºÃÒ¨éªk¶i¦æµn°O ¥qªkºÞÁҰϪºÃÒ¨éªk¡A¤£±o¦b¨S¦³µù¥U©Îµù¥U³B¾A¥ÎÁŧKªº±¡ªp¤U¦b¬ü°êµo°â©Î¥X°â |
|
|
·|û¡G³¯¤p©ú10152293 µoªí®É¶¡:2023/2/24 ¤U¤È 07:06:27²Ä 5953 ½g¦^À³
|
2023-02-24 ASLAN Pharmaceuticals «Å¥¬§¹¦¨ Eblasakimab ªvÀø¯SÀ³©Ê¥Öª¢±wªÌªº 2b ´Á TREK-AD ¬ã¨sªº©Û¶Ò EblasaKimab ¦b¯SÀ³©Ê¥Öª¢ (TREK-AD) ¬ã¨s¤¤ªº¸ÕÅç¤w¸g©Û¶Ò¤F³Ì²×±wªÌ ¹wp¦b 2023 ¦~ 7 ¤ë¤W¦¯¤½§G³»½uµ²ªG ¥[§QºÖ¥§¨È¦{¸t°¨¯S¶ø©M·s¥[©Y¡A2023 ¦~ 2 ¤ë 24 ¤é¡]Àô²y·s»DªÀ¡^-- ASLAN Pharmaceuticals¡]¡§ASLAN¡¨¡A¯Ç´µ¹F§JªÑ²¼¥N½X¡GASLN¡^¡A¤@®aÁ{§É¶¥¬q¡B±Mª`©ó§K¬Ì¾Çªº¥Íª«»sÃĤ½¥q¡AP¤O©ó¶}µo³Ð·sÀøªk¥H§ïÅܱwªÌªº¥Í¬¡ ¡A¤µ¤Ñ«Å¥¬¥¦¤w¸g¦b TREK-AD ¤¤©Û¶Ò¤F³Ì«á¤@¦W±wªÌ¡A³o¬O eblasakimab ¦b¤¤«×¦Ü««×¯SÀ³©Ê¥Öª¢¡] AD ¡^¦¨¤H¤¤ªº2b ´Á¾¯¶q½d³òÁ{§É¬ã¨s¡C ASLAN ¹wp±N¦b 2023 ¦~ 7 ¤ë¤W¦¯³ø§i³o¶µ¬ã¨sªº¥Dn¼Æ¾Ú¡C ÀH¾÷¡BÂùª¼¡B¦w¼¢¾¯¹ï·Ó¡B¾¯¶q½d³òªºÁ{§É¬ã¨s TREK-AD ©ó 2022 ¦~ªì±Ò°Ê¡A¥Hµû¦ô eblasakimab ¦b 16 ©PªvÀø´Á©M 12- ©P¦w¥þÀH³X´Á¡C ¸Ó¬ã¨s©Û¶Ò¤F¨Ó¦Û¥_¬ü¡B¼Ú¬w©M¨È¤Ó¦a°Ï 80 ¦hÓ¦aÂIªº±wªÌ¡C ¥DnÀø®Ä²×ÂI¬OÀã¯l±¿nÄY«µ{«×«ü¼Æ (EASI) µû¤À±q°ò½u¨ì²Ä 16 ¶gªº¦Ê¤À¤ñÅܤơC¦¸nÀø®Ä²×ÂI¥]¬A¹F¨ì¸gÅçÃÒªº¬ã¨sªÌ¥þ²yµû¦ô (vIGA) µû¤À 0¡]²M°£¡^©Î 1¡]´X¥G²M°£¡^ªº±wªÌ¤ñ¨Ò )¡BEASI ´î¤Ö 75% ©Î§ó¦hªº±wªÌ¤ñ¨Ò (EASI-75)¡B¹F¨ì EASI-50¡]´î¤Ö 50% ©Î§ó¦h¡^©M EASI-90¡]´î¤Ö 90% ©Î§ó¦h¡^ªº±wªÌ¤ñ¨Ò¡A¥H¤Î®pÈÅÜ¤Æ æ±Äoµû¤À¡C ¡§§ÚÌ«Ü°ª¿³¦b TREK-AD ¬ã¨s¤¤©Û¶Ò¤F³Ì«á¤@¦W±wªÌ¡A¨Ã´Á«Ý¦b 2023 ¦~ 7 ¤ë¤W¦¯¤À¨É³o¶µ«n¬ã¨sªº³»½uµ²ªG¡C³o¨Çµo²{±N§ó²M·¡¦a»¡©ú eblasakimab ªº®t²§¤Æ¡A¨Ãµ²¦X¥¿¦b¶i¦æªº TREK ¬ã¨sªº¼Æ¾Ú -DX ¬ã¨s¡A±N¤ä«ù¨ä§@¬° AD ±wªÌº¿ï¥Íª«»s¾¯ªº¼ç¤O¡A¡¨ASLAN Pharmaceuticals º®uÀç¾P©x Alex Kaoukhov ³Õ¤h»¡¡C ¡§§ÚÌ·PÁ°ѻP³o¶µ¬ã¨sªº©Ò¦³±wªÌ¡BÂå¥Í©M¸ÕÅç¬ã¨s¤Hû¡C ¥L̪º°Ñ»PÃÒ©ú¤F¹ïªvÀø AD ªº·sÀøªkªº»Ý¨D¡C¡¨ Ãö©ó eblasakimab Eblasakimab ¬O¤@ºØ¼ç¦bªº¤@¬y³æ§J¶©§ÜÅé¡A¹v¦V 2 «¬¨üÅ骺 IL-13 ¨üÅé¨È°ò¡A³o¬OÅX°Ê¦hºØ¹L±Ó©Êª¢¯g¯e¯fªºÃöÁä³~®|¡C Eblasakimab ¿W¯Sªº§@¥Î¾÷¨î¯à°÷¯S²§©ÊªýÂ_ 2 «¬¨üÅé¡A¨Ã¦³¥i¯à§ï¶i¥Ø«e¥Î©óªvÀø¹L±Ó©Ê¯e¯fªº¥Íª«»s¾¯¡C ³q¹LªýÂ_ 2 «¬¨üÅé¡Aeblasakimab ªý¤î³q¹L¥Õ²ÓM¤¶¯À 4 (IL-4) ©M¥Õ²ÓM¤¶¯À 13 (IL-13) µo¥X«H¸¹¡X¡X¯SÀ³©Ê¥Öª¢ (AD) ª¢¯gªº¥DnÅX°Ê¦]¯À¡C 1b ´Á¦h¾¯¶q»¼¼W¬ã¨sªº¿n·¥µ²ªG¬° eblasakimab «Ø¥ß¤F·§©ÀÅçÃÒ¡A¨Ã¤ä«ù¨ä§@¬° AD ªº·s«¬®t²§¤ÆªvÀøªº¼ç¤O¡C ¨È·à±d¥Ø«e¥¿¦b¶i¦æ TREK-AD¡A³o¬O¤@¶µ 2b ´Á¸ÕÅç¡A¦®¦bµû¦ô eblasakimab ¦b¥Íª«ªìªv¤¤«×¦Ü««× AD ±wªÌ¤¤ªºÀø®Ä¡A¹wp±N©ó 2023 ¦~ 7 ¤ëªì¤½§Gµ²ªG¡C¨È·à±dÁÙ¦b¬ã¨s eblasakimab ¦b¸g¾ú¹L dupilumab ªº¤¤«×¦Ü««× AD ±wªÌ¤¤ªºÀø®Ä 2 ´Á¸ÕÅç TREK-DX ¤¤ªº±wªÌ¡A¹wp¼Æ¾Ú±N©ó 2024 ¦~²Ä¤@©u«×¤½§G¡C |
|
|
·|û¡G¸Ø±i10133098 µoªí®É¶¡:2023/2/24 ¤U¤È 04:13:07²Ä 5952 ½g¦^À³
|
½Ð°Ý TANG CAPITAL PARTNERS LPªº«ùªÑ5,364,925ªÑ(7.6922%)¬O¤T¤è¦@¦³¡C ¦Ó§ó¦ªº TANG CAPITAL MANAGEMENT LLCªº«ùªÑ5,364,925ªÑ(7.6922%)¬O¦Û¤v«ù¦³¡A¬O¶Ü??? ³o¼Ë TANG CAPITAL MANAGEMENT LLC¥»¨¦³¶W¹L15%ªºªí¨MÅv¡A¬O¶Ü??? ½Ð±Ð¦U¦ì¤j¤j. |
|
|
·|û¡G³v®ö«È10146323 µoªí®É¶¡:2023/2/23 ¤U¤È 09:56:58²Ä 5951 ½g¦^À³
|
ªü´µÄõ»sÃÄ31.6%ªºªÑ¥÷¥Ñ¾÷ºc§ë¸êªÌ«ù¦³¡C ªü´µÄõ»sÃÄ4.7%ªºªÑ¥÷¥Ñ¤½¥q¤º³¡¤H¤h«ù¦³¡C ±j¤jªº¾÷ºc«ùªÑªí©ú¡A¤j«¬°òª÷ºÞ²z¤½¥q¡B®½ÃØ°òª÷©M¹ï½Ä°òª÷¬Û«H¡A¤@®a¤½¥q¦³±æ¹ê²{ªø´Á¼Wªø¡C ¡ãMarketBeat.com. |
|
|
·|û¡G¬õ¹Ð¦³¹Ú10150039 µoªí®É¶¡:2023/2/22 ¤U¤È 03:57:31²Ä 5950 ½g¦^À³
|
§Ú°O±o¦³¤@±ø³W©w¡A¬O¥i¥H©µªø¤é´Á ªº¤U¥«³W©w¡A¤£µM³Ì«á¥i¯à¨«¦V´î¸ê³o±ø¸ô ¤½¥q¦³¦b¥«³õÄw¸êªº¶·¨D¤£·|»´©ö¤U¥« |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2023/2/22 ¤U¤È 02:28:12²Ä 5949 ½g¦^À³
|
³¯¤j¡B ¤£¬ÝªÑ»ù¡B©ñ¸2¤@3Ó¤ë¡D ¤@¤ÁÀH½t! ©ÎªÌ¤£ºÞ¥¦¦³¸Ñª¼º¦10¿¼ç¤O¡B½æ±¼¥¦¡D |
|
|
·|û¡G³¯¤p©ú10152293 µoªí®É¶¡:2023/2/22 ¤U¤È 01:50:18²Ä 5948 ½g¦^À³
|
¤Ñ©R¤j ¦Ü3¤ë26¤é¶È³Ñ1Ó¤ë ¨È·à±dÁÙ¦³¤°»ò¤èªk¥i¦Û±Ï¡A °£¤F´î¸ê©Î¤U¥«¤èªk¥~¡A §Ú«ç»òı±o³o®a¤½¥q©R¹B¦h¦ß ¹B®ð«D±`¤£¨Î¡A ÁÙ¬O¯à¤O¤£¨¬¡A¤H¿Ñ¤£»N |
|
|
·|û¡G«Ó°¶10144972 µoªí®É¶¡:2023/2/22 ¤W¤È 08:05:40²Ä 5947 ½g¦^À³
|
¬Q±ß¤j¶^«á¡A·à¤l¦b¤T¤ë©³«e¯¸¤W1¬ü¤¸Ãø«×§ó°ª¤F ¦^·Q¨â¦~«e228³s°²¡A·à¤l¨g¼Qªº¼Ò¼Ë¾ú¾ú¦b¥Ø ¤µ¦~228¡A·à¤l¯àµ¹¤j®a¤@Ó°ª¼é¶Ü? ¤£³Ó®D¼N... |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2023/2/21 ¤W¤È 08:53:11²Ä 5946 ½g¦^À³
|
REGN ¤½¥q ²¤¶¡þ2023¦~¤G¤ë investor.regeneron.com/static-files/ff73fc12-062d-41c2-8ca4-98d63f3bcf49 1¡ADupilumab ¦b2022¦~¨ú±o5ÓFDAªº«¬IIª¢¯g¡C¬ÛÃöÃįg¡C 2¡ADupilumab ¦b2022¦~¦~¾P87»õ¬ü¤¸¡C¡]¥þ¤½¥q¦¬¤J¬ù200»õ¬ü¤¸¡Aµ|«e²b§Q¬ù60%¡^ 3¡AREGN 2023¦~±N§ë¤J43»õ¬ü¤¸¬ã¨s¶O¥Î¡C 4¡A2019¦~¨Ó®w¦sªÑ¬ù¶R¦^10»õ¬ü¤¸ 5¡B2023¦~¤G¤ë«Å¥¬¥t¥~±N¶R¦^®w¦sªÑ30»õ¬ü¤¸¡C |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2023/2/19 ¤W¤È 08:43:06²Ä 5945 ½g¦^À³
|
¦Xx ±ÂÅvFB825 .¦¬²{ª÷10»õ¥x¹ô ªÑ»ù¥Ñ30¤Wº¦¦Ü140¤¸¡B¥«È¼W¥[°_¹L400»õ(13»õ¬ü¤¸) ¦p¤µ FB825 p¹º°µ¾ô±µSCÁ{§É(¤w°±13Ó¤ë)¡B2bÁ{§É 预p2024¦~¶}©l¡D ¤w¸¨«áASLAN004 2bÁ{§É2¦~¡D ASLAN004 2b ¤»¤ë©³¸Ñª¼¡B Y¦p预´ÁIGA0,1>44%vs 15%(¹ï·Ó组) ³Ì°ª¨é°Ó¥Ø¼Ð»ù7¬ü¤¸¡D ¶Ò¸ê»ù7*80%=5.6¬ü¤¸¡D 5.6x7¸U¤dªÑADR=4.92»õ¬ü¤¸ µo¦æªÑ±N¹F15¸U¤dªÑ 15x5.6=8.4»õ¬ü¤¸(¥«È)¡D ¥H¤W¤è¬O¬O2b§¹¦¨ AD °ê»Ú¦æ±¡¡D(DERM §¹¦¨2b ¡B¤½§G¶Ò¸ê«á7.5»õ¥«È) ASLAN004 ¦bAD ¤w§¹¦¨·§©À©ÊÁ{§É(1b ITT¤À§é) ¦b²Îp¤W¦³©úÅã©M¹ï·Ó组¦³©úÃD®t²§¡D N=22v16 p=0.01 FB825 2a ADÁ{§ÉN=99 ¥¼³q¹L统pÀË©w¡Dp>0.05 ªÑ»ù¦p¦Ñ¤H²oªºª¯¡B¶]¤W¶]¤U¡B²×¦³¤@¤é¦^À³¦³»ùÈ¡D |
|
|
·|û¡Gªoºj·Æ±¼10153108 µoªí®É¶¡:2023/2/18 ¤U¤È 02:47:13²Ä 5944 ½g¦^À³
|
¤U¥«±N¦Ü¡A¥H¥Ø«e»ù®æ0.8¤¸¨Ó»¡¡AYn¦b¤U¥««e¼W¸ê¡A¥²¶·µo¥¬«¤j§Q¦h©Î¤½¥¬´Á¤¤³ø§i©Ô©ïªÑ»ù«á¤~¦³¼W¸êªº·N¸q¡A¤£µM´N¥u¯à¾a´î¸êºû«ùªÑ»ù¨ÓÁקK¤U¥«¡A¦Ó¥B»Ýn¦b0326«e³sÄò10¤Ñ»ù®æ°ª©ó1¤¸¡A¦ý¥H2023¦~0.4~0.8»ù®æ°Ï¶¡¨Ó»¡¡A§Y¨Ï´î¸ê¤¦¨»ù®æ¦^¤É¨ì1.6¤¸¡A¤]Ãø«O¤£·|¦b0313~0326¤§¶¡³Q¥´¤U1¤¸¤´n°h¥«¡A¹ï§Ú¨Ó»¡¡A°µ¤£¨ìµo¥¬«¤j§Q¦h©Î¤½¥¬´Á¤¤³ø§i©Ô©ïªÑ»ù¡A¶È¾a´î¸êºû«ù¦í¤W¥«¸ê®æ¡AºÞ²z¼h´N¤w¸gÅý¤HµLªk±µ¨ü¤F¡A±q¦¬¨ì°h¥«§ïµ½³qª¾¨ì²{¦b¡A¾ã¾ã¤@¦~¹L¥h¡AºÞ²z¼hªº§@¬°¦bþ?(20210301¬°¤FÄw¿ú¼W¸ê¡A¥i¬O³s¤@´ÁÂX¼W¸ÕÅç¤~è¶}©l¡A¦bÁ`¦¬®×¤H¼Æ18¤H¡Aç°£«á¹êÅç²Õ9¤H¡A¹ï·Ó²Õ5¤Hªº±¡ªp¤Uµo¥¬´Á¤¤³ø§i)ÁöµMASLANn°_¦º¦^¥Í¯uªº»Ýn2B¸Ñª¼¦¨¥\¡A¤£µM´N¬OÅܦ¨¾À¯È¡A¦ý¦b¦³®É¶¡À£¤Oªº±¡ªp¤U¡AºJ¶}004¦¨±Ñ»P§_¤£»¡¡A²{¦b³s´Á¤¤³ø§i³£¨S¦³¡A³oºÞ²z¼h¯uªº¥i¥HÅý¤H«HªA? |
|
|
·|û¡G«Ó°¶10144972 µoªí®É¶¡:2023/2/17 ¤U¤È 08:24:31²Ä 5943 ½g¦^À³
|
3/26¶V¨Ó¶Vªñ ·à¤lªÑ»ù¥Ø«eÁÙ¦b0.8©â´¡ ¦Ñ¹êÁ¿¥un¤½¥q¬£¦³¤ß±À¤W¥h1¬ü¤¸´X¤Ñ¡A¸Ñ°£¤U¥«¦M¾÷À³¸Ó¤£Ãø §Æ±æ·à¤l¤£n·d´î¸êµ}ÄÀ³o®M |
|
|
·|û¡G¸Ø±i10133098 µoªí®É¶¡:2023/2/17 ¤U¤È 05:24:13²Ä 5942 ½g¦^À³
|
Yn´î¸ê©Î°f¤À³Î¡A¦b¤W¦¸ªºÂX¼WªÑ¤ÀªÑªF·|´N·|¤@¨Ö°Q½×¤F ¦P·N+1 |
|
|
·|û¡G§d½n¶¯10142119 µoªí®É¶¡:2023/2/17 ¤U¤È 04:46:26²Ä 5941 ½g¦^À³
|
Yn´î¸ê©Î°f¤À³Î¡A¦b¤W¦¸ªºÂX¼WªÑ¤ÀªÑªF·|´N·|¤@¨Ö°Q½×¤F |
|
|
·|û¡G³v®ö«È10146323 µoªí®É¶¡:2023/2/17 ¤U¤È 04:42:21²Ä 5940 ½g¦^À³
|
¦b¤U¤ñ¸û¼ÖÆ[ »{¬°ªÑ»ù±q¥´©³¶¥¬q¡A¥¿´Â1¬ü«e¶i¡I Ä~Äò¬ÝÀ¸¡I |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2023/2/17 ¤U¤È 04:01:32²Ä 5939 ½g¦^À³
|
¿éŦb2bªº¼Æ¾Ú IGA0/1,>44%vs15%(¹ï·Ó²Õ) ³Q¨ÖÁÊ»ùȨӦۤWz2b¼Æ¾Ú¡G 资¥»ÂX¥R§Ö³t¦]¤waslan001ªº¥¢±Ñ¦¨¥»¡D Derm lebrikizumab 2b¸Ñª¼¦¨¥\¡B¶Ò¸ê«á¡B¥«È¬ù7.5»õ¬ü¤¸¡B³Ì«á11»õ¬ü¤¸³Q¨Ö¡D Ó¤H²`«H¤£·|¤ñDERM§ó®t¡D §Ú̦b²Ä8¶g®ÉªºIGA0.1¥i¬O 44%vs30%(lebr.)ªºÁͶաD |
|
|
·|û¡G©t¨àÃÄ10140658 µoªí®É¶¡:2023/2/17 ¤U¤È 03:42:39²Ä 5938 ½g¦^À³
|
¤£¿Ð¨¥¡A´î¸ê´N¬O¹ï¤j³¡¥÷²{¤µ«ùªÑ§ë¸ê¤H³Ì¤jªº¶Ë®`!!! |
|
|
·|û¡G§d½n¶¯10142119 µoªí®É¶¡:2023/2/17 ¤U¤È 03:41:35²Ä 5937 ½g¦^À³
|
²{¦b¬Ý¨ìªº¬O2022/12/31ªº«ùªÑ¡A 2022Q4 10/2-12/31 ±q0.586¡÷0.435 2023¨ì²{¦b¡A±q0.435¡÷0.8 n¬O¨S¦³¯S¦nªº¼Æ¾Ú¡A³»¦h´N³o¼Ë¤F |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2023/2/17 ¤U¤È 02:03:22²Ä 5936 ½g¦^À³
|
Y¬O´î¸ê50%«á¡B¶Ò¸ê»ùÁÙ¬O7x80%=5.6¬ü¤¸ ³o¥Nªí¤½¥q¤]»{¬°ASLAN004ªºÄvª§¤O¤£¬O³»±j¡D ³Q¨ÖÁÊ»ù¦ÛÀ³¤j´T¤UסD |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2023/2/17 ¤U¤È 01:52:41²Ä 5935 ½g¦^À³
|
¤@¡B°²³]´î¸ê50% ´î¸ê«á¥Ø¼Ð»ù14¬ü¤¸ ¶Ò¸ê»ù14x80%=11.2¬ü¤¸/ADR ¤G.°²³]¤£´î¸ê ¥Ø¼Ð»ù7¬ü¤¸ ¶Ò¸ê»ù7x80%=5.6¬ü¤¸ ¥¼¨Ó¤T´Á16¶g¸Ñª¼¦ô¦b2025¦~©³¡D ¤~¦³¥i¯à¦A¶Ò¸ê¡D ¦b¥ÃÁZ经À窺¦Ò¼{¤U¡D ¨º¤@Ó¤è®×¤ñ¸û¤£·|¨Ï¥¼¨Ó2026¦~¶Ò¸ê«eªÑ»ù¤S§C©ó¤@¬ü¤¸? §Ú¬O¤ä«ù´î¸ê¡D |
|
|
·|û¡G©t¨àÃÄ10140658 µoªí®É¶¡:2023/2/17 ¤U¤È 01:13:23²Ä 5934 ½g¦^À³
|
ªoºj¤j»¡±o¨S¿ù¡A¥H¦¹¦¸¾÷ºcªk¤Hªº«ùªÑ¨Ó¬Ý¡AÁ`¬A¨Ó¬Ýªº½T¬O½æ¥X¤j©ó¶R¶i¡A§Æ±æ3/26«e¯à¦³¯¸¤Wªº¨M¤ß¡F¤£µM´N¥u¯à¬O¥D¨ÆªÌ¥i¯à·QÅý¤½¥q´î¸ê¡AµM¦A§C»ù¼W¸ê¡A¶i¦Óµ}ÄÀÅv«¤jªº¨È¬w«ùªÑ¡C ¥H¤W¶È¨Ñ°Ñ¦Ò |
|
|
·|û¡G³v®ö«È10146323 µoªí®É¶¡:2023/2/16 ¤U¤È 09:26:37²Ä 5933 ½g¦^À³
|
¤Ú§JµÜ¦³¤½¥q¦bªü´µÄõ»sÃĦ³¤½¥q¡]¯Ç´µ¹F§J¡Gªü´µÄõ¡^¾Ö¦³ 283,000 ¬ü¤¸ªºªÑ²¼±±ªÑÅv ®Ú¾Ú¨ä³Ìªñ¦VÃÒ¨é¥æ©ö©eû·|¡]SEC¡^´£¥æªº¤å¥ó¡A¤Ú§JµÜ¦³¤½¥q¦b²Ä¤T©u«×«d´î¤F¨ä¦bªü´µÄõ»sÃĦ³¤½¥q¡]NASDAQ¡GASLN-Àò±oµû¯Å¡^ªºªÑ¥÷¦ì¸m 7.4¢H¡C¦b´Á¤º¡A°òª÷¦b½æ¥X 37,694 ªÑªÑ¥÷«á¾Ö¦³¸Ó¤½¥qªÑ²¼ªº 471,270 ªÑªÑ¥÷¡C¤Ú§JµÜ¤½¥q¾Ö¦³ 0.68¢H ªºªü´µÄõ»sÃÄ»ùÈ 283,000 ¬ü¤¸¦b³Ìªñ¤@Ó©u«×µ²§ô®É¡C ¨ä¥L¾÷ºc§ë¸êªÌ©M¹ï¨R°òª÷¤]¶R½æ¤F¸Ó¤½¥qªºªÑ²¼¡C¤dÁHºÞ²z¦³³d¥ô¤½¥q¦b²Ä¤G©u«×±N¨ä¦bªü´µÄõ»sÃĪº«ù¦³¶q´£°ª¤F 2.8%¡C¤dÁHºÞ²z¦³³d¥ô¤½¥q²{¦b¾Ö¦³¸Ó¤½¥qªº 1,613,113 ªÑªÑ²¼¡A»ùȬ° 804,000 ¬ü¤¸¡A¦b¦¹´Á¶¡ÃB¥~ÁʶR 43,949 ªÑªÑ²¼«á¡C¬ü°ê»È¦æ¤½¥q DE ¦b²Ä¤@©u«×¼W¥[¤F 34.4% ¦bªü´µÄõ»sÃĪº¦a¦ì.¬ü°ê»È¦æ¦b¤W¤@©u«×ÃB¥~ÁʶR 66,544 ªÑªÑ²¼«á¡A²{¦b¾Ö¦³¸Ó¤½¥qªÑ²¼ªº 259,722 ªÑ»ùÈ 233,000 ¬ü¤¸¡C¤åÃÀ´_¿³¬ì§Þ¦³³d¥ô¤½¥q¦b²Ä¤@©u«×¦¬ÁʤFªü´µÄõ»sÃĪº·s¦ì¸m $64,000.³Ì«á¡ADAFNA ¸ê¥»ºÞ²z¦³³d¥ô¤½¥q¦b²Ä¤G©u«×±N¨ä¦bªü´µÄõ»sÃĪº¦a¦ì¼W¥[¤F 41.0%¡CDAFNA ¸ê¥»ºÞ²z¦³³d¥ô¤½¥q²{¦b¾Ö¦³¸Ó¤½¥qªÑ²¼ 343,720 ªÑ¡A»ùÈ 17 ¸U¬ü¤¸¡A¦b¤W¤@©u«×ÃB¥~ÁʶR¤F 100,000 ªÑ¡C¾÷ºc§ë¸êªÌ©M¹ï¨R°òª÷¾Ö¦³¸Ó¤½¥qªÑ²¼ªº 31.59¢H¡C |
|
|
·|û¡Gªoºj·Æ±¼10153108 µoªí®É¶¡:2023/2/16 ¤U¤È 02:23:19²Ä 5932 ½g¦^À³
|
»P¨ä¬Ýºô¯¸¾ã²zµ²ªG¡A¬ÝSEC©x¤è¤å¥ó¤ñ¸û·Ç½T¡A¤å¥ó«Ü²M·¡¼g©ú¦@¦P¤À¨É26,824,625ªÑ´¶³qªÑ(¦@5,364,925ªÑ ADS)¡A©Ò¥H¤Gªk¤H+¤@Ó¤H¦Xp«ùªÑ5,364,925ªÑADS¥eASLANÁ`«ùªÑ7.8%.......¡A¤ñ¸û¥O¤H¦b·Nªº¬O쥻«ù¦³ªÑ¼Æ¤]¤£¤ÖªºRTW Investments,¤w¸g¥X²M«ùªÑ¤F......¡C |
|
|
·|û¡G¸Ø±i10133098 µoªí®É¶¡:2023/2/16 ¤U¤È 01:39:58²Ä 5931 ½g¦^À³
|
𤽥q¤£¯Ê¿ú¡A¥i¯àªº¨Mµ¦¬OÅý¨È·à±d°µ§¹¤T´ÁÁ{§É«á¡A¥H§ó°ª»ù¿ú³Q¨ÖÁÊ¡C |
|
|
·|û¡G¸Ø±i10133098 µoªí®É¶¡:2023/2/16 ¤W¤È 10:40:34²Ä 5930 ½g¦^À³
|
³oÓºô¯¸(www.nasdaq.com/market-activity/stocks/asln/institutional-holdings) ¨q¥Xªº«ùªÑ²Ä¤@¦W¬OTANG CAPITAL MANAGEMENT LLC«ùªÑ¨È·à±d5,364,925 ªÑ (¨S¨q¥XTANG CAPITAL PARTNERS LP«ùªÑ) ¦Ó³oÓºô¯¸(whalewisdom.com/stock/asln) ¨q¥Xªº«ùªÑ«e¨â¦W¾÷ºc¤À§O¬O 1.TANG CAPITAL PARTNERS LP«ùªÑ¨È·à±d26,824,625ªÑ 2.TANG CAPITAL MANAGEMENT LLC«ùªÑ¨È·à±d5,364,925 ªÑ ¦ÓTANG CAPITAL PARTNERS LP´N±q¥h¦~²Ä¤T©u¹s«ùªÑ´£¤É¨ì²Ä¥|©u«ùªÑ26,824,625ªÑ ±qwhalewisdom.com/stock/asln¸Óºô¯¸²Ä9¦æ(% Ownership)Åã¥Ü TANG CAPITAL PARTNERS LP(% Ownership)¬O38.4612% TANG CAPITAL MANAGEMENT LLC(% Ownership)¬O7.6922% TANG CAPITAL PARTNERS L©MTANG CAPITAL MANAGEMENT LLC¬O¦P¤@Ó¦ÑÁó ¦ÑÁó«À£¨È·à±dµL»~¡C ɥΤѩR¤j¡G ·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/9/29 ¤W¤È 11:43:48 Tang ¸ê¥»ºÞ²z¤w¨ú±o5555¤dªÑ¡Aªñ8%¡A µ´¹ï¦³¯à¤O¼vÅT¤½¥q¨Mµ¦¡C TANG CAPITAL PARTNERS LP¦³38.4612% ¨º¤£´N·Ç³Æ®³¤U¨È·à±d¨Mµ¦Åv??? |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2023/2/15 ¤U¤È 07:01:14²Ä 5929 ½g¦^À³
|
Tang Capital Partners. Tang Capital Partners beneficially owns 26,824,625 Ordinary Shares of the Issuer, in the form of 5,364,925 ADSs. Tang Capital Partners shares voting and dispositive power over such shares with Tang Capital Management and Kevin Tang. Tang Capital Management. Tang Capital Management beneficially owns 26,824,625 Ordinary Shares of the Issuer, in the form of 5,364,925 ADSs. Tang Capital Management shares voting and dispositive power over such shares with Tang Capital Partners and Kevin Tang. Kevin Tang. Kevin Tang beneficially owns 26,824,625 Ordinary Shares of the Issuer, in the form of 5,364,925 ADSs. ð¸ê¥»¦X¹Ù¤H¡C Tang Capital Partners ¹ê¯q¾Ö¦³µo¦æ¤H 26,824,625 ªÑ´¶³qªÑ¡A§Î¦¡¬° 5,364,925 ¬ü°ê¦s°U¾ÌÃÒ¡C Tang Capital Partners »P Tang Capital Management ©M Kevin Tang ¤À¨É¹ï³o¨ÇªÑ¥÷ªº§ë²¼Åv©M³B¸mÅv¡C ð¸ê¥»ºÞ²z¡C Tang Capital Management ¹ê¯q¾Ö¦³µo¦æ¤H 26,824,625 ªÑ´¶³qªÑ¡A§Î¦¡¬° 5,364,925 Ó¬ü°ê¦s°U¾ÌÃÒ¡C Tang Capital Management »P Tang Capital Partners ©M Kevin Tang ¦@¨É¹ï³o¨ÇªÑ¥÷ªº§ë²¼Åv©M³B¸mÅv¡C ð³Í¤å¡C Kevin Tang ¥H 5,364,925 ªÑ¬ü°ê¦s°U¾ÌÃÒªº§Î¦¡¹ê¯q¾Ö¦³µo¦æ¤Hªº 26,824,625 ªÑ´¶³qªÑ¡C ir.aslanpharma.com/static-files/ba66da24-32ee-49f4-b6eb-b181b975a000 |
|
|
·|û¡G©t¨àÃÄ10140658 µoªí®É¶¡:2023/2/15 ¤U¤È 06:09:33²Ä 5928 ½g¦^À³
|
¸Ø±i¤j¡A±zªºªÑ¼ÆÁÙn°£¥H¤¡A¥i¯àn¦A½T»{¤@¤U~¥H¤Uºô¯¸¨Ñ°Ñ www.nasdaq.com/market-activity/stocks/asln/institutional-holdings |
|
|
·|û¡G¸Ø±i10133098 µoªí®É¶¡:2023/2/15 ¤U¤È 05:25:37²Ä 5927 ½g¦^À³
|
¥h(111)¦~²Ä4©u«ùªÑ¨È·à±d§ë¸ê¾÷ºc«e2¦W 1.TANG CAPITAL PARTNERS LP«ùªÑ¨È·à±d26,824,625ªÑ(¦û38.4612%) 2.TANG CAPITAL MANAGEMENT LLC«ùªÑ¨È·à±d5,364,925 ªÑ(¦û7.6922%) 𤽥q«À£¨È·à±d46.1534% ¦U¦ì¤j¤j¦³¦ó¬Ýªk??? |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2023/2/15 ¤W¤È 06:50:20²Ä 5926 ½g¦^À³
|
¤Úµá¯S²Ä¥|©u½æ±¼86%ªº¥x¿n¹q«ùªÑ¡B¥Ø«e«ùªÑ¹s¦¨¥»¡D ·Q¤£¨ì! |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2023/2/10 ¤U¤È 12:05:01²Ä 5925 ½g¦^À³
|
ASLAN004¤@½uÀø®Ä预«h 400mg*Q2w >300mg*Q2W>600mg*Q4W>400mg*Q4W ®Ú¾Ú¡G Dupilumab/Lebrikizumab 2´ÁÀø®Ä IGA0,1¡G4¶g¤@针/2¶g¤@°w=70%¥ª¥k EASI75¡G4¶g¤@针/2¶g¤@针=93% ¥¼¨ÓASLAN004ªº¥|¶g¤@°w¡B¤T´ÁÁ{§É¡BÀ³¦pLebr¡D¥u¥Î¦b17~52¶gªº©µ¦ùÁ{§É¡D ©Ò¥H¤T´ÁÁ{§É³]p¥i¯à¦pLebr. AD¤T´Á ¾÷·|°ª¡D 400mgx2¶g¤@°wx16¶g ©M¹ï·Ó组(2¡G1)¡B¦@400¤H¡D ¶·2Ó3´Á¦@800¤H¡D ¥t°µ17-52¶g©µ¦ùÁ{§É¡D ²Ä¤TÓ¤T´Á¬°PK TCS¬ù250¤H¡D ¦Ü©ó¤G½u¤T´Á¡BLebr.¥u°µ120¤Hªºopen Lebvbl.¨S¹ï·Ó组¡D |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2023/2/10 ¤W¤È 11:20:48²Ä 5924 ½g¦^À³
|
Æ[¹î ASLAN004 ADªº¤G½u¥ÎÃÄÁ{§É ±Ä¨C¶g¤@°wx16°wx400mg 600mg/600mg/400mg...400mg ®Ú¾Ú¥h¦~9¤ë15¤éR&D ¤é ¤½¥q»{¬°¹w´ÁÀø®Ä¨¬¥H©M¤fªAÃĪ«(JAK§í¨î¾¯¡BIGA0,1=55%-60% ¬Û·í¡D Dupilumab ¤T´Á´¿¦P®É°µ¡B¨C¶g¤@°w/¨C¤G¶g¤@°w¡B¦Ó¥LÌ16¶gªvÀøIGA0,1Àø®Ä©M¹ï·Ó组®t²§¬Ò¦P¬°28%. IGA0,1=53%~65% vs15%(¹ï·Ó组) ®t²§38%~50% vs Dupilumab 28% IGA0,1Àø®Ä =38%/28%=135% ~ =50%/28%=178% ASLAN004¦b¨C¶g¤@°w¤W¤@¦³Àu©óDupilumab 35%~78%ªº预´ÁÀø®ÄÁÍ¶Õ YASLSN004¤@½u©MDupilumab Àø®Ä®t²§¤£¤j¡D ¥Ñ©ó¦b¤G½u¤Wªºµ´¨ÎªºÀø®ÄÀu¶Õ¡D ¥iÀ°§U¤@½uªº销°â¡D ¥H¤W§Y¬O¤½¥q³ø§i©Ò»¡ªº¼Æ¾Ú¼ÒÀÀ¡D ¼W¥[¤@½u°¾¦n¡B§Y¼W¥[³Q¨ÖÁÊ»ùÈ¡D |
|
|
·|û¡GDHL10147526 µoªí®É¶¡:2023/2/8 ¤U¤È 09:58:44²Ä 5923 ½g¦^À³
|
¥[ªo¡I |
|
|
·|û¡G«Ó°¶10144972 µoªí®É¶¡:2023/2/8 ¤U¤È 08:54:19²Ä 5922 ½g¦^À³
|
ªÑ»ù¶Z1¬ü¤¸¤w¤£»· §Æ±æ¥i¥H¦b3¤ë«e¯¸¤Wªü |
|
|
·|û¡G³v®ö«È10146323 µoªí®É¶¡:2023/2/8 ¤U¤È 05:30:39²Ä 5921 ½g¦^À³
|
Aslan Pharmaceuticals Receives Decision to Grant European Patent Titled ¡¦MALONATE SALT OF VARLITINIB (FOR THE TREATMENT OF CANCER)¡¦ ªü´µÄõ»sÃĤ½¥qÀò±o±Â¤©¼Ú¬w±M§Qªº¨M©w¡A¦W¬°¡u¥ï§Q´À¥§ªºÄ«ªG»ÄÆQ¡]¥Î©óªvÀøÀù¯g¡^¡v |
|
|
·|û¡G³¯¤p©ú10152293 µoªí®É¶¡:2023/2/8 ¤U¤È 03:58:51²Ä 5920 ½g¦^À³
|
Aslan Pharmaceuticals ¦¬¨ì±Â¤©¦W¬°¡§¤þ¤G»Ä´À¥§ªº¤þ¤G»ÄÆQ¡]¥Î©óªvÀøÀù¯g¡^¡¨ªº¼Ú¬w±M§Qªº¨M©w Aslan Pharmaceuticals Receives Decision to Grant European Patent Titled ¡¦MALONATE SALT OF VARLITINIB (FOR THE TREATMENT OF CANCER)¡¦ |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2023/2/8 ¤U¤È 02:15:23²Ä 5919 ½g¦^À³
|
003 ¥i¯à¦åÀùÁpÃÄ¡H ¤£ª¾´X½u¡H¥¼¨£Á{§É¸ê°T¡C |
|
|
·|û¡G¿ûÅK¨k¤l10144826 µoªí®É¶¡:2023/2/8 ¤U¤È 01:11:37²Ä 5918 ½g¦^À³
|
register.epo.org/application?number=EP19790887 |
|
|
·|û¡G¿ûÅK¨k¤l10144826 µoªí®É¶¡:2023/2/8 ¤U¤È 01:06:06²Ä 5917 ½g¦^À³
|
register.epo.org/application?number=EP19790887001 001«±Ò¶Ü? |
|
|
·|û¡G¥d¦b¥b¤s¸y10153098 µoªí®É¶¡:2023/2/6 ¤U¤È 11:41:44²Ä 5916 ½g¦^À³
|
²{¦b»ù®æ0.755 ¦b¥[¤@§â«l 1¬ü «Ü®e©ö¹F°} »ô¤ß¦X¤O¿ÂÃƯë¤j¶H |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2023/2/3 ¤U¤È 09:21:20²Ä 5915 ½g¦^À³
|
Dupilumab/Dupixent 2022¦~Q4°]³ø¥XÄl ¬°24.5»õ¬ü¤¸¡A 2022¦~À禬²Öp86.8»õ¬ü¤¸¡A¦ô2023¦~À禬¯}¦Ê»õ¬ü¤¸¡C ³æ¦ì:¦Ê¸U¬ü¤¸ USA(¬ü°ê)// ROW (¨ä¥L°Ï°ì)//¤pp 2022 Q1 1,325.6//484.8//1,810.4 Q2 1,582.1//509.7//2,091,8 Q3 1,824.0//506.1//2,330.1 Q4. //2,450.0 ¦Xp¡C //8¡A682 |
|
|
·|û¡G©t¨àÃÄ10140658 µoªí®É¶¡:2023/2/2 ¤W¤È 09:25:03²Ä 5914 ½g¦^À³
|
¤d¸U¤£n¦³°f¤À³Îªºª¬ªpµo¥Í¡A§Y¨Ï¤À³Î§¹«á¥«È¤£ÅÜ¡A¦ýªÑ²¼¬O¨C¤Ñªi°Ê¡A¸gÀçÆ[©Àª¬ªp®t¡AÁÙ·|¦A¦^¶^¨ì1¶ô¥H¤U¡A©Ò¥Hªü«i¤U¥x¤~¬O¸Ñ¤è¤§¤@¡AÅý»{¯u¸gÀçªÑ»ùªºCEO¤W¥x¥D«ù¡A¦¨¥\¸Ñª¼±a°ÊªÑ»ù¦^¨ì¥¿±`¡A¤~¬O¥¿¹D¡C |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2023/2/2 ¤W¤È 08:31:08²Ä 5913 ½g¦^À³
|
¦pªG3¤ë25¤éªÑ»ù¥¼¹F¤@¬ü¤¸¡A±N°õ¦æ°f¤À³Î¡C °²³]²{¦³ªÑ²¼5ªÑ¡]ì©lªÑ¡^´«1ªÑADR¡AÅܧó¬°10ªÑ¡]ì©lªÑ¡^´«1ªÑADR¡C «hì¥ý¤wµo¦æADR¡Aªñ7¸U¤dªÑÅܦ¨3¸U5¤d¤dªÑADR¡C ¨CӪѪF«ùªÑ´î50%¡C Y6¤ë©³¸Ñª¼¦¨¥\¡A²Å¦X¹w´Á¡A¨º¥Ø¼Ð»ù´N¥Ñì¥ý7¬ü¤¸¡Aº¦¤@¿¨ì14¬ü¤¸¤F¡C 7¬ü¤¸X7¸U¤dªÑ=4»õ9¤d¸U¬ü¤¸¡K¡K¥Ø¼Ð¥«È °f¤À³Î«á¥Ø¼Ð¥«È4»õ9¤d¸U¬ü¤¸¤£·|ÅÜ¡C ªÑ¥»´î¬°¤@¥b3¸U5¤d¤dªÑADR 4¡P9»õ¬ü¤¸¡þ3¡P5¸U¤dªÑADR=14¬ü¤¸¡þªÑ¡C µ²½×¡G°f¤À³Î¤£·l¥«È¡A«ÂI¦b¸Ñª¼Àø®Ä¬O§_¶W¥X¡þ²Å¦X¹w´Á¡C IGA0¡A1>44%¡]¹ï·Ó²Õ15%¡^ |
|
|
·|û¡G«Ó°¶10144972 µoªí®É¶¡:2023/2/2 ¤W¤È 12:35:52²Ä 5912 ½g¦^À³
|
¤Ï¥¿²{¦b½æ¤]®³¤£¦^¤°»ò¿ú ¤£¦p´N¤ß¥®ð©M¬Ý¤½¥q«ç»òª± ³ÌºC¤T¤ë©³¤]´Nª¾¹DÓ¤j·§(¬Ý«ç³B²z¤U¥«°ÝÃD) ¦Ñ¸Ü¤@¥y¡A¤j®a°µ¦nÃz±¼·Ç³Æ´N¬O¡A¦¨¥\ºâ¤¤¼Ö³z |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2023/2/1 ¤U¤È 06:37:16²Ä 5911 ½g¦^À³
|
¥h¦~10¤ë28¤éªº²Ä¤T©u°]³ø¤w§iª¾²Ä¤G©u¤½¥¬004 2b Topline data(¸Ñª¼³ø§i). ¤½¥q¦³¨Í§ï¶iªº¬O clinicaltrials.gov/ct2/show/NCT05158023 ºô¯¸¤Wªº ¹w¦ô¤é´Á没¦³ÀH¤§§ó°Ê,¥O¤H¤£ª¾ÁÙ¦³¤@§åªñ20%¥¼°µ. ³¯¤j駡ªº¦³²z. Anticipated upcoming milestones • First patient enrolled in the TREK-DX trial by the end of 2022. • New translational data highlighting the unique effects of eblasakimab¡¦s mechanism of action will be presented in early 2023. • Topline data from the Phase 2b TREK-AD trial of eblasakimab is expected in Q2 2023. ir.aslanpharma.com/static-files/b0ccbacc-0751-41fc-a55c-dee886e7e797 |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2023/2/1 ¤U¤È 06:18:19²Ä 5910 ½g¦^À³
|
¦pªG¶Ò¸ê¶Ò¤£¨ì¦pCNBC¡AªÑ»ù¶È¶W¹L¤@¬ü¤¸¡A¨º»ùÈ´N«Ü§C«Ü§C¡C ²{¦b¥«È¤£¨ì5¤d¸U¬ü¤¸¡C ¶·¶Ò4»õ¬ü¤¸¡C ¤ýµPY½¯à¶Ò4»õ¬ü¤¸¡A¤~·|½¡C°µ¤T´Á¤~°÷¡C ´Nµ¥¤½¥q¯à¥X¦óºØµP¡H ASLNªºCE0«ùªÑªñ5%¡A§ÚÁÙ¬O¤£¬Û«H·|´î¸ê¦Û¬å²Â³J¡A |
|
|
·|û¡G³¯¤p©ú10152293 µoªí®É¶¡:2023/2/1 ¤U¤È 05:29:47²Ä 5909 ½g¦^À³
|
³o®a¤½¥q§@¬°´N¬O²@µL¸Û«H¥i¨¥¡A«Ü·|ÄF ¤Ï¤Z¨ÆÁ׫´N»´ §Ú²{¦b´N¬O¨C¤Ñ¸ò¥¦EMAIL ½Ð¦w°ÝÔ ¥H¬ª¼« |
|
|
·|û¡Gªoºj·Æ±¼10153108 µoªí®É¶¡:2023/2/1 ¤U¤È 05:05:59²Ä 5908 ½g¦^À³
|
³£§Ö¤U¥«¤F¡A§ÚÁÙ¤`µPù¡A´Nºâ´î¸êÀ±¸ÉÁ«·l¸ú¹L¤U¥«¡A§A¦U¦ì¤§«á¨p¶Ò¡B¨é°Ó¥]¾P¤]¨S¥÷¡A´Nºâ¸Ñª¼¦¨¥\¡A´î¸ê«á¤â¤¤«ùªÑ¤S³Ñ¦h¤Ö?§ó¹N½×¸Ñª¼¦³¥¢±Ñ¥i¯à¡A¦Ó¥B1/30¥[¶}¦¬®×¤¤¤ß¾ãÅé®Éµ{©µ«á¡AÃø¹D1/6§ó·s¤½¥q²³øªº®ÉÔ¤½¥q¤£ª¾¹D?§Ú¬ÝÁÙ¬O«Ü¼ÖÆ[¹wpQ2¼Æ¾Ú¥X¨Ó°Ú¡A³o®a¤½¥qµ¹¤Hªº·Pı´N¬O¤£¦Ñ¹ê¡A¤j·§·|¨«¦V¥xÆWµL¨}¤½¥q´î¸ê¦A¼W¸êªº¸ô½u¡A§Y¨Ï³Ì«á¦¨¥\¡A즳ªÑªF¤]¤À¤£¨ì¤°»ò¦n³B¡A¨Ó¬Ý¬Ýµ²ªG·|¤£·|¥´§ÚÁy¡C |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2023/2/1 ¤W¤È 10:46:33²Ä 5907 ½g¦^À³
|
¸Ø±i¤j , ´Á¤¤³ø§i¬O¤ýµP. ©Ò¦³¤§«e¦ôp¶Ò¸ê®Éµ{·|©µ«á2~3Ó¤ë. 6¤ë©³2b ¤@½u¸Ñª¼ 6¤ë©³2b¤G½u¤j¬ù¥i¤½§G´Á¤¤³ø§i(39¤H). ¥i¼W¥[¨C¶g¤@°w*16¶gªº¤G½u³Q¨Ö»ùȦôºâ. |
|
|
·|û¡G¸Ø±i10133098 µoªí®É¶¡:2023/2/1 ¤W¤È 10:30:07²Ä 5906 ½g¦^À³
|
·s¼W18Ó¦¬®×¤¤¤ß¡AY¦U¦¬5Ó¸ÕÅçªÌ¡A«h¦@¬°90¤H¡A 2bÁ{§É¸ÕÅç¹ï¶H¦@295¤H¡A¦©°£90¤H¡A¾l205¤H¡A¦ý¤£·|³o»ò·¥¡AÀ³¸Ó¾l250¤H¥ª¥k¡A ¥t±q³o18Ó¦¬®×¤¤¤ß90¤H¤¤¬D45¤H¸ûÀuªº¼Æ¾Ú¥X¨Ó¡C 250+45=295¤H ¤£ºÞ¬O205¤H©Î250¤H·í´Á¤¤³ø§i³£¤w¨¬°÷ ¦A¾a45¤H©Ô¼Æ¾Ú¡A¬O§_¬ü¤Æ¼Æ¾Ú¡H(³Q¨Ö¦n»ù¿ú) ¥tì®Éµ{¬O§_¦³²§°Ê¡H 1.¦ô2¤ë15¤é´£¥X4»õ¬ü¤¸¶Ò¸êp¹º 2.¦ô3¤ë15¤é«e¤½¥q¤º³¡¸Ñª¼¡B¨Ã§¹¦¨¤@µ§¨p¶Ò»ù¦ô 7¬ü¤¸x80%x88%=4.928¬ü¤¸/ªÑ 3.¦ô4¤ëªì¤½¥¬ASLAN0042b¸Ñª¼µ²ªG(®Éµ{¬O§_²§°Ê¡H)(©Î§ï¬°´Á¤¤³ø§i¡H) ¥]¾P»ù7¬ü¤¸x80%=5.6¬ü¤¸ 4.ASLAN004¼Ú¬w°Ï°Ó·~¤Æ±ÂÅv. (®Éµ{¬O§_§ï¦Ü7¤ë¡H) |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2023/2/1 ¤W¤È 09:06:17²Ä 5905 ½g¦^À³
|
¤À§åÁ{§É¸ÕÅ祻¬O©Ò¦³ªºÁ{§É³]p¡D ¥i³v§å¤ñ¹ï¡B§ó±µªñÀH¾÷¸ÕÅç¡D ºC3Ӥ맹¦¨¡BÁÙ¦b¦X²z½d³ò¡D Ó¤HÆ[¹îCNTBªº2ÓADÁ{§É¡B ¥i¯à¦p004 1b¡B¦¬¤F¤@©w¤ñ²vªº «D¶Ç²ÎAD±wªÌ¡D ¥L̪º2b°ò½uEASI°¾»´¯g¬Æ¦h¡D ±M·~ªº¦n¦n°µ¥XÀ³¦³ªºÀø®Ä¡B³Ì«n¡D |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2023/2/1 ¤W¤È 08:53:31²Ä 5904 ½g¦^À³
|
2¤ë¡A3¤ë¶}©l·s¤@½üÁ{§É¬OÁ׶}12¤ë¤¤¨l¡ã¤¸¤ë¤¤¦¯ªº¡A¼Ú¡B¬ü´H°²¡C |
|
|
·|û¡G©t¨àÃÄ10140658 µoªí®É¶¡:2023/2/1 ¤W¤È 08:22:22²Ä 5903 ½g¦^À³
|
©çÁ¡A¾nÀ]§ï¬°¥DºÞ~ |
|
|
·|û¡G©t¨àÃÄ10140658 µoªí®É¶¡:2023/2/1 ¤W¤È 08:15:32²Ä 5902 ½g¦^À³
|
COVID-19¬Ì±¡ªº¼vÅT¤w¤T¦~¦h¤F¡A³o®É¤~»¡COVID·|¼vÅT¡Aªí¥Üt³dÁ{§É¾nÀ]¤ÎCEO¥¢Â¾¡A³¯¤j»¡ªº¨S¿ù¡Aªü«iªº½T¤£¾A¥ô¡C |
|
|
·|û¡G³v®ö«È10146323 µoªí®É¶¡:2023/1/31 ¤U¤È 07:21:38²Ä 5901 ½g¦^À³
|
2023¦~1¤ë31¤é¡AASLAN Pharmaceuticals Limited¡]¤½¥q¡^¥l开¤F¤@¦¸¯S别ªÑ东¤j会¡]会议¡^¡C¦b这¦¸会议¤W¡A¤½¥qªºªÑ东对两项ú¨议进¦æ¤F§ë²¼¡A这¨Çú¨议¦b¯S别ªÑ东¤j会³qª¾¡]§@为¤½¥q2022¦~12¤ë21¤é´£¥æ给证¨é¥æ©ö©e员会ªº6-Kªí®æªº¥~国¨p¤H发¦æ¤H报§iªºªþ¥ó99.1¡^¤¤¦³©Ò´yz¡A¨C项ú¨议³£±o¨ì¤F开°Ò¸s岛¤½¥qªk¡]×订ª©¡^©M¤½¥q经×订©M«zªº¤½¥q组织³¹µ{¤j纲©M条´Ú规©wªº¥²nªÑ东ªº¥¿¦¡§åã¡C ²Ä1项ú¨议¡C ²Ä 1 号ú¨议¡G§@为¤@项´¶³qú¨议¡Aú¨©w¼W¥[¥»¤½¥qªºªk©wªÑ¥»¡C (A) 从¡C(A) 从5,000,000¬ü¤¸¤À为500,000,000ªÑ´¶³qªÑ¡A¨CªÑ±È为0.01¬ü¤¸¡C (B) ¦Ü¡C10,000,000¬ü¤¸¡A¤À为1,000,000,000ªÑ´¶³qªÑ¡A¨CªÑ±È©Î²¼±É²È为0.01¬ü¤¸¡C 赞¦¨ ¤Ï对 弃权 337,974,366 2,625,200 1,381,425 ²Ä2项ú¨议¡C ²Ä2项ú¨议¡G³q过¤@项¯S别ú¨议¡A¥H·sªº组织³¹µ{¤j纲©M细则¡]§Y¥»¤½¥q²Ä¤Q¤@¥÷经×订©M«zªº组织³¹µ{¤j纲©M细则¡^¥þ±¨ú¥N¥»¤½¥q现¦³ªº组织³¹µ{¤j纲©M细则¡]§Y¥»¤½¥q²Ä¤Q¤@¥÷经×订©M«zªº组织³¹µ{¤j纲©M细则¡^¡C 赞¦¨ ¤Ï对 弃权 338,230,036 2,292,410 1,458,545 |
|
|
·|û¡G³¯¤p©ú10152293 µoªí®É¶¡:2023/1/31 ¤U¤È 04:38:04²Ä 5900 ½g¦^À³
|
³Ìªñªº°ÝÃD¬O¤µ¦~3¤ë©³«e¡AªÑ»ù¦p¥¼¯à¯¸¤W1¬üª÷«ùÄò10¤Ñ¥H¤W¡A ªÑ²¼´Nn´î¸ê©Î¤U¥«¥i¯à¡A 004 2bÁ{§É¸ÕÅçªø¹F5Ó¦h¤ë¥¼§ó·s¡A¥i¨£¤½¥q¤§µL¯à¤ÎµL¬°¡A¨ä¤¤¨ÃµL¥ô¦ó»¡©ú¡A ¦³»~¾É§ë¸êªÌ¸ÕÅç¤w¹F¦¬®×¤H¼Æ¤§¶ûºÃ¡A£½ ¬Ý¼Ë¤l±¡ªp¤w¤£®e¼ÖÆ[¥H¹ï¡A ³o®a¤½¥q«e¬ìõìõìÁj¦ËÃø®Ñ¡A¸Ñª¼«e¼ÖÆ[¡A¸Ñª¼«á¥²±Ñ¡AµL¤@¦¨¥\¡A ¸ÕÅ穵´Á´N§ä²z¥Ñ·e¶ë¡AÂk©SCOVID-19 ¸Ñ¨M¤§¹D´N¬O´«±¼µL¯àCEO CARL FIRTH §Ú¤wEMAIL¥h·s¥[©Y¡Aªí¹F°ÝÔ |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2023/1/31 ¤U¤È 02:42:37²Ä 5899 ½g¦^À³
|
clinicaltrials.gov/ct2/show/study/NCT01859988?term=NCT01859988&draw=2&rank=1 Dupilumab 2b Á{§É¡A©Û¶Ò¤¤¤ß¦@84Ó¡A¦@13Ӥ맹¦¨16¶gªvÀøªºÀøµ{¼Æ¾Ú¨ú±o¡C ¡]380¤H¡þ6Ó¤£¦PArm) ASLAN004 2b ,83Ó©Û¶Ò¤¤¤ß¡A295¤H¡þ5 Arm ,¹wp16Ӥ맹¦¨¥Dnªº16¶gªvÀø«áªº¼Æ¾Ú¡C ¦]¨ü¬Ì±¡¼vÅT¡A¸¨«á3Ó¤ë¡Aªñ¤T¦~¨ÓªºÁ{§É´¶¹M¦³ªºª¬ªp¡C |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2023/1/31 ¤U¤È 12:40:44²Ä 5898 ½g¦^À³
|
±Æ°£±ø¥ó¦h¤@±ø. 14.Active COVID infection at baseline. ±Æ°£ °ò½u®Éªº¬¡°Ê©Ê COVID ·P¬V¡C clinicaltrials.gov/ct2/show/NCT05158023 ¥»¦¸¼W¥[¤Wz¤@±ø©Û¶Ò®Éªº±Æ°£±ø¥ó. ±Æ°£°ò½uCOVID ·P¬VªÌ¡C ¤]³\¨üCOVID¼vÅT¤Ó¦h,¬°¸É¨¬295¤H¦Ó¦b¤@¶}©l´N¦p¦¹Á{§É³]p?! ¥h¦~¤¸¤ë¤½§G2b Á{§É¥»n¦³100Ó¦¬®×¤¤¤ß,¥B§t¼Ú¬w. Dupilumab/Lebrikizumab 2b¬Ò¥Î13Ӥ맹¦¨,¦ÓASLAN004 2¤ë¥Î¤F16Ӥ맹¦¨ªì¨B¸ê®Æ¦¬¶°. |
|
|
·|û¡G³¯¤p©ú10152293 µoªí®É¶¡:2023/1/31 ¤W¤È 11:59:55²Ä 5897 ½g¦^À³
|
¦b¬Û¹j5Ó¤ë«á¡A¤~¦b112¦~1¤ë27¤é¤½¥¬¥[¶}¼Ú¬w¦¬®×¤¤¤ß¡A §Ú»{¬°±¡ªp¤£¦n¡A©Ò¥H¬Q±ß«®À8.7%¡A³o¥Nªí004 2b ¹êÅç¼Æ¾Ú¤í¨Î¡A ¤~»Ýn¦b¬Û¹j20©P«á°µªº¸É±Ï±¹¬I¡A¤£n¦b¦Û§Ú³Â¾K嘞¡An¦U¦Û°k©R嘞¡A ³o®a¤½¥q±q¨Ó¥u³ø³ß¤£³ø¼~ ©{¦p¶BÄFªÅ´ß¤½¥q¡Ä |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2023/1/31 ¤W¤È 11:56:25²Ä 5896 ½g¦^À³
|
¤µ¦~6¤ë©³§¹¦¨16¶gªvÀøªºªì¨BÁ{§É¸ê®Æ¦¬¶°¡C ¤¸¤ë©³¶}©l©Û¶Ò¡A3¤ëªì§¹¦¨³Ì«á¤@§å18Ó¤¤¤ßªº²Ä¤@¾¯ª`®g¡C¡]2¤ë©³¡ã3¤ëªì¤½¥¬§¹¦¨©Û¶Ò¡^ 18¡þ83=20% ¤½¥q¤w¦³80%ªº16¶gªvÀø§¹¦¨ªº¥¼¸Ñª¼¸ê®Æ¡C ¥[¤J¼Ú¬wÁ{§É¡]¥HªiÄõ°µ¥Nªí¡^¡A¥»¦¸18Ó¤¤¤ß¬Ò¬°ASLNªºÁ{§É¤¤¤ß¡AªÖ©wÄY®æ¿zÀË©Û¶Ò¤H¿ï¡A¨CÓ¤¤¤ß¥§¡©Û3¡ã4¦ì±wªÌ¡A §Æ±æ¥i±NªvÀø«áªº¦U¶µ«ü¼Ð¦A¥Î¦¹20%©Ô¤É¡A¾ãÓÁ{§É³]p¬Û·í¤p¤ß¡A±M·~¡C |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2023/1/31 ¤W¤È 11:11:49²Ä 5895 ½g¦^À³
|
clinicaltrials.gov/ct2/show/NCT05158023 Phase 2b Study of ASLAN004 in Adults With Moderate-to-Severe Atopic Dermatitis ³Ì·sÁ{§É§ó·s: 2023/01/30 1.¦¬®×¤¤¤ß¥Ñ65Ó¼W¥[¦Ü83Ó,¼W¥[¼Ú¬wªiÄõ9Ó... 2.Estimated Primary Completion Date : June 30, 2023(¥i¯àªº¸Ñª¼¤é´Á?) |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2023/1/26 ¤U¤È 06:17:37²Ä 5894 ½g¦^À³
|
¤ÀªR®v¥Ø¼Ð»ù7¬ü¤¸ 2b ITT¸Ñª¼µ²ªG²Å¦X 1.IGA0,1=44%vs15%(¹ï·Ó组)¡B ¥H¤W¦p1bªºmITT¡D Ó¤H¦ôIGAÀ³¦b50%~60%¤§¶¡¾÷²v¤j¡D ¬G²Ä¤@µ§ªº¨p¶Ò»ù¥i¯à¶W¥X¤W¤@½g¤åªº预´Á«Ü°ª¡B¦³¾÷·|¿¼Æ¡D 14x80%x88%....¤£µL¥i¯à?! |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2023/1/26 ¤U¤È 05:29:14²Ä 5893 ½g¦^À³
|
®Éµ{¡G 1.¤¸¤ë31¤éªÑªF·|¡B´£°ªªÑ¥»¦Ü20¸U¤dªÑADR¡B¥Ø«e¤wµo¦æ7¸U¤dªÑ¡B¥t¥~¤@¸U¤dªÑ¬°¤½¥q¤º³¡¤Hû¿EÀyp¹º¡D 2.¦ô2¤ë15¤é´£¥X4»õ¬ü¤¸¶Ò¸êp¹º 3.¦ô3¤ë15¤é«e¤½¥q¤º³¡¸Ñª¼¡B¨Ã§¹¦¨¤@µ§¨p¶Ò»ù¦ô 7¬ü¤¸x80%x88%=4.928¬ü¤¸/ªÑ 4.¦ô4¤ëªì¤½¥¬ASLAN0042b¸Ñª¼µ²ªG ¥]¾P»ù7¬ü¤¸x80%=5.6¬ü¤¸ x7¸U¤dªÑ. 5¡DASLAN004¼Ú¬w°Ï°Ó·~¤Æ±ÂÅv. |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2023/1/24 ¤W¤È 07:27:17²Ä 5892 ½g¦^À³
|
ASLAN004 ªvÀø¦³¨Ï¥Î¹LDupilumab¡]¤G½u¥Íª«»s¾¯¡^Á{§É¹êÅç¤w¸g©ó¤W¤ë21¤é¶}©l¡C ¥Ø«e¶}³]¬ü°ê¤@Ó¤¤¤ß©Û¶Ò¤¤¡C Study of Eblasakimab in Male or Female Moderate-to-Severe Atopic Dermatitis Patients Previously Treated With Dupilumab clinicaltrials.gov/ct2/show/NCT05694884?term=Study+of+Eblasakimab+in+Male&draw=2&rank=1 Study Design Go to sections Study Type : Interventional (Clinical Trial) Estimated Enrollment : 75 participants Allocation: Randomized Intervention Model: Parallel Assignment Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) Primary Purpose: Treatment Official Title: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial to Evaluate the Efficacy and Safety of Eblasakimab in Male or Female Moderate-to-Severe Atopic Dermatitis Patients Previously Treated With Dupilumab Actual Study Start Date : December 21, 2022 Estimated Primary Completion Date : December 16, 2023 Estimated Study Completion Date : December 16, 2023 |
|
|
·|û¡G«Ó°¶10144972 µoªí®É¶¡:2023/1/22 ¤U¤È 08:34:31²Ä 5891 ½g¦^À³
|
¤µ¦~´N¬O¤µ¦~¤F «ù¦³¨È·à±d³o»ò¤[¡A¤µ¦~¬OÃöÁä¤@¦~ ¯¬¨È·à±d¤µ¦~¼Æ¾Ú¦n¨ìÃzªí ¯¬·à¤Í¨ß¦~¸U¨ß¶¶§Q¡A°]·½¼s¶i |
|
|
·|û¡G³v®ö«È10146323 µoªí®É¶¡:2023/1/22 ¤U¤È 06:15:54²Ä 5890 ½g¦^À³
|
Ä@ ¨¦üµÐ´£µL¾ð¡A¤ß¦p©úÃèµL¥x¡A ©Ù«o¹Ð®JµLµ·¡AÀ³µL©Ò¦íµLê¡I |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2023/1/22 ¤W¤È 07:51:34²Ä 5889 ½g¦^À³
|
·sÄ@µÐ´£¦¨ ¦~¦~¬Ò¥¦w §Ö®©Æ[¦Û¦b ¼ÖÐä¨ì©¼©¤ |
|
|
·|û¡G¥d¦b¥b¤s¸y10153098 µoªí®É¶¡:2023/1/22 ¤W¤È 12:06:50²Ä 5888 ½g¦^À³
|
½Ð°Ý¦U¦ì¤j¤j ¸Ñ¦£¦¨¥\·§²v°ª¶Ü ¥H«e¦b¥xªÑ¶Rªº §Ñ¤FÂàadr ¤@ª½«ù¦³¨ì²{¦b ·Ç³Æ¦bÉu¥L¤@¦¸ |
|
|
·|û¡G³¯¤p©ú10152293 µoªí®É¶¡:2023/1/20 ¤U¤È 12:08:30²Ä 5887 ½g¦^À³
|
·sªº¤@¦~¡A·sªº§Æ±æ ³o»ò¦h¦~¤F¡A·PÁ¤j®a¤@ª½ªº¤À¨É¡A ¯¬¤j®a·sªº¤@¦~¹Ú·Q¦¨¯u¡A |
|
|
·|û¡G¸Ø±i10133098 µoªí®É¶¡:2023/1/18 ¤U¤È 12:41:58²Ä 5886 ½g¦^À³
|
½Ð°Ý TREK-DX ¤½¥q¦³¤½§i¦¬®×¤¤¤ß¦¨¥ß¶¡¼Æ¤F¶Ü?? ÁÂÁ |
|
|
·|û¡G©t¨àÃÄ10140658 µoªí®É¶¡:2023/1/17 ¤W¤È 11:43:28²Ä 5885 ½g¦^À³
|
¦p¤Ñ©R¤jª÷¤f¡A§Æ±æ´Á¤¤¼Æ¾Ú«ü¤Þ¥¿¦V¸Ñª¼µ²ªG¡AÅý¤@¤Á¨«¦V¨ÖÁÊ«eªº°ªªÑ»ù~¥[ªo¡A·à¤ÍÌ·s¬K´r§Ö! |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2023/1/14 ¤U¤È 03:42:44²Ä 5884 ½g¦^À³
|
Y2b IGA0,1>53%¥H¤W®É ¥]¾P³æ»ù©Ô°ª¨é°Ó¥Ø¼Ð5.6¬ü¤¸¤@ªÑªº4¿=5.6*4=22.4¬ü¤¸¡C «h¥»¦¸©Ò»Ý7¸U¤dªÑADR¥i°¬°1/4=1¡P75¸UªÑ´N°÷¶Ò¨ì3¡P8»õ¬ü¤¸¸êª÷ «h¦~©³³Q¨ÖÁʪѥ»¡×7+1+1¡P75¡×9¡P75¸UªÑADR 50»õ¬ü¤¸¦¬Áʪ÷ÃB¡þ9¡P75¸U¤dªÑ¡×50¬ü¤¸¡þªÑ¤@¤@ADR ¥H¤W¼ÒÀÀ¡A Ų½ÐASLN ¤½¥q¤Å¥²±N2b¥]¾P¡þ¨p¶Ò»ù®æ©Ô°ª¨ì¦X²z»ù®æ¡C |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2023/1/14 ¤U¤È 03:20:53²Ä 5883 ½g¦^À³
|
¤@¡B2b IGA0,1´Á±æȦôp¤èªk¤@¡G ¨ÌASLAN004 1b mITT IGA0,1=44%=7/16 ¨ä¤¤ì¥»«D¶Ç²ÎAD6¦ì¡A°ò缐EASI19ªº»´¯g¡A8¶gªvÀø«á0¦ì¦ì¹FIGA0,1(mITT¤w±Æ°£¡^ Y¨Ì¶Ç²ÎADªvÀø¡]Y1b¿z¿ïÄY®æ±Æ°£«D¶Ç²ÎAD¡^ ¦Ü¤Ö4/6¡ã6/6·|¹FIGA0,1 «hIGA0,1±N¦^Âk (7+4)/(16+6)=50% (7+5)/(16+6)=55% (7+6)/(16+6)=60% ¤G¡B2b EASI75´Á±æȦôp¡G ¨ÌASLAN004 1b mITT EASI75=11/16=69% ¨ä¤¤ì¥»«D¶Ç²ÎAD6¦ì¡A°ò缐EASI19ªº»´¯g¡A8¶gªvÀø«á0¦ì¦ì¹FEASI75¡C¡]mITT¤w±Æ°£¡^ Y¨Ì¶Ç²ÎADªvÀø¡]Y1b¿z¿ïÄY®æ±Æ°£«D¶Ç²ÎAD¡^ ¦Ü¤Ö5/6¡ã6/6·|¹FEASI75 «hEASI75±N¦^Âk (11¤Q5)/(16+6)=73% (11+6)/(16+6)=77% ¥t¥~¤¤Â_²v3/16=19% ¨Ì¾Ú¤T´Á¤¤Â_²v¶È7%¡ã8% EASI75¡]11+6¡^/¡]16+6-1¡^=81% 81%vs24%(¹ï·Ó组)¡BPÈ<0.001 ¤T¡B2b ¦ôIGA0,1 ¤èªk¤G ®Ú¾ÚLebrikizumab 2b EASI75 61%-IGA0,1 45%=16%) ASLAN004 2b IGA0,1 53%vs15%(¹ï·Ó组)¡BPÈ<0.001 ¡X¡XIGA0,1=EASI75-16% 69%-16%=53% 81%-16%=65% |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2023/1/14 ¤W¤È 11:00:20²Ä 5882 ½g¦^À³
|
¨Ì¥H¤U2b¸Ñª¼¼ÒÀÀ¡B ³Q¨ÖÁʪ÷额50»õ¬ü¤¸¡B¨CªÑ33.3¬ü¤¸ADR¡B15¸U¤dªÑADRªÑ¥»¡B ¦ô¤µ¦~¦~©³¡B©ú¦~ªì³Q¨ÖÁÊ¡D IGA0,1¤W¬Ý50%~60%,¥i°l¤W¤G½u¤fªA¥ÎÃĪ«(°ª°Æ§@¥Î) Ų½Ð¤½¥q¤Å¥²´£°ª¥]¾P³æ»ùªñ24¬ü¤¸/ADR 33/1.4=24¬ü¤¸ ¦p¦¹¤~³Q¨Ö³æ»ù¸û®e©ö¹F33¬ü¤¸¡D ¨ÖÁʪ̦ô»ù¥²°Ñ¦Ò¥«»ù¤Î¨é°Ó¥Ø¼Ð»ù¡D DERM³Q¨Ö³æ»ù18.75/¥]¾P³æ»ù13.25 =1.4 2020/01DERM ³Q¨ÖÁÊ»ù18.75¬ü¤¸ 2019/02DERM ¥]¾P¼W¸ê»ù13.25¬ü¤¸/ªÑ ¤@¡BASLAN004 2b EASI¥§¡°´T预¦ô¬°76%vs40%(¹ï·Ó²Õ),p<0.001 ¨Ì1b mITTx8¶g EASI¥§¡°73%*16¤H 쥻°ò½uEASI19,6¤H¡BY·íªì¦³¿z¿ï¬°¶Ç²ÎAD±wªÌ ¦ô6¤H¤§EASI¥§¡°´T ¨Ìdupilumab ¤T´Á¸ê®Æ预¦ô¡D ¬°77%/67%x73%=84% (Dupilumab ¤T´Á¡G °ò½u TRAC§C组/¥§¡EASI25.5,预«á¥§¡EASI°´T77% °ò½u TRAC¤¤组/¥§¡EASI32,预«á¥§¡EASI°67%) 22¤H¤§EASI¥§¡°´T=73%x16+6x84%=76% 2b N=59/59¤H¡B EASI¥§¡°´T 76% (ASLAN004) vs 40% (¹ï·Ó²Õ)¡BP<0.001 ¤G¡B2b EASI75´Á±æȦôp¡G ¨ÌASLAN004 1b mITT EASI75=11/16=69% ¨ä¤¤ì¥»«D¶Ç²ÎAD6¦ì¡A°ò缐EASI19ªº»´¯g¡A8¶gªvÀø«á0¦ì¦ì¹FEASI75¡C¡]mITT¤w±Æ°£¡^ Y¨Ì¶Ç²ÎADªvÀø¡]Y1b¿z¿ïÄY®æ±Æ°£«D¶Ç²ÎAD¡^ ¦Ü¤Ö5/6¡ã6/6·|¹FEASI75 «hEASI75±N¦^Âk (11¤Q5)/(16+6)=73% (11+6)/(16+6)=77% ¥t¥~¤¤Â_²v3/16=19% ¨Ì¾Ú¤T´Á¤¤Â_²v¶È7%¡ã8% EASI75¡]11+6¡^/¡]16+6-1¡^=81% 81%vs24%(¹ï·Ó组)¡BPÈ<0.001 ¤T¡B2b ¦ôIGA0,1=53%vs15%(¹ï·Ó组)¡BPÈ<0.001 IGA0,1=EASI75-16% 69%-16%=53% (®Ú¾ÚLebrikizumab 2b EASI75 61%-IGA0,1 45%=16%) |
|
|
|